VALENCIA / ES

EUROPEAN SOCIETY OF GASTROINTESTINAL AND ABDOMINAL RADIOLOGY

ESGAR 2009

FINAL Photo by: Chosovi; created under the “Creative Commons Attribution ShareAlike 2.5” License

PROGRAMME
TH
JUNE 23 – 26
20 ANNUAL MEETING AND POSTGRADUATE COURSE
.artundwork designbüro

Simplify your
lesion treatment.
MRI
OASISTM, 1.2T
The ultimate Patient MRI – open

CT
ECLOS
The patient friendly,
scalable multislice CT

Ultrasound
HI VISION Preirus
A compact premium ultrasound platform
that adapts to your environment

Fusion imaging meets HI RVS (Hitachi Real-time Virtual Sonography)

An innovative technology for multimodal image fusion

Hitachi's Real-time image fusion software utilises magnetic
position tracking sensors on the ultrasound transducer (Real-time
Virtual Sonography Magnetic Sensor) to display real-time free-hand
ultrasound images alongside synchronous CT or MR images.
Correlating anatomical cross-sections can be viewed at any
position and angle of the transducer in accordance with the
previously acquired and stored CT or MR volume data set.
Our innovative multimodal image fusion technology brings you
• improved diagnostic accuracy and
• more precise image-guided interventions
• perfect image illustration to facilitate diagnosis and its
management

Hitachi Medical Systems Europe Holding AG · Sumpfstrasse 13 · CH-6300 Zug

www.hitachi-medical-systems.com
FINAL PROGRAMME

ESGAR 2009
JUNE 23 – 26, VALENCIA, SPAIN

20TH ANNUAL MEETING AND POSTGRADUATE COURSE OF ESGAR

EUROPEAN SOCIETY OF GASTROINTESTINAL AND ABDOMINAL RADIOLOGY

TABLE OF CONTENTS

Important Addresses / Sponsors / CME Credits 05

Committees 06
Welcome Addresses 10
Honorary Fellows 14
Gold Medal 17
Information Scientific Programme 19
Preview Centre 22
General Information 24
Evening Events 26
Programme Overview 29
Tuesday, June 23 31
Wednesday, June 24 40
Thursday, June 25 58
Friday, June 26 76
EPOS™ Presentations 90
List of Exhibitors 112
Floorplans 113
Alphabetical Index/Speakers/Presenters 116
Notes 120
Membership Form 127
Membership Information 128

PATRONAGE
SEDIA
Sociedad Española de Diagnóstico por Imagen
del Abdomen

© all rights reserved by the

EUROPEAN SOCIETY OF GASTROINTESTINAL AND ABDOMINAL RADIOLOGY
Date of printing: June, 2009
No responsibility can be accepted for printing and typesetting errors.
 X-RAY

Risk of contrast-medium-induced nephropathy

in high-risk patients undergoing MDCT
A pooled analysis of two randomized trials

The relative Iomeprol Iopamidol injection

endpoint i.e., SCr ≥ 25%
is sensitive in patients
with less renal impairment
while in SCr ≥ 05, mg/dl is
more sensitive in patients with
higher renal impairment,
both endpoints are not
interchangeable

There were no
differences between
patients with milder renal
impairment as the variations
of SCr, equal or higher than
25%, are similar to both
groups, LOCM and
IOCM

In patients with
In patients
more severe renal
at high risk (i.e.,
impairment
eGFR <40mL/min)
(eGFR <40 mL/min
CIN cases were
or <30 mL/min), iodixanol
observed only with
caused a significantly higher
iodixanol
Objective The objective of the study was to investigate the rate of CIN compared
incidence of CIN in patients with glomerular filtration rate (GFR) to iopamidol and
<60 ml min undergoing contrast-enhanced MDCT examinations iomeprol
and to compare the rates of CIN following the IV administration
of low-osmolar contrast media (LOCM, iopamidol and iomeprol)
and an iso-osmolar contrast medium (IOCM, iodixanol).
Methods A total of 301 adult patients with moderate-to-severe renal failure received a similar IV contrast dose (40 gI). Serum creatinine (SCr) was measured
at screening, baseline and 48–72±6 h after the MDCT examination.
Conclusions The risk of significant CIN seems to be low. The IOCM iodixanol caused a higher rate of CIN than the LOCM iopamidol and iomeprol,
especially in high-risk patients. Differences in osmolality between these LOCM and iodixanol do not play a role in the genesis of CIN.

Henrik S. Thomsen, Sameh K. Morcos, Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT – A pooled analysis of two randomized trials.
Eur Radiol DOI 10.1007/s00330-008-1206-4

Please see full Prescribing Information. Before use, please consult the locally approved Summary of Product Characteristics, which will be made available upon request.

www.braccoimaging.com
 X-RAY
IOMERON® - CORE SUMMARY OF PRODUCT CHARACTERISTICS Conventional selective 300, 350, 400 Adults: 4-10 ml artery repeat as both experimentally and clinically to increase BBB permeability. This facilitates the
1. NAME OF THE MEDICINAL PRODUCT. IOMERON 150 mg/ml Solution for coronary arteriography necessary passage of iodinated agents into the cerebral tissue, possibly leading to CNS disor-
Injection. IOMERON 200 mg/ml Solution for Injection. IOMERON 250 mg/ml ERCP 150, 200, 300 Adults: up to 100 ml ders. Caution must be exercised in alcoholics because of the possibility of a reduced
Solution for Injection. IOMERON 300 mg/ml Solution for Injection. IOMERON Arthrography 200, 300, 350 Adults: up to 10 ml per injection seizure threshold. Drug addiction. Caution must be exercised in drug addicts because
350 mg/ml Solution for Injection. IOMERON 400 mg/ml Solution for Injection. Hysterosalpingography 200, 300, 350 Adults: up to 35 ml
of the possibility of a reduced seizure threshold. Keep away of reach of children.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION IOMERON 150 contains Special Precautions for use In relation to the patient. Hydration: Any severe disorders
Fistulography 300, 350, 400 Adults: up to 100 ml
(quantity/100 ml): Active ingredient: Iomeprol: 30.62 g. IOMERON 200 contains of water and electrolyte balance should be corrected. Especially in patients with mul-
(quantity/100 ml): Active ingredient: Iomeprol: 40.82 g. IOMERON 250 contains Discography 300 Adults: up to 4 ml tiple myeloma, diabetes mellitus, polyuria, oliguria, hyperuricemia, as well as in babies,
(quantity/100 ml): Active ingredient: Iomeprol: 51.03 g. IOMERON 300 contains Galactography 300, 350, 400 Adults: 0.15 - 1.2 ml per injection small children and elderly patients adequate hydration must be ensured before ex-
(quantity/100 ml): Active ingredient: Iomeprol: 61.24 g. IOMERON 350 contains Dacryocystography 300, 350, 400 Adults: 2.5 - 8 ml per injection amination. Dietary advice: Unless otherwise instructed by the doctor, a normal diet
(quantity/100 ml): Active ingredient: Iomeprol: 71.44 g. IOMERON 400 contains Sialography 300, 350, 400 Adults: 1 - 3 ml per injection may be maintained on the day of the examination. Adequate fluid intake must be
(quantity/100 ml): Active ingredient: Iomeprol: 81.65 g. For excipients see 6.1 MCU 150 Adults: 100 - 250 ml ensured. However, it is advised that the patient should refrain from eating for two
3. PHARMACEUTICAL FORM Solution for injection displaying the following 150 Paediatric patients: 40 - 210 mla hours prior to the procedure. Pre-medication: In patients with phaeochromocytoma
physicochemical characteristics by Iodine Strengths as below Retrograde cholangiography 200, 300, 350 Adults: up to 60 ml pre-medication with alpha-receptor blockers is recommended because of the risk of
Iodine concentration Osmolality Viscosity Retrograde ureterography 200, 300 Adults: 20 - 100 ml blood pressure crises. Hypersensitivity: In patients with an allergic disposition, known
MgI/mL MosmL/kg water (x ± s.t95)* MPa.s (x ± s.t95) Retrograde pyelo- 200, 300 Adults: 10 - 20 ml per injection hypersensitivity to iodinated contrast media and a history of asthma, pre-medication
37°C 20°C 37°C ureterography with anti-histamines and/or corticoids is recommended to prevent possibile anaphy-
Myelography 200, 250, 300 Adults: 200: 13-22 ml, 250: lactoid reactions. Anxiety: Pronounced states of excitement, anxiety and pain can be
150 301 ± 14 2.0 ± 0.2 1.4 ± 0.1
a = According to body weight and age
the cause of side effects or intensify contrast-related reactions. These patients may be
200 362 ± 17 3.1 ± 0.2 2.0 ± 0.2 given a sedative. Concomitant Treatments: Treatment with drugs that lower the sei-
250 435 ± 20 4.9 ± 0.4 2.9 ± 0.3 b = Do not exceed 250 ml. Single injection volume depends on the vascular area to be
examined
zure threshold such as neuroleptics, analgesics, anti-emetics, and phenotiazine de-
300 521 ± 24 8.1 ± 0.7 4.5 ± 0.4 rivatives should be discontinued 48 hours before the examination. Treatment should
350 618 ± 29 14.5 ± 1.1 7.5 ± 0.6 c = Do not exceed 350 ml
not be resumed until 24 hours post-procedure. Anticonvulsant therapy must not be
400 726 ± 34 27.5 ± 2.3 12.6 ± 1.1 4.3 Contra-indications Hypersensitivity to the active principle and to any of discontinued and should be administered in optimal dosage. In relation to the proce-
*Vapour tension method its ingredients. Intravascular administration There are no precise and abso- dure. Coagulation, flushing of catheters. A property of non-ionic contrast media is
lute contraindications to the use of non-ionic uroangiographic contrast media. the extremely low interference with normal physiological functions. Non-ionic contrast
4. CLINICAL PARTICULARS media have less anti-coagulant activity in-vitro than ionic contrast media. Medical
4.1 Therapeutic indications This medicinal product is for diagnostic use only Investigations of the female genitalia are contraindicated in suspected or con-
firmed pregnancy and in cases of acute inflammation. Intrathecal administra- personnel performing vascular catheterisation should be aware of this and pay me-
Iomeron 150 Infusion urography, digital substraction phlebography, CT (brain ticulous attention to the angiographic technique and catheter flushing so as to mini-
and body) cavernosography, intravenous and intraarterial DSA, ERCP, MCU, MCU tion Concomitant administration of Iomeprol with corticosteroids is contraindi-
cated (see 4.5 Interactions). Due to overdose considerations, immediate repeat mize the risk of procedure-related thrombosis and embolism, including catheter
in paediatrics. Iomeron 200 Peripheral phlebography, digital subtraction phle- flushing with physiological saline solution (if necessary with heparin added). Observa-
bography, CT (brain and body), cavernosography, intravenous and intraarterial myelography in the event of technical failure is contraindicated.
4.4 Special warnings and special precaution for use Special Warnings General for tion of the patient. Intravascular administration of contrast media should, if possible,
DSA, ERCP, arthrography, hysterosalpingography, cholangiography, retrograde be done with the patient lying down. The patient should be kept under close supervi-
urethrography, retrograde pyelo-ureterography, myelography. Iomeron 250 Intra- all administration routes: Consideration of possible serious side effects, the use of
iodinated contrast media should be limited to cases for which there is a precise need sion for 15 minutes following the injection as the majority of severe reactions occur at
venous urography, peripheral phlebography, CT (brain and body), intravenous and this time. Intrathecal administration. After completion of direct cervical or lumbo-cer-
intraarterial DSA, myelography. Iomeron 300 Intravenous urography (in adults for a contrast examination. The need should be evaluated on the basis of the clinical
status of the patient, in particular in relation to history of pathologies of the cardiovas- vical procedures: - raise the head of table steeply (45° angle) for about two minutes
and paediatrics), peripheral phlebography, CT (brain and body), cavernosography, to restore CM to lower levels, - raise head of stretcher to at least 30° before moving
intravenous DSA, conventional angiography, intraarterial DSA, angiocardiography cular, renal and/or hepatobiliary systems. The use of contrast media should be
avoided in case of Waldenstroem’s paraproteinemia, and multiple myeloma and of patient into it; - avoid excessive and particularly active patient movement or straining;
(in adults and paediatrics), conventional selective coronary arteriography, inter- - maintain the patient under close observation, quiet and in a “head up” position, es-
ventional coronary arteriography, ERCP, arthrography, hysterosalpingography, advanced hepato and/or renal diseases. Cardioangiographic diagnostic procedures
that involve the use of any radiopaque contrast media should be carried out in Hospi- pecially in the first few hours; - the patient should remain supine and at bed rest
fistulography, discography, galactography, cholangiography, dacryocystography, during this period; - encourage oral fluids and diet as tolerated. Pre-testing. Sensitiv-
sialography, retrograde urethrography, retrograde pyelo-ureterograpy, myelogra- tals where appropriate emergency facilities and personnel trained in life support is
readily available. After any other contrast-enhanced X-ray procedures, competent ity test doses are not recommended since severe or fatal reactions to contrast media
phy. Iomeron 350 Intravenous urography (in adults and paediatrics), CT (body), are not predictable from a patient’s history or a sensitivity test. Extravasation: Extreme
intravenous DSA, conventional angiography, intraarterial DSA, angiocardiogra- personnel and adequate emergency facilities should be available (AMBU, oxygen,
antihistaminics, vasoconstrictors, cortisonics, etc.) in the radiology departments of caution during injection of contrast media is necessary to avoid extravasation. This is
phy (in adults and paediatrics), conventional selective coronary arteriography, especially important in patients with severe arterial or venous disease.
interventional coronary arteriography, arthrography, hysterosalpingography, public or private clinics. After any other contrast-enhanced X-ray procedures, compe-
tent personnel and adequate emergency facilities should be available (AMBU, oxygen, 4.5 Interaction with other medicinal products and other forms of interaction
fistulography, galactography, retrograde cholangiography, dacryocystography, Epidural and intrathecal corticosteroids should never be concurrently administered
sialography. Iomeron 400 Intravenous urography (in adults including those with antihistaminics, vasoconstrictors, cortisonics, etc.) in the radiology departments of
public or private clinics. Special care should be taken in patients with suspected when iodinated contrast media are used, because corticosteroids may promote and
renal impairment or diabetes), CT (body), conventional angiography, intraarterial affect the signs and symptoms of arachnoiditis. (see 4.3 Contraindications) Thyroid
DSA, angiocardiography (in adults and paediatrics), conventional selective coro- thrombosis, phlebitis, severe ischemia, local infection or artero-venous obstruction.
Use in specific patients: Neonates, infants, children. Young infants (age < 1 year) function tests. Following administration of iodinated contrast media, the capacity
nary arteriography, interventional coronary arteriography, fistulography, galactog- of the thyroid tissue to take up radioisotopes for the diagnosis of thyroid disorders
raphy, dacryocystography, sialography. CT: Computed Tomography, DS: Digital especially neonates, are particularly susceptible to electrolyte imbalances and
haemodynamic alterations. Care should be taken regarding the dosage to be used, is reduced for up to two weeks, or even longer in individual cases. The results of
Subtraction, DSA: Digital Subtraction Angiography, ERCP: Endoscopic Retrograde Protein Binding Iodine and radioactive iodine uptake studies, which depend on iodine
Cholangio-Pancreatography, MCU: Micturating Cisto-Urethrography. the details of the procedure and the patient’s status. Elderly. The elderly are at special
risk of reactions due to CM high dosage. Myocardial ischemia, major arrhythmias and estimations, will not accurately reflect thyroid function for up to 16 days follow-
4.2 Posology and method of administration Instructions for use: Dosage and ing administration of iodinated contrast media. However, thyroid function tests not
rate of administration may vary depending on the clinical question, the tech- extrasystoles are more likely to occur in these patients. The frequently encountered
combination of neurological disturbances and severe vascular pathologies constitutes depending on iodine estimations, e.g., T3 resin uptake and total or free thyroxine
nique to be employed, the body area to be examined, the instrumentation, as (T4) assays are not affected. Oral Cholecystographic Agents. Recent literature has
well as on the age, body size, cardiac output and patient’s clinical conditionsIn a serious complication. The probability of acute renal insufficiency is higher in these
subjects. Women Of Child-Bearing Potential: Appropriate investigations and mea- revealed no evidence of interactions of renally-excreted contrast media with oral
the CNS the imaging window has been shown to be up to 60 minutes after the cholecystographic contrast media. Laboratory tests. High concentrations of contrast
administration. In the liver delayed imaging can be performed between 40 and sures should be taken when exposing women of child-bearing potential to any X-ray
examination, whether with or without contrast medium. Use in patients with specific media in serum and urine can interfere with laboratory test results of bilirubin, pro-
120 minutes following the injection, depending on the individual imaging needs. teins or inorganic substances (e.g. iron, copper, calcium, phosphate).
pathologic conditions. Hypersensitivity to iodinated contrast media. Hypersensitiv-
Indication Formulation mg Proposed dosages ity or a previous history of a reaction to iodinated contrast media also increases the 4.6 Pregnancy and lactation Animal studies do not indicate any teratogenic or
(iodine)/ml risk of recurrence of a severe reaction with non ionic media. Allergic disposition. It is foetotoxic effects. As with other non-ionic contrast media, there are no adequate
Intravenous urography 250, 300, 350, 400 Adults: 50 - 150 ml generally agreed that adverse reactions to iodinated contrast media are more com- and well-controlled studies in pregnant women to confirm no harmful effect also
Newborns: 3 - 4.8 ml/kg mon in patients having a history of allergy: hay fever, hives and food allergy. Asth- in human beings. Whenever possible, radiation exposure, either with or without
Infants: 2.5 - 4 ml/kg matic patients. The risk of bronchospasm, inducing reactions in asthmatic patients, contrast media use, should be avoided during pregnancy and its benefit accurately
Paediatric patients: 1 - 2.5 ml/kga is higher after contrast. Hyperthyroidism, nodular goitre. The small amount of free weighted against the possible risks. Iodinated contrast media are poorly excreted
Infusion urography 150 Adults: 250 ml inorganic iodide that may be present in contrast media, might have some effects on in human breast milk, and from experience it appears there should be no damage
Paediatric patientsa thyroid function: these effects appear more evident in patients with hyperthyroidism or to the breast-fed baby. However, as a cautionary measure, breast-feeding should
goitre. Thyroid storms have been reported following administration of ionic contrast be discontinued prior to the administration of iomeprol and should not be recom-
Peripheral phlebography 200, 250, 300 Adults: 10 - 100 ml. repeat as
media. Intraarterial and intravenous administration. Use in patients with specific menced until at least 24 hours after the administration of the contrast medium.
necessaryb
pathologic conditions. Renal failure. Pre-existing renal impairment may predispose 4.7 Effects on ability to drive and use machines No data is available. However,
(10 - 50 ml upper extremities;
to acute renal dysfunction following contrast media administration. Preventive mea- given the rare possibility of delayed adverse reactions to contrast media, driving
50 - 100 ml lower extremities)
sures include: identification of high risk patients; ensuring adequate hydration before or using machinery should be avoided for 24 hours following the administration.
Phlebography in DS 150, 200 Adults: 10 - 100 ml. repeat as 4.8 Undesirable effects General The use of iodinated contrast media may cause
necessaryb CM administration, preferably by maintaining i.v. infusion before and during the pro-
cedure and until the CM has been cleared by the kidneys; avoiding whenever possible, untoward side effects. They are usually mild to moderate. However, more serious
(10 - 50 ml upper extremities; reactions up to anaphylactoid shock, with possible fatal outcome, may occur. In
50 - 100 ml lower extremities) the administration of nephrotoxic drugs or major surgery or procedure such as renal
angioplasty, until the CM has been cleared; postponing a new contrast agent exami- most cases reactions occur within minutes of dosing up. However, reactions may
CT brain 150, 200, 250, 300 Adults: 50 - 200 ml manifest also later on up to 24 hours from the injection, depending on the adminis-
Paediatric patientsa nation until renal function returns to pre-examination levels. Patients on dialysis may
receive CM, such as iomeprol, before dialysis.Diabetes mellitus. The presence of tration route. Anaphylaxis (anaphylactoid/hypersensitivity reactions) may manifest
CT body 150, 200, 250, 300, Adults: 100-200 ml with various symptoms, and rarely does any one patient develop all the symptoms.
350, 400 Paediatric patientsa
renal damage in diabetic patients is one of the factors predisposing to renal impair-
ment following CM administration. This may precipitate lactic acidosis in patients who Typically, in 1 to 15 min (but rarely after as long as 2 h), the patient complains
Cavernosography 150, 200, 300 Adults: up to 100 ml are taking biguanides. As a precaution, biguanides should be stopped 48 hours prior of feeling abnormal, agitation, flushing, feeling hot, sweating increased, dizziness,
Intravenous DSA 250, 300, 350, 400 Adults: 100-250 ml to the CM examination and reinstated only after control of renal function has been lacrimation increased, rhinitis, palpitations, paraesthesia, pruritus, head throbbing,
Paediatric patientsa regained. Multiple myeloma, paraproteinaemia (Waldestroem’s paraproteinemia). pharyngolaryngeal pain and throat tightness, dysphagia, cough, sneezing, urticaria,
Conventional angiography It is necessary to consider that the presence of myelomatosis or paraproteinaemias is erythema, and mild localised oedema or angioneurotic oedema and dyspnoea
Arteriography of upper 300, 350 Adultsb a factor predisposing to renal impairment following CM administration. Adequate hy- owing to tongue and laryngeal oedema and/or laryngospasm manifesting with
extremities: dration and monitoring the renal function are recommended. Phaeochromocytoma. wheezing and bronchospasm. Nausea, vomiting, abdominal pain, and diarrhoea
Arteriography of pelvis and 300, 350, 400 Adultsb These patients may develop severe (rarely uncontrollable) hypertensive crises follow- are less common. These reactions, which can occur independently of the dose ad-
lower extremities ing intravascular CM-usage during radiological procedures. Sickle Cell Disease. ministered or the route of administration, may represent the first signs of circulatory
Abdominal arteriography: 300, 350, 400 Adultsb Contrast media may promote sickling in individuals who are homozigous for sickle cell collapse. Administration of the contrast medium must be discontinued immediately
Arteriography of descending 300, 350 Adultsb disease. Adequate hydration is recommended. Myasthenia Gravis. The administra- and, if needed, appropriate specific treatment urgently initiated via venous access.
aorta: tion of iodinated contrast media may aggravate myasthenia signs and symptoms. Severe anaphylactic reactions involving the cardiovascular system, such as vaso-
Severe liver and renal dysfunctions. It is necessary to consider that a combination of dilatation, with pronounced hypotension, reflex tachycardia, dyspnoea, agitation,
Pulmonary angiography: 300, 350, 400 Adults: up to 170 ml
severe hepatic and renal impairment can delay CM excretion, therefore predisposing cyanosis and loss of consciousness progressing to respiratory and/or cardiac arrest
Cerebral angiography: 300, 350 Adults: up to 100 ml may result in death. These events can occur rapidly and require full and aggressive
Paediatric arteriography: 300 Children: up to 130 mla to untoward reactions. Severe cardiovascular disease.There is an increased risk of
severe reactions in individuals with severe cardiac disease and particularly in those cardio-pulmonary resuscitation. Primary circulatory collapse, can occur as the only
Interventional: 300, 350, 400 Adultsb and/or initial presentation without respiratory symptoms or without other signs or
Paediatric patientsa
with heart failure and coronary artery disease. The intravascular CM injection may
precipitate pulmonary oedema in patients with manifest or incipient heart failure, symptoms outlined above. From Clinical Studies Adverse experiences reported
Intraarterial DSA whereas CM administration, in pulmonary hypertension and heart valvular diseases, among patients treated with Iomeprol during clinical trials are shown below.
- Cerebral: 150, 200, 300, 350 Adults: 30 - 60 ml for general view; may lead to pronounced haemodynamic changes. Ischaemic ECG changes and major Common Uncommon Rare
5 - 10 ml for selective injections arrhythmias are commonest in elderly patients and in those with preexisting cardiac Cardiovascular Bradycardia, Vasodilatation,
Paediatric Patientsa disease: their frequency and severity appear to be related to the severity of cardiac (mainly after cardio- tachycardia, cyanosis, circulatory
- Thoracic: 200, 300 Adultsb: 20 - 25 ml (aorta) repeat as impairment. Severe and chronic hypertension may increase the risk of renal damage vascular procedures/ hypertension, collapse
necessary 20 ml (bronchial arteries) following CM administration and the risks associated with the catheterisation proce- interventions) hypotension
- Aortic arch: 150, 200, 300, 350 Adultsc dure. CNS disorders. Particular care should be paid to the intravascular administration Nervous System Asthenia, Dizziness, paralysis, Tremor, muscle
- Abdomen: 150, 200, 250, 300 Adultsc of CM in patients with acute cerebral infarction, acute intracranial haemorrhage, and syncope, agitation spasms,
conditions involving blood-brain-barrier (BBB) damage, brain oedema and acute de- headache confusion, loss of
Aortography 150, 200, 300, 350 Adultsc myelination. The presence of intracranial tumors or metastases and a history of epi- consciousness,
Translumbar aortography 150, 200, 300 Adultsb lepsy may increase the probability of the occurrence of convulsive seizures. Neuro- visual field defect,
Peripheral arteriography: 150, 200, 250, 300 Adults: 5 - 10 ml for selective logical symptoms due to degenerative, inflammatory or neoplastic cerebrovascular aphasia, convulsions,
injections up to 250ml pathologies may be exacerbated by CM administration. Vasospasm and consequent coma
Paediatric patientsa cerebral ischaemic phenomena may be caused by intravascular injections of CM, Gastrointestinal Nausea Vomiting
Interventional: 150, 200, 300 Adults: 10-30 ml for selective often procedurally related and possibly triggered by the tip of the catheter or excess of system
injections up to 250ml catheter pressure. Patients with symptomatic cerebrovascular diseases, recent stroke
Angiocardiography 300, 350 ,400 Adultsb or frequent TIA (transient ischaemic attack) have an increased risk of transient neuro-
Paediatric patientsa logical complications. Alcoholism. Acute and chronic alcoholism have been proven

www.braccoimaging.com

Respiratory system Dyspnoea, nasal rare, generally mild and in the form of skin reactions. However, the possibility of
congestion, severe anaphylactoid reactions cannot be excluded. (see beginning of chapter “Un-
laryngeal desirable effects” ). As with other iodinated contrast media, pelvic pain and malaise
oedema may occur after hysterosalpingography.
Skin and Wheals, pruritus, 4.9 Overdose Overdose may lead to life-threatening adverse effects mainly through
Subcutaneous Tissue rash effects on the pulmonary and cardiovascular system. Treatment of overdosage is di-
General Injection site Back pain, chest Anaphylactoid reaction rected toward the support of all vital functions, and prompt institution of symptomatic
warmth and pain, rigors, injection (characterized therapy. Iomeprol does not bind to plasma or serum proteins and is therefore dialys-
pain, pallor site haemorrhage, by cardio- able. If needed, hemodialysis can be used to eliminate iomeprol from the body. If
pyrexia, sweating vascular,respiratory intracranial entry of the medium occurs, prophylactic anticovulsant treatment with
increased and cutaneous diazepam or barbiturates orally for 24 to 48 hours should be considered.
symptoms) 5. PHARMACOLOGICAL PROPERTIES
Renal and Urinary Renal insufficiency, 5.1 Pharmacodynamic properties Pharmacotherapeutic category: Radiological
Disorders oliguria, proteinuria, contrast media: hydrosoluble, nephrotropic, low osmolality. ATC code: V08AB10. The
blood creatinine active ingredient of Iomeron formulations is iomeprol, N,N’-bis(2,3-dihydroxypropyl)-
increased 5-[(hydroxyacetyl)-methylamino]-2,4,6-tri-iodo-1,3-benzenedicarboxamide, a tri-
iodinated, non-ionic contrast agent, and is indicated for use in X-ray examinations.
Some of these events may occur as a consequence of the procedure. Post Mar- 5.2 Pharmacokinetic properties Intravascular Administration The pharmaco-
keting Surveillance. The following undesirable effects have been reported during kinetic, tolerability and diagnostic efficacy of Iomeprol in solutions containing up
post- marketing in <3/10.000 patients. Intravascular and intra-thecal administra- to 400 mg iodine/mL have been determined in healthy volunteers and patients
tion: - General: shock, malaise, fatigue, hot flushes, flushing, cold sweat, coldness requiring urographic, angiographic, computed tomography (CT) and body cav-
local, taste abnormality, thirst, injection site reaction. - Nervous system: hyperkinetic ity examinations. There were no clinically significant changes in laboratory test
syndrome, encephalopathy, paralysis, oculomotor nerve paralysis, paraesthesia, values and vital signs. The pharmacokinetic of Iomeprol, for intravascular admin-
dysarthria, dizziness, dysphonia,faecal incontinence, brain oedema, -Cardiovascu- istration, when described by a two-compartment model, shows a rapid phase for
lar: cardiac arrest, myocardial infarction, angina pectoris, extrasystoles, arrhythmia, drug distribution and a slower phase for drug elimination. In healthy volunteers
ventricular or atrial fibrillation, tachycardia, palpitations, atrioventricular block, elec- the mean half-lives of the distribution and elimination phases of Iomeprol were
trocardiogram abnormal, ST segment elevation. - Respiratory: respiratory arrest, 23 14 (s) min and 109 20 (s) min, respectively. Iomeprol is excreted mainly
pulmonary oedema, acute respiratory distress syndrome (ARDS), bronchospasm, through the kidneys following intravascular administration. In the absence of
asthma, pharyngeal oedema, laryngeal stridor, rhinitis, cough, hyperventilation, renal dysfunction, the cumulative urinary excretion of iomeprol, expressed as
hypoxia, pharynx and/or laryngeal discomfort. - Skin and subcutaneous tissue disor- percentage of administered intravenous dose, is approximately 24 to 34% at 60
ders: angioneurotic oedema, eczema, urticaria, wheals - cold sweat., - Vascular (ex- minutes, 84% at 8 hours, 87% at 12 hours, and 95% in the 24 to 96 hour pe-
tracardiac): cerebrovascular disorder, transient ischaemic attack.- Gastrointestinal riod after administration. In patients with impaired renal function, the elimination
disorders: pancreatitis acute, ileus, diarrhea, abdominal pain, salivary hypersecre- half-life is prolonged dependent upon the degree of impairment. Iomeprol does
tion, dysphagia. - Urogenital: urinary incontinence, blood urea increased. - Senses: not bind to serum or plasma proteins. Intra-thecal Administration The pharma-
parosmia - Eye disorders: blindness transient, visual disturbance, conjunctivitis, cokinetics of iomeprol after intra-thecal administration shows that Iomeprol is
lacrimation increased, photopsia, photophobia. - Musculoskeletal: arthralgia, muscle completely absorbed from the cerebrospinal fluid about 3 to 6 hours. The half-
stiffness. - Psychiatric disorders: amnesia, anorexia, anxiety, somnolence. - Liver and life of elimination is between 8 to 11 hours and is independent from the dose.
biliary system: liver function tests abnormal. - Platelets, bleeding and coagulation: Plasma concentrations were quantifiable up to 24 hours in 93% of the patients. It
thrombocytopenia. Administration to body cavities Blood amylase increase is com- is completely excreted from the body through the kidney as unchanged Iomeprol.
mon following ERCP (Endoscopic retrograde cholangiopancreatography). Rare cases The majority of urinary excretion occurs in the first 24 hours post-dose, with
of pancreatitis have been described. The reactions reported in cases of arthrography smaller percentage excreted during the 24-48 hour period.
and fistulography usually represent irritative manifestations superimposed on pre- 5.3 Preclinical safety data Pre-clinical data reveal no special hazard for humans
existing conditions of tissue inflammation. Generalised hypersensitivity reactions are based on conventional studies of safety pharmacology, repeated dose toxicity,
IOPAMIDOL INJECTION - CORE SUMMARY OF PRODUCT CHARACTERISTICS Crystals may occasionally be found in a bottle of iopamidol injection® solution. It
1. NAME OF THE MEDICINAL PRODUCT IOPAMIRO® IOPAMIRON® ISOVUE® has been demonstrated that this is caused by a damaged or defective container,
SOLUTRAST® JOPAMIRO® JOPAMIRON® NIOPAM® mg/ml injectable solution. and the contents should therefore not be used. Iopamidol injection®, as with
(The trade name is different in different countries; please also see section 7). other iodinated contrast media, may react with metal surfaces containing copper
2. QUALITATIVE AND QUANTITATIVE COMPOSITION: (e.g. brass), so the use of equipment where the product comes into direct contact
Active ingredient iopamidol injection® with such surfaces should be avoided. Use of contrast media must be limited
150 mg/ml 200 mg/ml 300 mg/ml 370 mg/ml to cases where there is a precise clinical indication for the procedure. Prod-
injectable injectable injectable injectable ucts for cardioangiographic examination may only be administered in hospitals
solution solution solution solution and clinics equipped and staffed for emergency intensive care. For other, more
common diagnostic procedures requiring use of contrast agents, the radiological
IOPAMIDOL 306.2 408.2 612.4 755.3
departments, whether public or private, should be supplied at all times with all
3. PHARMACEUTICAL FORM: injectable solution equipment and drugs necessary for treatment of any emergency situation (Ambu
4. CLINICAL PARTICULARS balloon, oxygen, antihistamines, vasoconstrictors, cortisones, etc.). Do not limit
4.1 Therapeutic indications: non-ionic, water-soluble contrast medium for fluid intake of babies and children and correct any water or electrolyte imbal-
radiological diagnostic procedures. ance before use of hypertonic contrast media. Radiological examinations should
4.1.1 Neuroradiology: - Myeloradiculography - Cisternography and Ventricu- only be performed in patients with hyperthyroidism if the attending physician
lography considers it absolutely necessary. In patients scheduled for thyroid examination
4.1.2.1 Angiography: - Cerebral angiography - Coronary angiography - Tho- with radioactive iodine, bear in mind that iodine uptake by the thyroid gland will
racic aortography - Abdominal aortography - Angiocardiography - Selective be reduced for several days, sometimes up to two weeks, after use of renally
visceral arteriography - Peripheral arteriography - Venography excreted iodized contrast medium.
4.1.2.2 Digital subtraction angiography (D.S.A): - cerebral artery D.S.A., 4.4.1 Neuroradiological precautions: In the event of liquid flow blockage,
peripheral artery D.S.A., abdominal D.S.A. remove as much of the contrast agent as possible. Patients under treatment
4.1.3 Urography: - Intravenous urography. with anticonvulsants must continue treatment before and after the radiological
4.1.4 Other indications: Contrast enhancement in C. T. (computerized axial examination. Should a convulsive seizure occur during the examination, intra-
tomography) and - Arthrography - Fistulography - Hysterosalpingography venous administration of diazepam or sodium phenobarbital is recommended.
Iopamidol injection® 150 mg/ml injectable solution is indicated for pediatric 4.4.2 Angiography precautions: Advanced arteriosclerosis, hypertension,
radiology and digital angiography. heart failure, major systemic diseases, recent cerebral embolism or thrombosis
4.2 Posology and method of administration increase the risk of severe side effects with this type of examination. During
4.2.1 Neuroradiology: the angiocardiographic examination, special attention should be paid to the
condition of the right heart and pulmonary circulation; in the event of failure,
Concentration (mg I/ml) Recommended dose (ml)
additional volumes of contrast medium may provoke circulatory overload with
Myeloradiculography 200-300 5-15 brachycardia and systemic hypotension. Injection of contrast medium into the
Cisternography and Ventriculography 200-300 3-15 right heart of cyanotic neonates with pulmonary hypertension and impaired
4.2.2 Angiography: heart function requires particular caution. During aortic arch examination, care-
ful positioning of the catheter tip is recommended. Excess pressure from the
Concentration (mg I/ml) Recommended dose (ml) injector into the brachiocephalic branches may cause hypotension, bradycardia
Cerebral angiography 300 5-10 per bolus and CNS injury. Likewise, excess pressure from the automatic pump in abdomi-
Coronary angiography 370 8-15 per bolus nal aortography may cause renal infarction, spinal cord injury, retroperitoneal
Angiocardiography 370 1.0-1.2/kg hemorrhage, and intestinal infarction and necrosis. In peripheral arteriography,
Thoracic aortography 370 1.0-1.2/kg use of iopamidol injection® 370 mg/ml injectable solution may cause a painful
Abdominal aortography 370 1.0-1.2/kg reaction, which is not found with the “300” concentration. It has been dem-
Selective visceral arteriography 300-370 according to examination onstrated in vitro that at equal concentrations, nonionic contrast media have
a lower inhibitory effect on coagulation activity than ionic contrast media. It
Peripheral arteriography 300-370 40-50
Digital subtraction angiography 150-370 according to examination is therefore necessary to follow angiographic procedures correctly: catheters
must be frequently washed and prolonged contact between blood and the con-
Venography 300 30-50
trast medium in catheters and syringes must be avoided.
4.2.3 Urography: The recommended dose for this type of examination is 30- 4.5 Interaction with other medicinal products and other forms of interac-
tion: Do not mix other drugs with the contrast medium during injection.
50 ml in adults. The reduced induction of osmotic diuresis makes iopamidol
injection® 370 mg/ml injectable solution particularly suitable for patients with 4.5.1 Intrathecal application: Neuroleptics must be completely avoided, as they
lower the seizure threshold. The same applies to analgesics, antihistamines and
mild or moderate renal insufficiency and neonates. Diagnostically useful ne-
phrography may be obtained even in patients with severe renal insufficiency. phenothiazine group sedatives. Wherever possible, treatment with such drugs
should be suspended at least 48 hours before administration of the contrast
4.2.4 Other diagnostic procedures:
medium and may be resumed not earlier than 12 hours after the examination.
Concentration (mg I/ml) Recommended dose (ml)
4.6 Pregnancy and lactation: Radiological examinations should only be performed
Contrast enhancement in C. T. 300-370 0.5-2/kg in pregnant women if the attending physician considers it absolutely necessary.
Arthrography 300 4.7 Effects on ability to drive and use machines: Nothing to report.
Fistulography 300 4.8 Undesirable effects: Use of organic iodine compounds may cause secondary
Hysterosalpingography 200-300-370 5-20 undesired effects and anaphylactic or medication-type shock: nausea, vomiting,
widespread erythema, generalized sensation of heat, headache or symptoms of co-
For contrast enhancement in C.T. scans, the contrast medium may be injected
intravenously as a bolus, by infusion or by a combination of the two. For hyster- ryza of laryngeal edema, fever, sweating, asthenia, dizziness, pallor, dyspnea, or mild
hypotension. Skin reactions may occur as various types of rash or widespread blister
oalpingography, the total dose to be injected depends on the patient’s anatomi-
cal, biological and pathological condition. formation. More severe reactions involving the cardiovascular system, such as pe-
ripheral vasodilation with pronounced hypotension, tachycardia, dyspnea, agitation,
4.3 Contra-indications: There are no specific absolute contraindications for use
of these substances, with the realistic exception of Waldenström’s macroglob- cyanosis and loss of consciousness may require emergency treatment.
4.8.1 Neuroradiology: Clinical studies have shown good general tolerability,
ulinemia, multiple myeloma and severe liver or kidney diseases. The intrathecal
use of organic iodized contrast media may be contraindicated for patients with especially by the central nervous system. Side effects have been reported:
headache, sometimes with delayed onset, nausea, vomiting, pain at the injec-
a history of epilepsy. The presence of blood in the cerebral spinal fluid also con-
traindicates the use of iopamidol injection®. In this case, the operator should tion site, generally mild and of short duration; more rarely, dizziness, neck stiff-
ness, lumbar pain, sciatic-type pain in the legs, often as transient worsening
carefully assess the need for the diagnostic procedure against any possible risks
to the patient. Female genital tract examination is contraindicated during con- of existing symptoms, and temperature increase. Exceptionally, patients have
developed muscle spasms or generalized convulsions, sometimes relating to
firmed or suspected pregnancy and in the case of acute inflammation.
4.4 Special warnings and special precaution for use: Once opened, the bottle an epilepsy under treatment with neuroleptics and involuntary overdose. Very
rare cases of transitory mental confusion have been observed.
must be used immediately; any remaining contrast medium must be discarded.
www.braccoimaging.com
X-RAY
genotoxicity, toxicity to reproduction. Results from studies in rats, mice and dogs
demonstrate that iomeprol has an acute intravenous or intra-arterial toxicity similar
to that of the other non-ionic contrast media, as well as a good systemic tolerability
after repeated intravenous administrations in rats and dogs. LD50 of iomeprol in g
(Iodine)/kg and the relevant 95% confidence limits in animals are as follows: Intra-
venous administration: 19.9 (19.3-20.5) (mouse); 14.5 (13.2-16.0) (rat); > 12.5
(dog) Intraperitoneal administration: 26.1 (23.3-29,2) (mouse); 10 (8.9-11.3)
(rat); Intracerebroventricular administration: 1.4 (1.3-1.6) (mouse); Intracisternal
administration: >1.2 (rat) Intracarotid administration: 5.8 (4.64-7.25) (rat)
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients Trometamol, hydrochloric acid (d=1.18), water for injection
6.2 Incompatibilities Contrast media must not be mixed with other medicinal
products, to avoid eventual incompatibilities.
6.3 Shelf life 5 years
6.4 Special precautions for storage Expiry date refers to the product stored cor-
rectly in intact packaging. Protect from light. Although the sensitivity of iomeprol
to X-rays is low, it is advisable to store the product out of reach of ionizing radia-
tion. Parenteral products should be inspected visually for particulate matter and
discoloration prior to administration, whenever solution and container permit. Do
not use the solution if it is discolored or particulate matter is present.
6.5 Nature and contents of container Type I or Type II glass vials or bottles
with halobutyl stoppers and an aluminium crimp seal.
6.6 Instruction for use/handling Vial or bottles containing contrast media solution
are not intended for the withdrawal of multiple doses. The rubber stopper should
never be pierced more than once. The use of proper withdrawal cannulae for
piercing the stopper and drawing up the contrast medium is recommended. The
contrast medium should not be drawn into the syringe until immediately before
use and should not be diluted. Solutions not used in one examination session or
waste material, such as the connecting tubes, should be disposed. Any residue of
contrast medium in the syringe must be discarded. Bottles of 500 ml should be
used in conjunction with an injector system. After each patient examination, the
connecting tubes (to the patient) and relevant disposable parts should be disposed
because could be contaminated with blood. At the end of the sessions, the left
over solution in the bottle and in the connecting tubes as well as any disposable
parts of the injector system should be discarded. Any additional instructions from
the respective equipment manufacturer must also be adhered to.
7. MARKETING AUTHORISATION INFORMATION
The Marketing Authorisation Holder, Number, and Date of Approval may be dif-
ferent in different Countries. Volumes, presentations, and indications may also
differ. Refer to Local Summary of Product Characteristics. Please contact Bracco
Imaging SpA Via Egidio Folli, 50 20134 Milano- Italy for further information.
8. DATE OF PREPARATION OF THIS DOCUMENT
May 2006
4.8.2 Angiography: Use of Iopamidol in cerebral angiography may provoke side
effects, generally mild and of short duration. A sense of heat around the face and
neck is often experienced. Headache is rarely reported. Cardiovascular reactions
may be common: transitory bradycardia and systemic hypotension, not requiring
treatment. It should be borne in mind that severe neurological reactions may
arise as direct complications of existing patient pathologies. These reactions may
vary and include tonic/clonic convulsions, aphasia, fainting, transient narrow-
ing of field of vision, hemiparesis and coma. In peripheral arteriography, use of
iopamidol injection® 370 mg/ml injectable solution may cause a painful reaction,
which is not experienced with the “300” concentration.
4.8.3 Urography: Side effects which may arise in connection with intravenous
urography are as described in paragraph 4.8.
4.8.4 Other diagnostic procedures: Reactions reported for arthrography and
fistulography are usually related to worsening of an existing inflammatory
condition. Vaso-vagal manifestations may arise during hysterosalpingography.
4.9 Overdose: Most side effects (see point 4.8) are not dose-dependent and may
require therapeutic intervention as specified in point 4.4. In the event of voluntary or
accidental administration of higher than normal doses, excretion should be facilitated
by ensuring patient hydration, as clearance almost totally occurs via the kidney. In
the event of renal insufficiency, whether pre-existing or manifesting after contrast
medium introduction, dialysis will eliminate the contrast medium.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties: Pharmacotherapeutic category: Radio-
logical contrast media: hydrosoluble, nephrotropic, low osmolality. ATC code:
V08AB04 Iopamidol is a non-ionic radio-opaque hydrosoluble substance
with strongly reduced toxicity and no teratogenic effects. Its use at doses 2
to 4 times higher than for clinical use provoked transient bradycardia and
hypotension in dogs, followed by mild hypertension and increased respiratory
frequency. Base values were returned to in 2-4 minutes.
5.2 Pharmacokinetic properties: Excretion: the vast majority is via renal route.
In dogs, 93-95% of the administered dose was excreted renally and 0.5%
through the biliary route in 7-10 hours. In humans, more than 90% of the dose
is excreted by the urinary route in 24 hours. Blood half life in the excretion
QIBTF
5
t
#
JT
BQQSPYJNBUFMZ

NJOVUFT
JO
EPHT
BOE

NJOVUFT
JO

humans. Intrathecal administration leads to circulation in the blood, peaking
from 90-150 mins, with almost total excretion within 24 hours. Iopamidol does
not undergo detectable metabolic processes in animals or humans.
5.3 Preclinical safety data: DL 50 (confidence limits 95%)
Route Animal g/kg
Intravenous Mouse 144.5 (41.0 - 48.2)
Rat 28.2 (23.3 - 34.1)
Rabbit 19.6 (16.9 - 22.5)
Dog 34.7 (30.4 - 39.6)
Intracarotid Rat 23.5 (20.8 - 26.5)
Intracerebral Mouse 3.0 ( 2.5 - 3.5)
Toxic symptoms for lethal and sublethal doses These are practically the same for
different animal species and mainly consist of breathing difficulties and convulsions.
Death occurs in a few hours in almost all cases. Maximum tolerated dose for i.v.
administration repeated daily Rat: 6.0 g/kg, Dog: 8.2 g/kg. Reproductive function In
rats and rabbits doses of up to 8.2 and 4.1 g/kg respectively had no teratogenic
effects. Furthermore, iopamidol does not affect fertility and has no mutagenic effect.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients: Trometamol, Sodium calcium edetate, Hydrochloric acid
(d=1.18), Water for injection
6.2 Incompatibilities: See point 4.5
6.3 Shelf life: 5 years
6.4 Special precautions for storage: The expiry date refers to the product
stored correctly in intact packaging. Protect from light. See point 4.4
6.5 Nature and contents of container: Type I or II glass vials or bottles with halobutyl
stoppers and aluminium crimp seal.
6.6 Instruction for use/handling: See point 4.2.
7. MARKETING AUTHORISATION INFORMATION
The product name, the Marketing Authorisa-
tion Holder, Number, and Date of Approval may
be different in different Countries. Volumes,
presentations, and indications may also differ.
Refer to Local Summary of Product Character-
istics. Please contact Bracco Imaging SpA – Via
Egidio Folli, 50 20134 Milano- Italy for further
information.
8. DATE OF PREPARATION OF THIS DOCUMENT:
April 2009
IMPORTANT ADDRESSES / SPONSORS / CME CREDITS

ORGANISING SECRETARIAT HOTEL ACCOMMODATION / TRAVEL AGENT

Central ESGAR Office Viajes El Corte Inglés, S.A.
Neutorgasse 9 Gran Vía Fernando El Católico, N 3 bajo
AT – 1010 Vienna, Austria ES – 46008 Valencia, Spain
Phone: +43 1 535 89 27 Phone: +34 96 310 71 89
Fax: +43 1 535 70 37 Fax: +34 96 341 10 46
E-Mail: office@esgar.org E-Mail: esgar2009@viajeseci.es

EXECUTIVE DIRECTOR CONFERENCE VENUE

Ms. Brigitte Lindlbauer Palacio de Congresos de Valencia
Avda. Cortes Valencianas, N 60
WEBSITE ES – 46015 Valencia, Spain
www.esgar.org

EXHIBITION MANAGEMENT
MAW – Medizinische Ausstellungsgesellschaft
Freyung 6
AT – 1010 Vienna, Austria
Phone: + 43 1 536 63 35
Fax: + 43 1 535 60 16
E-Mail: maw@media.co.at

SPONSORS
ESGAR WISHES TO GRATEFULLY ESGAR ALSO THANKS THE FOLLOWING
ACKNOWLEDGE THE SUPPORT OF ITS COMPANIES FOR GENEROUSLY SUPPORTING
CORPORATE MEMBERS: THE MEETING:

AGFA HEALTHCARE ESPAÑA

BAYER SCHERING PHARMA ESPAÑA
BOSTON SCIENTIFIC IBERICA S.A
CARESTREAM HEALTH SPAIN
COVIDIEN SPAIN
FUJIFILM ESPAÑA
GE HEALTHCARE ESPAÑA
GUERBET ESPAÑA
PHILIPS HEALTHCARE ESPAÑA
ROVI
SIEMENS ESPAÑA
TOSHIBA MEDICAL SYSTEMS IBERIA

CME CREDITS

The European Society of Gastrointestinal and
Abdominal Radiology, ESGAR, is accredited by the
European Accreditation Council for Continuing Medical
Education (EACCME). The EACCME is an institution
of the European Union of Medical Specialists (UEMS).
www.uems.be
ESGAR 2009 has been accredited with 24 CME
credits.
Regulations:
- Each participant should claim only those hours of
credit that he/she actually spent in the educational
activity (CME record).
- European Accreditation is granted by the EACCME
in order to allow participants to validate the credits
obtained at this activity in their home European
Country.
- EACCME credits are recognised by the American
Medical Association towards the Physician’s
Recognition Award (PRA). To convert EACCME
credit to AMA PRA category 1 credit, contact the
AMA. Please see:
www.ama-assn.org/ama/pub/category/14348.html

5
COMMITTEES

ESGAR MEETING PRESIDENT ESGAR PROGRAMME COMMITTEE

Dr. Luis Martí-Bonmatí CHAIRMAN:

Dr. Pesent University Hospital C. Bartolozzi, Pisa/IT
Resonancia Magnetica - Servicio de Radiologia
Gaspar Aguilar, 90 MEMBERS:
ES – 46017 Valencia, Spain O. Akhan, Ankara/TR
F. Caseiro-Alves, Coimbra/PT
N. Gourtsoyiannis, Heraklion/GR
ESGAR EXECUTIVE COMMITTEE S. Jackson, Plymouth/UK
A. Laghi, Latina/IT
PRESIDENT M. Laniado, Dresden/DE
B. Marincek, Zurich/CH B. Marincek, Zurich/CH
L. Martí-Bonmatí, Valencia/ES
PRESIDENT-ELECT Y. Menu, Paris/FR
Y. Menu, Paris/FR G. Morana, Treviso/IT

VICE PRESIDENT
F. Caseiro-Alves, Coimbra/PT
LOCAL ORGANISING COMMITTEE
SECRETARY
S. Jackson, Plymouth/UK J.M. Alustiza, San Sebastián/ES
C. Ayuso, Barcelona/ES
TREASURER E. Girela Baena, Murcia/ES
A. Palkó, Szeged/HU R. Bouzas, Vigo/ES
J. Lafuente, Madrid/ES
PAST PRESIDENT J. Martínez Rodrigo, Valencia/ES
C. Bartolozzi, Pisa/IT A. Talegón Menéndez, Sevilla/ES
F. Tardáguila Montero, Vigo/ES
BY-LAWS COMMITTEE
C. Matos, Brussels/BE

EDUCATION COMMITTEE HONORARY COMMITTEE

A. Laghi, Latina/IT
Don Filipe and Doña Letizia
MEMBERSHIP COMMITTEE (Prince and Princess of Spain)
J.S. Laméris, Amsterdam/NL
Doña Trinidad Jimenez
MEETING PRESIDENT (Spanish Government Health Minister)
L. Martí-Bonmatí, Valencia/ES
Don Francisco Camps
PRE-MEETING PRESIDENT (Local Government President)
M. Laniado, Dresden/DE
Doña Rita Barberá
PRE-PRE-MEETING PRESIDENT (Mayor of Valencia)
G. Morana, Treviso/IT
Don Manuel Cervera
FELLOWS REPRESENTATIVES (Local Government Health Minister)
L.H. Ros Mendoza, Zaragoza/ES
W. Schima, Vienna/AT Don Francisco Tomás
(University of Valencia Rector)

6
COMMITTEES
ABSTRACT REVIEWING PANEL
D. Akata, Ankara/TR
O. Akhan, Ankara/TR
M.M. Amitai, Tel Aviv/IL
M.A. Bali, Brussels/BE
R.G.H. Beets-Tan, New York, NY/US
P. Boraschi, Pisa/IT
R. Bouzas, Vigo/ES
G. Brancatelli, Palermo/IT
D.J. Breen, Southampton/UK
C. Bru, Barcelona/ES
J.-M. Bruel, Montpellier/FR
F. Caseiro-Alves, Coimbra/PT
C. Catalano, Rome/IT
L. Crocetti, Pisa/IT
M.C. Della Pina, Pisa/IT
A. Denys, Lausanne/CH
M. D’Onofrio, Verona/IT
N. Elmas, Izmir/TR
B. Fox, Plymouth/UK
A.H. Freeman, Cambridge/UK
A.R. Gillams, London/UK
P. Goffette, Brussels/BE
J.A. Guthrie, Leeds/UK
S. Halligan, London/UK
A. Hatzidakis, Heraklion/GR
T. Helmberger, Munich/DE
P. Huppert, Darmstadt/DE
F. Iafrate, Rome/IT
S. Jackson, Plymouth/UK
M. Karcaaltincaba, Ankara/TR
C. Kay, Bradford /UK
H.-U. Laasch, Manchester/UK
A. Laghi, Latina/IT
J.S. Lameris, Amsterdam/NL
E. Leen, London/UK
P. Lefere, Roeselare/BE
R. Lencioni, Pisa/IT
EPOS™ JURY
D. Akata, Ankara/TR
C. Ayuso, Barcelona/ES
R.G.H. Beets-Tan, New York, NY/US
D.J. Breen, Southampton/UK
F. Caseiro-Alves, Coimbra/PT
L. Crocetti, Pisa/IT
N. Elmas, Izmir/TR
A.R. Gillams, London/UK
S. Halligan, London/UK
S. Jackson, Plymouth/UK
A. Laghi, Latina/IT
A. Madureira, Porto/PT
D.E. Malone, Dublin/IE
L. Martí-Bonmatí, Valencia/ES
D.J. Lomas, Cambridge/UK
M. Maher, Wilton/IE
D.E. Malone, Dublin/IE
T. Mang, Vienna/AT
L. Martí-Bonmatí, Valencia/ES
C. Matos, Brussels/BE
R.M. Mendelson, Perth, WA/AU
Y. Menu, Paris/FR
G. Morana, Treviso/IT
M. Morrin, Dublin/IE
E. Neri, Pisa/IT
B. Op De Beeck, Edegem/BE
A. Palkó, Szeged/HU
P.L. Pereira, Heilbronn/DE
P. Pokieser, Vienna/AT
P.K. Prassopoulos, Alexandroupolis/GR
M. Puckett, Torquay/UK
J. Puig Domingo, Sabadell/ES
A.S. Roberts, Cardiff/UK
P. Rodgers, Leicester/UK
G.A. Rollandi, Genova/IT
P.R. Ros, Boston, MA/US
L.H. Ros Mendoza, Zaragoza/ES
W. Schima, Vienna/AT
M. Staunton, Toronto, ON/CA
G.W. Stevenson, Sudbury, ON/CA
J. Stoker, Amsterdam/NL
Z. Tarjan, Budapest/HU
I. Távora, Lisbon/PT
S.A. Taylor, London/UK
V. Valek, Brno-Bohunice/CZ
D. Vanbeckevoort, Leuven/BE
V. Vilgrain, Clichy/FR
D. Weishaupt, Zurich/CH
A. Wuttge-Hannig, Munich/DE
S.D. Yarmenitis, Heraklion/GR
C.J. Zech, Munich/DE
D.F. Martin, Manchester/UK
C. Matos, Brussels/BE
G. Morana, Treviso/IT
N. Papanikolaou, Heraklion/GR
P. Pokieser, Vienna/AT
P.K. Prassopoulos, Alexandroupolis/GR
L.H. Ros Mendoza, Zaragoza/ES
W. Schima, Vienna/AT
M. Staunton, Toronto, ON/CA
Z. Tarjan, Budapest/HU
S.A. Taylor, London/UK
J. Venancio, Lisbon/PT
D. Weishaupt, Zurich/CH
C.J. Zech, Munich/DE
7
1 Huppertz A, Haraida S, Kraus A et al. Enhancement of Focal Liver Lesions at Gadoxetic Acid-enhanced MR Imaging: Correlation with Histopathologic Findings and Spiral CT – Initial Observations. Radiology 2005; 234:468–478
Halavaara J, Breuer J, Ayuso C et al. Liver Tumor Characterization: Comparison Between Liver specifi c Gadoxetic Acid Disodiumenhanced MRI and Biphasic CT – A Multicenter Trial. J Comput Assist Tomogr 2006; 30:345–354
2 Huppertz A, Balzer T, Blakeborough A et al. Improved Detection of Focal Liver Lesions at MR Images: Multicenter Comparison of Gadoxetic Acid-enhanced MR Images with Intraoperative Findings. Radiology 2004; 230:266–275.
Bluemke DA, Sahani D, Blakeborough A et al. Effi cacy and Safety of MR Imaging with Liver specifi c Contrast Agent: U.S. Multicenter Phase III Study. Radiology 2005; 237:89–98

Primovist® 0.25 mmol/mL solution for injection. Composition 1 mL solution for injection contains 181.43 mg gadoxetic acid, Gd-EOB-DTPA disodium, equivalent to 0.25 mmol Gd-EOB-DTPA disodium. Indications Primovist® is indicated for the detection of focal liver lesions and provides information on the character of lesions in T1-weighted magnetic resonance imaging (MRI). This medical product is for diagnostic use
only. Contraindications Hypersensitivity to the active substance or to any of the excipients. Undesirable effects During the clinical development phase the overall incidence of adverse reactions which were classified as related was below 5 %. Most of the undesirable effects were transient and of mild to moderate intensity. No individual adverse reaction reached a frequency greater than 1/100QNervous system disorders
headache, dizziness, paresthesia, taste disturbance, vertigo, akathisia, tremor, parosmiaQCardiac disorders bundle branch block, palpitationQVascular disorders flushing, hypertensionQRespiratory, thoracic and mediastinal disorders dyspnea, respiratory distressQGastrointestinal disorders vomiting, nausea, dry mouth, oral discomfort, salivary hypersecretionQ Skin and subcutaneous tissue disorders rash, pruritus,
maculopapular rash, hyperhidrosisQGeneral disorders and administration site conditions chest pain, injection site reactions, feeling hot, chills, discomfort fatigue,malaise, feeling abnormal. Laboratory changes as elevated serum iron, elevated bilirubin, increases in liver transaminases, decrease of hemoglobin, elevation of amylase, leucocyturia, hyperglycemia, elevated urine albumin, hyponatremia, elevated inorganic
phosphate, decrease of serum proteine, leucocytosis, hypokalemia, elevated LDH were reported in clinical trials. ECGs were regularly monitored during clinical studies and transient QT prolongation was observed in some patients without any associated adverse clinical events. In very rare cases anaphylactoid reactions leading to shock may occur. Precautions General information The usual safety precautions for MRI
must be observed, e.g. exclusion of cardiac pacemakers and ferromagnetic implants. Diagnostic procedures that involve the use of contrast agents should be carried out under the direction of a physician with the prerequisite training and a thorough knowledge of the procedure to be performed. The patient should refrain from eating for two hours prior to examination to reduce the risk of aspiration, as nausea and
vomiting are known possible adverse reactions. Whenever possible, the contrast agent should be administered with the patient lying down. After the injection, the patient should be kept under observation for at least 30 minutes, since experience with contrast media shows that the majority of undesirable effects occur within this time. Caution should be exercised in patients with severe renal impairment due to reduced
elimination capacity of Gd-EOB-DTPA. Patients with renal impairment: There have been reports of Nephrogenic Systemic Fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with - acute or chronic severe renal impairment (GFR< 30ml/min /1.73 m2) or - acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
As there is a possibility that NSF may occur with Primovist®, it should therefore only be used in these patients after careful risk/benefit assessment and if the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). All patients should be screened, in particular patients over the age of 65, for renal dysfunction by obtaining a history and/or laboratory tests.
Haemodialysis shortly after Primovist® administration in patients currently receiving haemodialysis may be useful at removing Primovist® from the body. There is no evidence to support the initiation of haemodialysis for prevention or treatment of NSF in patients not already undergoing haemodialysis. Caution should be exercised in patients with severe renal impairment due to reduced elimination capacity of Gd-EOB-
DTPA. Caution should be exercised when Primovist® is administered to patients with severe cardiovascular problems because only limited data are available so far. It cannot be excluded that Gd-EOB-DTPA may cause torsade de points arrhythmias in an individual patient. Hypersensitivity Allergy-like reactions, including shock, are known to be rare events after administration of gadolinium-based MRI contrast media.
Patients with a history of allergic/allergoid reactions or bronchial asthma might be at higher risk for severe reactions. Most of these reactions occur within half an hour after administration of contrast media. However, as with other contrast media of this class, delayed reactions may occur after hours to days in rare cases. Adequate measures for resuscitation should be made readily available prior to administration of
contrast agents. Hypersensitivity reactions can be more intense in patients on beta-blockers, particularly in the presence of bronchial asthma. It should be considered that patients on beta-blockers may be refractory to standard treatment of hypersensitivity reactions with beta-agonists. If hypersensitivity reactions occur, injection of the contrast medium must be discontinued immediately. Local intolerance Intramuscular
administration may cause local intolerance reactions including focal necrosis and should therefore be strictly avoided. Date of preparation of the text October 2007. Please note! For current prescribing information refer to the package insert and/or contact your local BSP organisation. Bayer Schering Pharma AG, 13342 Berlin, Germany. Adverse reactions can be reported to GPV.CaseProcessing@bayerhealthcare.com

EU.DI.01.2009.0061 April 2009

The Fine Art

of Liver Imaging

Q Mastership 1

in tolerability
Q Masterpieces

Q Master’s degree 2
and characterization
in detection, delineation

diagnosis and treatment

of clear imaging support clear
Defining Liver Imaging
HONORARY COMMITTEE
La Zarzuela Palace
Madrid, February 11, 2009
Dear Friend,
I am pleased to inform you that Their Royal
Highnesses the Prince and Princess of Asturias,
in response to your kind offer, have accepted the
Presidency of the Honorary Committee of the “20th
Annual Meeting and Postgraduate Course of the
European Society of Gastrointestinal and Abdominal
Radiology, ESGAR 2009”, that will be held in
Valencia June 23 rd to 26 th, for which I enclose the
corresponding document.
Sincerely yours,
JAIME ALFONSÍN
La Zarzuela Palace
February 11, 2009
Their Royal Highnesses the Prince and Princess
of Asturias, have accepted the kind request of
Presidency of the honorary committee of the “20th
Annual Meeting and Postgraduate Course of the
European Society of Gastrointestinal and Abdominal
Radiology, ESGAR 2009” that will be held in Valencia,
June 23rd to 26th.
Sincerely yours,
Head of the Royal Household of HM the King.
President of the Organizing Committee Valencia
9
WELCOME
Dear Colleagues and Friends,
Ask twenty abdominal and gastrointestinal radiologists
to defi ne the key developments in the past twenty
years and you probably will get thirty different answers.
Such varied view is less an expression of puzzlement
within our profession but rather a reflection on the
incredible evolutions that have made abdominal and
gastrointestinal radiology the dynamic discipline it is
today. Twenty years ago our role in patient care was
not considered of particular clinical significance. Today
abdominal and gastrointestinal radiology represents
one of the most innovative fields in medical imaging.
Exciting advances based on research in areas of
morphologic and functional imaging have been the
key of growing success of our specialty.
In such a fast moving profession it is of utmost
importance to stay abreast of developments,
innovations and ideas being discussed. The best way
to do that is to meet. Therefore it is my privilege to
invite you on behalf of the Executive Committee of the
European Society of Gastrointestinal and Abdominal
Radiology to celebrate our 20 th Annual Meeting in
lively and dynamic Valencia from June 23 – 26, 2009.
Valencia is the ideal city to celebrate our anniversary,
as it reflects our history pretty much! For long Valencia,
the third largest city in Spain, was in the shadow of
its bigger rivals Madrid and Barcelona. But it is a city
that through innovation and hard work became a very
important part of Spain, a city not only with unique
cultural appeal but also strong industry and sports – it
was the first European city to host the America’s cup
two years ago. It has a long history, being founded
by the Romans 138 B.C. and later falling in the
10
hands of the Arabs before El Cid got it back for the
Christians. That lasted only 8 years, however, and
it was not until 1238 King Jacob of Aragonia won it
back for Christianity and made Valencia the capital of
his kingdom. Banking was established early and the
banks of Valencia financed Queen Isabella’s venture
that ended up in Columbus’ discovering the Americas.
In the time since then Valencia had to suffer through
various wars and secessions but never gave up. One
of the last big innovations was the moving of the main
river Turia, which goes through the city, outside the
centre and making a big park, a green lung for the city.
Change and innovation are at the roots of Valencia’s
success – as mentioned earlier an ideal place for us
to meet as it reflects very much our profession!
This year we already commemorate our 20 th
Anniversary. That is worth a quick look at our history.
It was during the 1988 meeting of the British Institute
of Radiology in Glasgow that a group of foresighted
colleagues were discussing the possibility of founding
a scientific and educational organisation in order to
create a forum to the radiologists in Europe, who
worked in the subspecialty of gastrointestinal
radiology. A year later 18 leading radiologists held a
founding meeting on the occasion of the International
Congress of Radiology in Paris, which laid down the
essential rules and objectives of the Society. At 14:00
on Thursday, July 6, 1989 at the Parc de Versailles,
the “European Society of Gastrointestinal Radiologists”
was brought into being. Daniel Nolan (UK) was
elected as the fi rst Society president, Jean-Michel
Bigot (FR) and Aksel Kruse (DK) were voted in as vice
presidents, Roger Frost (UK) became secretary and
David Beckly (UK) was appointed treasurer. Nicholas
Gourtsoyiannis (GR) agreed on a very short notice to
organise the inaugural meeting in Crete in June 1990.
Further annual meetings were held in various parts
of Europe. In recognition of the role of the Society in
all modalities of imaging of the gastrointestinal tract
and its associated abdominal organs, the name of
the Society was changed at the 1994 meeting in
Taormina to “European Society of Gastrointestinal and
Abdominal Radiology”.
With expanding membership and growing meeting
attendance it became evident that the Society needed
a permanent office led by a professional manager
and supported by a secretarial office. Thus, a Central
Office was set up in Vienna in 1999 and Brigitte
Lindlbauer was appointed as executive director and
manager of the Society in 2002. Over the years the
Society has grown steadily and counts today more
than 800 members. The acceptance and importance
of ESGAR is also illustrated by the success of its
annual meetings: the 2007 meeting in Lisbon saw
an all time high of more than 1400 participants. But
ESGAR is more than just meetings: the generous
support of corporate members of industry enabled
the Society to develop many specific educational
courses such as CT-Colonography, Image-guided
Ablation and Liver Imaging.
The most important feature of the Society’s calendar,
however, is the Annual Meeting and Postgraduate
Course. Carlo Bartolozzi, our President from
2005 – 2007, was in charge of assembling this year’s
scientific and educational programme. I would like
to thank him and the members of his Programme
Committee for arranging a great programme, which
fully supports our aim to build a platform to learn
about latest innovations, to refresh knowledge and to
exchange ideas in order to provide the best possible
care to the patient.
A lot of work has gone into the organisation of the
conference itself as well as the social parts. My
thanks also go to Luis Martí-Bonmatí and his Local
Organising Committee. They are working with
great enthusiasm and will be superb hosts of an
unforgettable 20th Anniversary ESGAR meeting 2009.
Last but not least I would like to mention the Central
Office in Vienna that is working in overdrive again this
year to make sure that the meeting will be prepared
properly. A big “thank you” to Brigitte Lindlbauer and
her staff.
ESGAR has come of age but it is young-at-heart. I
am looking forward to seeing you all in Valencia where
we will raise the glass not only for the past 20 ESGAR
years, but also for many, many more years to come!
Prof. Borut Marincek
President of ESGAR
11
WELCOME
Dear Colleagues and Friends,
As Meeting President, it is my great honour and
pleasure, on behalf of the Local Organising Committee,
to welcome you to the beautiful city of Valencia for
the ESGAR 2009 Annual Meeting and Postgraduate
Course. This outstanding event constitutes the 20 th
Anniversary of our Society’s Annual Meetings and
therefore deserves an outstanding and exciting
scientific programme as well as a lot of the special
ESGAR atmosphere.
The 20th Annual Meeting will be a highly appreciated
forum for integrated abdominal imaging education
and research activities with interactions between
Europe, America and Asia. The ESGAR Executive
Committee, presided by Prof. Borut Marincek, and
all the Programme Committee members, under the
leadership of Prof. Carlo Bartolozzi, have prepared
a scientifically very relevant and socially attractive
and encouraging event in our nice city located at the
sea side. Valencia is proud to host the high quality
of science, topics, clinical advances and research
proposals that will be presented here. As the
ESGAR Meetings continue to attract more and more
participants, senior and junior radiologists, residents in
training, medical students, researchers and technicians
will share a common constructive space and medical
knowledge in Valencia. A close cooperation between
our industrial partners and attendees through the
technical exhibition will revitalise present actions and
future developments in the field.
12
The Programme Planning Committee has constructed
a highly interesting Educational and Scientific
Programme with the traditional quality seal of ESGAR
to offer our distinguished members the opportunity to
share scientific knowledge and technical expertise.
Attendants of this meeting practice all aspects of
abdominal radiology with all imaging modalities. We
are therefore strongly committed to provide them
with an up-to-date, high quality technical exhibition
and scientific programme. We have selected the
best faculty members from European countries and
overseas, providing a timely update of all recent
advances in abdominal imaging, from diagnosis to
intervention, covered from a multidisciplinary and
multimodality perspective.
The Postgraduate Course is dedicated to “Liver
imaging: from morphology to quantification”. The
main interest of the course is to fill the gap between
conventional radiology to evidence-based quantitative
imaging in focal and diffuse liver diseases, with a
comprehensive coverage of most recent advances
and applications.
The Research Corner of ESGAR 2009 will continue
with two highly interesting hot topics devoted to
“Imaging biomarkers” and “Functional evaluation of
the effect of therapy”. These sessions focus on the
importance of quantitative and functional imaging in
evaluating the presence and severity of abdominal
disorders, and assessing the effect of therapy, in a
multimodality arena.
This year there is a wide coverage of interventional
radiology with the “Intervention – a practical approach”
sessions, providing a forum for classroom discussion
devoted to practical issues. Also, the “Clinical Files –
interactive case discussion” will illustrate the various
diagnostic and therapeutic options available, stressing
the central role of clinical based radiology in patient
management. Also, do not miss the “Foundation
Course: Radiologic-pathologic correlations” as well as
the many different lectures and workshops.
As in recent years, Satellite Symposia are scheduled
from Tuesday to Thursday at lunch time. Attendees
to the meeting greatly appreciate the contribution of
industrial partners to the success of the congress.
I would like to thank all authors who submitted
abstracts for oral presentations during the 15 scientific
sessions as well as abstracts for scientific exhibits
presented in the EPOSTM format. It is a great honour to
announce that this year it was possible to surpass the
submissions from last year once more and reach an all
time record high!
Furthermore I would like to thank the reviewing panel
and the EPOS TM jury for reviewing the submissions
and for making certain that the content of our meeting
will be outstanding. Last but not least we would like
to express my gratitude to the Executive and the
Programme Committee, without whose efforts this
final programme could not have been realised.
Although the Valencia Conference Centre has
excellent infrastructure and plenty of exhibition
space and scientific activity, here in Spain the social
component should not be left aside. There are various
opportunities for sharing well-deserved moments of
architecture, gastronomy, friendship, relaxation and
motivation in Valencia. Do not miss the Welcome
Reception at the Congress venue and the ESGAR
Evening at the “Oceanogràfic” – all arranged to
celebrate this Anniversary together!
Finally I also wanted to thank our Spanish colleagues
and the Spanish Abdominal Radiological Society
(SEDIA) for their help and friendship.
Welcome to Valencia! Enjoy your time here!
Luis Martí-Bonmatí
Meeting President
13
HONORARY FELLOW
A.H. FREEMAN, CAMBRIDGE/UK
Alan H. Freeman was born on January 21, 1945 in
Bath, UK.
H e s t u d i e d c l i n i c a l m e d i c i n e a t We s t m i n s t e r
Hospital Medical School, London and received his
Bachelorship in Medicine and Surgery in 1968. He
held house office appointments at Westminster
Hospital and Kingston Hospital in Surrey from 1968 to
1970 and after that became a registrar in Radiology
at Westminster. In 1972 Alan Freeman obtained his
Diploma in Medical Radio-Diagnosis. He occupied
senior registrar posts in Radiology at Addenbrooke’s
Hospital in Cambridge from 1973 – 1974 and was
appointed Consultant Radiologist at that hospital
in 1975, specialising in Gastroenterology.He was
appointed as Associate Lecturer at Cambridge
University in 1976 and has been a Fellow of the Royal
Collegeof Radiologists since 1974.
As a result of a Kodak scholarship Alan Freeman
spent some months in the United States working
with Prof. A. Margulis at the University of California,
San Francisco.
Alan Freeman has acted as Assistant Editor of the
British Journal of Radiology from 1985 to 1997 and
as Assistant Editor for Clinical Radiology from 1997
to 2008. He was Overseas Editor of the West African
Journal of Medical Ultrasound and occasionally edits
papers for GUT and BMJ.
He has been an examiner for the Fellowship of the Royal
College of Radiologists in London (1993 – 1998) and
has also held positions as an external examiner at the
Royal College of Surgeons in Ireland (2000 – 2005), the
College of Physicians and Surgeons in Karachi, Pakistan
(1999 – 2000) and at the University of Malaysia (2003).
HONORARY FELLOWSHIP WILL BE AWARDED DURING THE
OPENING CEREMONY ON TUESDAY, JUNE 23
14
Alan Freeman’s major interest in radiology is the
gastrointestinal tract which encompasses contrast
studies, ultrasound, computed tomography and
endoscopy. He also has an interest in Breast Imaging
and is actively involved in the UK National Breast
Screening Programme.
He has published over 40 articles, written a number of
book chapters and 2 books entitled “Radiology of
the Stomach and Duodenum” and “Radiology for the
Surgeons in Clinical Practice”.
Alan Freeman has given numerous invited lectures,
and has lectured and tutored at various universities
in United Kingdom as well as at the University of
Budapest and the University of Benghazi (Libya).
Since 2006 he has been a lecturer for the ESOR
(European School of Radiology) Galen Foundation
Courses on Colorectal Cancer.
Alan Freeman, who is one of the founding members
of ESGAR and who has participated in every one of
the last 19 Annual ESGAR Meetings, was previously
Secretary General and then Treasurer of the Society. He
also is a member of the British Institute of Radiology,
the British Society of Gastroenterology, the Royal
Society of Medicine, the British Medical Association
and the European Society of Radiology.
His contribution to gastrointestinal and abdominal
radiology and his longlasting support and commitment
to our Society highly qualify Alan Freeman as Honorary
Fellow of the European Society of Gastrointestinal and
Abdominal Radiology.
HONORARY FELLOW
A.J. MEGIBOW, NEW YORK, NY/US
Alec J. Megibow was born in 1947.
He graduated at Case Western Reserve University in
1969 and obtained his medical degree from the State
University of New York in 1974. The next three years
he was a resident in diagnostic radiology at the New
York University Medical Centre and then became as
a fellow in abdominal radiology in 1977. He received
his board certification in 1978. In the same year he
became Assistant Professor at the Department of
Radiology at the New York University and Associate
Professor in 1984. In 1988 Alec Megibow was
appointed Professor at the Department of Radiology
at the same university. In 1999 Alec Megibow also
received his Master in Public Health.
His hospital appointments included teaching at
such prominent facilities as Cornell University
Medical Center, New York Downtown Hospital, and
Hackensack Hospital. From 2001 on he served as
Vice Chairman for education at the Department of
Radiology at New York University Medical Centre
and became Director of Outpatient Imaging Services
in 2005. In addition, he has served as a Visiting
Professor at numerous institutions across North
America including the University of Pennsylvania, the
University of Nebraska, the University of Connecticut,
Emory University, the Mallinkrodt Institute of Radiology
at the Washington University, Columbia University, Yale
University, McGill Medical School, and the University of
Manitoba.
Alec Megibow’s research interest focuses on CT and
MR imaging in liver, pancreas, and alimentary tract as
HONORARY FELLOWSHIP WILL BE AWARDED DURING THE
OPENING CEREMONY ON TUESDAY, JUNE 23
well as non-invasive angiography, cholangiography
and pancreatography.
He has extensively published on these topics having
authored or co-authored more than 150 books, book
chapters, and journal articles, and has presented more
than 230 scientific and professional presentations and
abstracts around the globe.
Many of his former residents and fellows, such as Neil
Rofsky, Bernard Birnbaum, Michael Macari among
others, have become leaders in the field of GI imaging.
Alec Megibow attended the first ESGAR meeting
held in Crete in the summer of 1990. In 2000, he met
Professor Carlo Procacci beginning a fruitful trans-
Atlantic collaboration that has resulted in 2 textbooks
on pancreatic imaging.
Alec Megibow has received multiple awards for editing
such journals as Radiology, the American Journal
of Radiology, and Gastrointestinal Radiology, and
has been honored by the Society of Gastrointestinal
Radiology, the Radiological Society of North America,
the Society of Genitourinary Radiologists and the
American Roentgen Ray Society.
He is also engaged in managed care issues related to
Radiology.
In recognition of his outstanding contribution to
gastrointestinal and abdominal radiology, Alec
Megibow is awarded Honorary Fellowship of the
European Society of Gastrointestinal and Abdominal
Radiology.
15
16
GOLD MEDALLIST
C. BARTOLOZZI, PISA/IT
Carlo Bartolozzi is an inspirational researcher and
visionary who has made invaluable contributions to
gastrointestinal and abdominal radiology.
Born in Jesolo (Venezia), he graduated from Medical
School at the University of Padova in 1972. After
completing his residency, he became Radiology
Assistant at the University of Firenze in 1977 and
Associate Professor in Radiology at the same
institute in 1980. 10 years later he was appointed a
full Professor in Radiology at the University of Pisa
and became Director of the Chair of Radiology and
Chairman of the Radiology Residency Programme
at the University of Pisa, a position he has held until
today. From 1999 – 2007 he was Director of the
Department of Oncology, Transplants, and Advanced
Technologies in Medicine of the University of Pisa.
Carlo Bartolozzi's major fields of scientific interest
are liver imaging with different modalities, diagnosis
of HCC, and interventional procedures for HCC
treatment. He has experimented and developed
innovative techniques in the fi elds of oncology and
gastrointestinal radiology, such as microbubbles
in ultrasound, perfusion imaging in MSCT, and MR
elastography for liver imaging. A productive writer, he
has authored or co-authored over 270 papers and
also published 12 monographs.
From 2000 – 2001 Carlo Bartolozzi was President
of the European Society of Magnetic Resonance in
Medicine and Biology (ESMRMB).
In 2005 he organised the 16th ESGAR Annual Meeting
in Florence, which was a milestone in the history of
ESGAR, both in terms of attendance and atmosphere.
Carlo Bartolozzi has served the Society ever since
1997, when he first entered the Executive Committee
as Fellow Representative. He acted as Chairman of
the Membership Committee from 2000 until 2003
and was elected Vice President of the Society in
2002. Consequently Carlo Bartolozzi was President of
ESGAR from 2005 – 2007. As Programme Committee
THE ESGAR GOLD MEDAL WILL BE AWARDED DURING THE
OPENING CEREMONY ON TUESDAY, JUNE 23
Chairman he was responsible for the outstanding
scientific programmes of ESGAR 2008 and ESGAR
2009. His interest in liver imaging can also be seen as
the ignition spark for the successful ESGAR workshop
series on “Image-guided Ablation” and “Liver Imaging”.
His international reputation has gained him Honorary
Membership of the Belgian Radiological Society
and Austrian Radiological Society, as well as
Corresponding Membership of the Swiss Radiological
Society and Turkish Radiological Society. He has held
invited lectures in over 30 countries. In 2009 Carlo
Bartolozzi’s contributions to the development of
gastrointestinal imaging were highly recognised as he
gave the “Josef Lissner Honorary Lecture” during the
European Congress of Radiology.
Carlo Bartolozzi is Section Editor for Hepatobiliary-
pancreas of the Journal “European Radiology” and
was EURORAD Editor for the Section: Liver, Biliary
System, Pancreas and Spleen from 1997 – 2004.
He acts as partner of the EU founded project for the
European Institute for Biomedical Imaging Research
(EIBIR) and is founding member of the Erasmus Project
Course on MRI (EMRI).
He also coordinated the University of Pisa research
group in over 10 EU funded projects and over 20
Italian projects.
As members of ESGAR we know that Carlo Bartolozzi
has not only a passion for radiology, but he is also a
big friend of the study of history, art and music.”The
use of radiological investigations in these fields
represents a fascinating bridge between our profession
and humanism” said Carlo.
For his tireless efforts and contributions to the Society
over many years and his outstanding achievements in
the field of gastrointestinal and abdominal radiology,
ESGAR presents the Gold Medal to Carlo Bartolozzi
with gratitude.
Because Gd3+ can bite... Control it!

Contrast for Life,

DOTAREM
®

Gadoteric acid
by Choice
Dotarem® 0.5 mmol/mL, solution for injection in vials and pre-filled syringes: Indications and approvals may vary in different countries. Please refer to the local Summary
of Product Characteristics (SPC) before prescribing. Further information available on request. - QUALITATIVE AND QUANTITATIVE COMPOSITION PER 100 mL: Gadoteric acid*
(27.932 g) corresponding to DOTA (20.246 g) - Gadolinium oxide (9.062 g) - Excipients: Meglumine, water for injections (*Gadoteric acid: gadolinium complex of 1,4,7,10
tetraazacyclododedane-N,N’,N’’,N’’’ tetraacetic acid). CLINICAL PARTICULARS: Therapeutic indications: Magnetic Resonance Imaging for cerebral and spinal disease, diseases
Terre Neuve - P08 038 DOT - May 2009.

of the vertebral column, and the other whole-body pathologies (including angiography). Posology and method of administration: The recommended dose is 0.1 mmol/kg,
ie 0.2 mL/kg in adults, children and infants. In angiography, depending on the results of the examination being performed, a second injection may be administered during the same
session if necessary. In some exceptional cases, as the confirmation of isolated metastasis or the detection of leptomeningaeal tumors, a second injection of 0.2 mmol/kg can be
administered. The product must be administered by strict intravenous injection. Contraindications: History of hypersensitivity to gadolinium salts. Contraindications related to MRI: subjects
with a pacemaker, subjects with a vascular clip. Special warnings and special precautions for use: Administer only by strict intravenous injection. Dotarem® must not be administred
by subarachnoid (or epidural) injection. Caution is recommended for anaphylactic-like reactions, renal insufficiency and CNS disorders. There have been reports of Nephrogenic Systemic
Fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with severe renal impairment (GFR < 30 ml/min/1.73 m2). As there is a possibility that
NSF may occur with Dotarem®, it should only be used in these patients after careful consideration. Interactions with other medicinal products and other forms of interaction.
None known to date. Pregnancy and lactation: Dotarem® should be used during pregnancy only if strictly necessary. It is advisable to stop breast-feeding for a few days following
the examination with Dotarem®. Undesirable effects: As for any injection of paramagnetic complex, rare anaphylactic-like reactions exceptionally fatal may occur, requiring an emergency
treatment. Very rare general disorders and incidents related to the injection site (extravasation), very rare skin and subcutaneous tissue disorders, very rare nervous system disorders, very
rare muscular disorders. FRENCH PRESENTATION AND MARKETING AUTHORISATION NUMBER: 358 954.2: 5 mL in vial (glass) - 331 713.4: 10 mL in vial (glass) - 358 953.6:
10 mL in pre-filled syringes (glass) - 331 714.0: 15 mL in vial (glass) - 338 403.0: 15 mL in pre-filled syringes (glass) - 331 715.7: 20 mL in vial (glass) - 338 404.7: 20 mL in pre-filled
syringes (glass). GUERBET - BP 57400 - 95943 Roissy CdG Cedex - tel: +33.(0)1.45.91.50.00 (ref.06/07). For detailed information, see Dictionnaire Vidal. Revised: May 2007.

Para las indicaciones y presentaciones autorizadas en España consultar la ficha técnica local.
INFORMATION SCIENTIFIC PROGRAMME
ABBREVIATIONS
The following abbreviations are used in the programme:
HL Honorary Lecture
IR Interventional Radiology
LS Lecture Session
P EPOS™ Presentation
PG Postgraduate Course
PS Plenary Session
RC Research Corner
SS Scientific Session
SY Lunch Symposia
WS Workshop
CASES OF THE DAY
There is a tradition in ESGAR to offer “unknown cases
of the day”.The cases are accessible via the EPOS™
Workstations located on Level 1 of the conference
centre. Participants have the opportunity to log in with
their badge number and to access and solve the “cases
of the day”. Different cases will be displayed each day
from Tuesday through Friday. Once a participant has
logged in with his/her password and participated in
solving a case, he/she will see the results the next day
when accessing the system again and find out whether
his/her tip was correct. The results will be saved and
evaluated by the Programme Committee after the
meeting. The participant who solves the most cases
will receive a diploma and be announced in the ESGAR
newsletter. The coordinator of the ESGAR 2009 “cases
of the day” competition is S. Jackson, Plymouth/UK.
CLINICAL FILES:
INTERACTIVE CASE DISCUSSION
(Wednesday, June 24, 15:00 – 16:00 /
Thursday, June 25, 15:00 – 16:00)
An expert moderator will present three themed
challenging cases consisting of correlated imaging
modalities to a radiology panel. Each case will
be chosen to illustrate the various diagnostic and
therapeutic options available in the clinical management
of the patient. The moderator will then lead a highly
interactive discussion with emphasis on audience
participation. The aim of this innovative session is to
stress the central role of clinical based radiology in
patient management.
CME ACQUISITION PROCEDURE
A detailed record of session attendance for your CME
credits can only be provided, if
• the questionnaire provided at the entrance of
each room before the respective session is fully
completed,
• your unique personal CME sticker, which you will
receive together with your badge, is affixed,
• and the form is dropped into the provided box
immediately after the respective scientific session.
The combined participation and evaluation questionnaire
considerably helps the next organising committee to
select subjects for future ESGAR meetings.
Guidance
Confirmation of participation in the scientific programme
is to be obtained as follows:
Scientific / Educational Sessions
1. Participate in the session of your interest
2. Questionnaires / evaluation forms will be handed
out at the door before the session; make sure to
personalise it with your unique personal CME
sticker, otherwise it is not possible to allocate the
forms afterwards and to provide a detailed record
of attendance
3. Complete the form during the session
4. Drop the completed form into the designated
“Evaluation” box at the exit of the room when
leaving the session
Scientific Exhibition – EPOS™ (Electronic
Presentation Online System)
Your attendance and evaluation are automatically
recorded online in EPOS™:
1. Enter EPOS™ and view the posters of your
interest. If you logout EPOS™, you will be asked to
complete the evaluation form.
2. Fill in this form completely and press the ‘Submit’
button. A maximum of 3 hours of attendance
at the scientific exhibition (SE) will be listed if the
participant has completed and submitted the
online SE evaluation form using EPOS™ (Electronic
Presentation Online System).
Please note that confirmations of any additional
attendance of the scientific programme, for which
you have not submitted an evaluation form during the
congress, cannot be claimed at a later date as late
requests cannot be processed and can thus not be
included in your record of attendance.
CME Record/ Certificate of Attendance
Every participant will be able to view, download and
print his/her personal record of attendance from
the ESGAR website at www.esgar.org (My Personal
ESGAR account) on the condition that the above
mentioned procedures have been accomplished. This
service is available online within a couple of days after
the congress. Please note that your PersonaliD, printed
on your badge, is required for login. The printout of
your record of attendance has to be submitted by the
participant to the national accreditation society.
Please note that the record of attendance will be
issued only to the participant. It will not be supplied to
any accreditation agency or other organisation/health
authority.
Although participants may partially attend multiple
concurrent sessions, the total number of hours printed
at the end of the list limits the credit to the equivalent of
a single session during that time slot.
19
INFORMATION SCIENTIFIC PROGRAMME
CTC HANDS-ON CENTRE
With this additional educational feature ESGAR
responds to the increasing need and importance of CT-
Colonography trainings. The programme offered at the
“CTC Hands-on Centre” will be similar to the programme
offered at the traditional ESGAR CTC Hands-on
Workshops. There will be introductory lectures and case
reviews as well as the opportunity for familiarisation with
different workstations on an individual basis and will
gain hands-on experience.
The “CTC Hands-on Centre” will be open on the
following days:
Wednesday, June 24, 2009 14:00 – 18:00
Thursday, June 25, 2009 14:00 – 18:00
Friday, June 26, 2009 08:00 – 11:00 and 12:30 – 13:30
Remaining places will be allocated on a first come first
serve basis. Please ask at the Registration Desk.
ESGAR TOP 20
The best 20 abstracts, submitted by residents, who
appear as the first author on the respective abstract
and who will actually present their paper during the
meeting, form the “ESGAR Top 20”. Authors will receive
a diploma, confirming that their abstracts have received
the best ratings among other abstracts submitted
(Diplomas are available at the Registration Desk).
ESGAR Top 20 authors can be recognised by a special
badge during the meeting.
EPOS™ PRESENTATIONS
All scientific exhibits are displayed in EPOS™ format.
32 computer terminals will be available for viewing
the presentations. The EPOS™ area is located on
Level 1 of the conference centre. Please refer to pages
91 – 110 of this programme for a complete listing of
presented posters. The EPOS™ area is accessible
during the following opening hours:
Monday, June 22 16:00 – 20:00
Tuesday, June 23 07:30 – 20:00
Wednesday, June 24 08:45 – 18:00
Thursday, June 25 08:45 – 18:00
Friday, June 26 08:45 – 17:00
20
EPOS™ PRESENTATION – PRIZES
(Award Ceremony: Friday, June 26, 15:45)
The evaluation of the EPOS™ presentations was
completed in advance of the meeting by a jury and
was based on novelty, accuracy, educational value
and design. The winners are indicated as such in the
EPOS™ System.
The 10 best scientific exhibits (EPOS™ presentations)
receive a diploma. There is one Magna Cum Laude,
two Cum Laude and seven Certificates of Merit. A new
feature of ESGAR are the “Recommended Posters”.
These are EPOS™ Posters, which were not selected
for an award but are recommended by the jury for their
interesting and well prepared scientific content.
EVALUATION
The Education Committee of ESGAR conducts an
evaluation of the educational programme of ESGAR
2009 (Postgraduate Course, Workshops, Lecture
Sessions, Plenary Sessions, Interventional Radiology
Sessions, Research Corner). Evaluation Forms will
be handed out at the entrance to the lecture halls
at the beginning of each session. Participants are
kindly asked to return the completed evaluation forms
affixed with the unique personal CME sticker after
the respective session (see also CME acquisition
procedure).
FOUNDATION COURSE
(Friday, June 26, 13:30 – 15:45)
This educational feature, which was successfully
held during the last three Annual Meetings will be
repeated with different topics at ESGAR 2009. As
its name implies, the Foundation Course is designed
to provide fundamental information about abdominal
and gastrointestinal radiology for all registrants from
residents to senior radiologists.
INTERVENTION – A PRACTICAL APPROACH
This new feature is introduced during ESGAR 2009
and is designed to meet the increasing demand
for abdominal and gastrointestinal interventions.
Interventional radiology has always been an integral part
of annual ESGAR meetings, with workshops, lecture
sessions, scientific papers and posters.
This new format within the existing scientific programme
aims to provide an interactive forum for classroom
discussion. From Wednesday to Friday, a daily session
led by three experts will be devoted to practical issues
in interventional radiology from basic to advanced
knowledge and skills. The purpose of the new format
is to encourage expert interaction with a small group of
abdominal and gastrointestinal radiologists and to allow
ample time for discussion of useful tips and tricks.
INFORMATION SCIENTIFIC PROGRAMME
LECTURE SESSIONS
All lecture sessions are dedicated to a special area
of interest with defined lecture objectives to ensure
integration and avoid overlap. Sessions are designed
not only to describe modalities for imaging and therapy,
but also to stress clinical relevance and outcomes.
Discussion will be facilitated.
LUNCH SYMPOSIA (12:45 – 13:45)
From Tuesday to Thursday at lunchtime, symposia will
be held in collaboration with industrial companies and
corporate partners. The subjects of these symposia
will include a variety of “hot topics” concerning the
ongoing development in some major fields of abdominal
diagnostic and interventional radiology.
MODERATORS’ DESK
Moderators are kindly asked to check in at the
Moderator Desk, which is integrated in the main
Registration Desk, 30 minutes before the session they
are chairing to pick up their documents.
POSTGRADUATE COURSE
(Tuesday, June 23 / all day)
“Liver imaging: from morphology to quantification”
The Postgraduate Course takes place on the first day
of the meeting. Translation into Spanish will be offered
for the Postgraduate Course. The course is dedicated
to “Liver imaging: From morphology to quantification”
and has been structured in four main topics dedicated
to “Liver disease: Clinical questions and morphological
answers”, “Imaging beyond morphology: Quantification
methods”, “Quantification in diffuse liver diseases” and
“Quantification in liver tumours”. The main interest is to fill
the gap between conventional radiology and evidence-
based quantitative imaging with a comprehensive
coverage of most recent advances and applications.
RESEARCH CORNER
The Research Corner, successfully introduced at
ESGAR 2008, is designed to illustrate and promote
aspects of radiological research in the field of abdominal
imaging in Europe. Research is currently performed
in a broad and variable way, ranging from individual
endeavours to large multi-centre trials and from non-
funded to competitive large-scale grants. The main
goal of the Research Corner is to provide a discussion
forum to allow senior academic radiologists to interact
with junior researchers at an early stage of their
career development as well as a networking forum for
researchers with common interests. It will surely help to
improve the quality of research in abdominal diagnostic
and interventional radiology across Europe.
The Research Conner will continue this year with two
highly interesting and hot topics devoted to “Imaging
biomarkers” and “Functional evaluation of the effect of
therapy”. These sessions will focus on the importance
of quantitative and functional imaging in evaluating the
presence and severity of abdominal disorders, and
assessing the effect of therapy, in a multimodality arena.
The evolving interface between basic sciences and
clinical image is of crucial importance to the future of
abdominal imaging. The Research Corner will show how
research projects may be developed and presented and
how results may be obtained, validated and published.
SCIENTIFIC SESSIONS
Researchers will present original proffered papers on
new and original aspects of abdominal imaging and
intervention. Selected papers are presented in 5 parallel
scientific sessions from Wednesday, June 24 to Friday,
June 26 from 11:00 – 12:30.
WORKSHOPS
ESGAR 2009 continues a project to enhance the
educational impact of workshops. Throughout the
meeting, different workshop formats will be offered to
the registrants. Most workshops will be delivered in the
traditional format, but there will also be interactive and
small group workshops. Please note that all workshops
will run in parallel. Each participant can attend only one
workshop per day.
Subscription to workshops was possible together
with the registration to the meeting. Thank you for
your understanding that several workshops are fully
booked. Fully booked workshops are marked with * in
the programme and participants are kindly asked for
their co-operation by giving participants who have pre-
registered for workshops priority over walk ins.
TRADITIONAL WORKSHOPS
Each of these workshops is given by two faculty
members. Active interaction between the instructors
and the “students” will be encouraged, as appropriate.
Compared to a lecture, it is intended that the smaller
workshop environment will facilitate discussion between
instructors and audience, allowing registrants to have
specific learning needs addressed. There are several
“Tracks” within the traditional workshops:
• GI Diagnostic Imaging
• Hepatobiliary Imaging
• Acute and Post Traumatic Abdomen
• Technical Aspects of Modern Imaging
• “The Essentials”: This track is specifically intended
to be of interest and value to residents and those
radiologists seeking basic and comprehensive
reviews of key topics. The workshop topics
are “From the European Radiology Curriculum”.
There are 10 GI and Abdominal Radiology
subsections in the basic curriculum. Several will be
covered at each annual ESGAR meeting. Thus, over
21
INFORMATION SCIENTIFIC PROGRAMME
a period of 5 years maximum, a resident attending
all meetings could review this whole section of the
curriculum. In 2009, the segmental anatomy of the
liver (section 2.8), mesenteric ischaemia (section 2.4
and 2.7) and pelvic floor dysfunction (section 2.5)
will be covered.
GI Diagnostic Imaging WS 4, 11, 17, 18
Hepatobiliary Imaging WS 1, 8, 15
Acute and Post Traumatic Abdomen WS 3, 10
Technical Aspects of Modern Imaging WS 2, 9, 16
The “Essentials” WS 5, 12, 19
INTERACTIVE WORKSHOPS
Interactive workshops are designed to transfer
knowledge in a context close to that in which it will
eventually be used, thus enhancing its retention. In this
format, audience size will be limited and the teaching
methods will be designed to maximise active audience
involvement. ”Hands-on” workshops have been a
feature of the ESGAR meeting for several years now. As
in previous years there will be daily workstation-based
workshops on MR of rectal carcinoma.
MR Rectal Carcinoma WS 7, WS 14, WS 21
PREVIEW CENTRE
The Preview Centre is located on the Entrance Level
(Please see floor plan on page 114)
Data projection is the “standard” technical equipment
(Slide projection is not possible). Presentations will be
uploaded on a centralised server in the Preview Centre
from where they will be transmitted to the workstations
in the respective lecture rooms. Please note that your
own laptop cannot be used for presentation in the
lecture halls.
Speakers are requested to hand in their presentations
not later than 90 minutes before the beginning of
their session. For workshops taking place in the early
morning please hand in your presentation on the
previous day. Presentations have to be handed in using
the following format: PowerPoint for PC version MS
Office 97 – 2007 (Macintosh presentations cannot be
accommodated). The presentation has to be saved on
a CD-ROM, DVD-ROM or USB stick (no ZIP disks). The
22
EVIDENCE-BASED PRACTICE (EBP)
This is a course of 3 workshops (WS 6, WS 13, WS 20)
in which a small group will receive training to improve:
• Their understanding of what “evidence-based
practice” means and where it fits in practice.
• Their literature searching skills to help them answer
• questions that arise in day-to-day work.
• Their ability to confidently and reliably appraise
diagnostic test performance literature.
• Their understanding of how guidelines are
constructed and maintained.
This workshop series is for pre-registered participants
only since each participant has been asked to identify an
abdominal radiology problem from his/her department
that the tutors will help them address during the course.
All three workshops have to be attended. Printed,
software and Internet-based resource materials will be
provided.
The tutors will be:
D.E. Malone, Dublin/IE
M. Staunton, Toronto, ON/CA
S.A. Taylor, London/UK
R.M. Mendelson, Perth, WA/AU
size of one presentation should not exceed 700 MB. If
there are video sequences included please make sure
to save the video files on your CD-ROM in addition.
To avoid missing links please save your PowerPoint
presentation as “pack&go” (“.pps”).
Presenters have the opportunity to test their
presentations directly in the Preview Centre which we
strongly recommend. Due to space and time limits it
is not possible to prepare and rehearse your complete
presentation at the Preview Centre.
Opening hours:
Monday, June 22 16:00 – 20:00
Tuesday, June 23 07:30 – 20:00
Wednesday, June 24 07:15 – 18:00
Thursday, June 25 07:15 – 18:00
Friday, June 26 07:15 – 16:00
 O N C O L O G Y WORKSTATION

Timely prevention
Brought to you by the world's first
Oncological Workstation with innovative
medical imaging solutions for early detection,
prevention and therapy planning

im3D S.p.A. Medical Imaging Lab

via Lessolo, 3 - 10153 Torino - Italy (I)
Tel.+39 011 195.08.773
Fax+39 011 195.08.968
http://www.i-m3d.com
GENERAL INFORMATION

CERTIFICATE OF ATTENDANCE/CME RECORD LECTURE HALLS

The certificate of attendance as well as your CME
record will be available online in “My Personal ESGAR Entrance Level
Account” on the ESGAR website (www.esgar.org) right Auditorium 1, Auditorium 2, Auditorium 3A, Auditorium 3B
after the congress. For detailed informtion on the CME
accreditation procedure, please refer to page 19. Level 1
EPOSTM Area (and Internet), Room 1 + 2, Room 3 + 4,
CONFERENCE LANGUAGE Room 5, Room 6 + 7, Room 8 + 9
The meeting will be held in English. Simultaneous
translation from English into Spanish will be offered for For the detailed location, please refer to the floor plans
the Postgraduate Course on Tuesday, June 23, 2009. on pages 114 – 115.

CONFERENCE VENUE LIABILITY

The Palacio de Congresos de Valencia, an architectural ESGAR is not liable for personal injury and loss of
masterpiece by Norman Foster, is situated on one of or damage to private property. Participants and their
the main avenues leading into the modern metropolis accompanying persons should have the respective
of Valencia. The venue is located close to the personal travel insurance.
international airport and has excellent links into the city NEVER LEAVE YOUR BAG UNATTENDED!
centre by metro, bus and tram. The conference centre
has disabled access to any part of the building. LUNCH
Lunch boxes are kindly made available by several
Address companies to the participants of the respective
Palacio de Congresos de Valencia lunch symposium before or after each symposium. In
Avda. Cortes Valencianas, N 60 addition you can find a cafeteria on the Entrance Level
ES – 46015 Valencia, Spain of the conference centre. A list of restaurants in the
vicinity can be obtained at the “Information and Travel”
COFFEE CASH BAR desk.
Within the Palacio de Congresos there is one
coffee cash bar – on the Entrance Level between NAME BADGES
Auditorium 1 and Auditorium 2. It is obligatory for all participants to wear their badge
visible throughout the meeting as it is the entrance
Tuesday June 23 07:30 – 18:00 ticket to all sessions and the exhibition area. The
Wednesday June 24 07:30 – 17:00 name badge is not transferable. In case of badge loss,
Thursday June 25 07:30 – 17:00 please contact the Registration Desk.
Friday June 26 07:30 – 15:00
OPENING HOURS VALENCIA
Furthermore you can find a cafeteria on the Entrance The siesta is still very much respected in Valencia. The
Level opposite to the Registration Area. Please refer to hours vary – some places close from 13:30 to 16:30,
pages 114 – 115 for detailed floor plans. some from 14:00 to 17:00. Opening hours differ
greatly too – some shops will open at 07:30 while most
CURRENCY won't until 10:00. The closing time is usually 19:30 or
The Euro (€) is the official currency in Spain. 20:00. Large supermarkets, megastores and shopping
malls are usually open throughout the day without the
ELECTRICITY break – until 21:00 to 24:00. Banks are open 09:00 to
Electrical current is 220 or 225 volts, 50Hz. European- 14:00 and closed on Saturdays and Sundays.
style two-pin plugs are standard.
POSTAL SERVICES
EMERGENCY The Central Post and Telegraph Office (Plaza del
For emergency calls dial 112. Ayuntamiento, 24) is open on weekdays from 08:30
to 20:30 and between 09:30 and 14:00 on Saturdays.
INTERNET ACCESS Stamps are available in all tobacco stores.
Internet terminals are available free of charge for
participants of ESGAR 2009 in the Internet Areas on
Level 1 and in front of Auditorium 3A and 3B (Entrance
Level) throughout the meeting. Furthermore there
will be internet access at the ESGAR booth from
Wednesday to Friday.

24
GENERAL INFORMATION

REGISTRATION TECHNICAL EXHIBITION

On-site Fees: The Exhibition Area is located on the Entrance Level
ESGAR / Faculty Member € 580.00 of the Conference Centre. For a complete list of
Non Member € 710.00 exhibitors and a floor plan of the Exhibition Area,
Resident* (ESGAR Member) € 305.00 please refer to pages 112 – 113.
Resident* (Non Member) € 355.00
Radiographer* € 355.00 The opening hours of the Exhibition are:
Accompanying Person € 35.00 Tuesday, June 23 09:30 – 18:00
Wednesday, June 24 09:30 – 17:00
All prices are listed in Euro (€). The “ESGAR Member” Thursday, June 25 09:30 – 17:00
registration fee is only applicable for members in good Friday, June 26 09:30 – 17:00
standing – the ESGAR membership fee for 2009 has
to be settled! *Residents must present a letter from
the head of their department confirming their status as TELEPHONES
a resident. When phoning to Spain from another country, the
Registration fees may be paid in cash in Euro (€) or by code is +34 plus the city code 96 for Valencia. When
credit card (VISA or Mastercard). phoning abroad from Spain, you need to dial 00
followed by the suitable national and provincial codes
REGISTRATION FEE INCLUDES and the corresponding telephone number.
• Admittance to all sessions, scientific exhibition
(EPOS™) and technical exhibition TIME
• Final programme book Standard time zone: GMT +1 hour
• Abstracts (electronic version) Daylight saving time: +1 hour
• Certificate of Attendance and CME Record
• Welcome Reception TRAVEL DESK
• Access to the “ESGAR Electronic Congress” The official travel agent of ESGAR 2009 “Viajes
El Corte Inglés” is represented at the Palacio de
ACCOMPANYING PERSON FEE INCLUDES Congresos with an “Information and Travel” desk.
• Admittance to the Opening Ceremony Here you will receive information on Valencia and
• Welcome Reception Spain in general. You can book last-minute places
for sightseeing tours (provided that the minimum
REGISTRATION DESK – OPENING HOURS number of participants has been reached), get tips for
On-site telephone number: +34 96 317 94 35 shopping and recommendations for restaurants, ask
On-site fax number: +34 96 317 94 36 for the best places to have a drink and pick up your
free city map.
Monday, June 22 16:00 – 20:00
Tuesday, June 23 07:30 – 20:00 Opening hours:
Wednesday, June 24 07:15 – 18:00 Monday June 22 16:00 – 19:00
Thursday, June 25 07:15 – 18:00 Tuesday June 23 09:30 – 14:30; 16:00 – 18:00
Friday, June 26 07:15 – 17:00 Wednesday June 24 09:30 – 14:30; 16:00 – 18:00
Thursday June 25 09:30 – 14:30; 16:00 – 18:00
Ticket Counter Friday June 26 09:30 – 14:30; 16:00 – 18:00
Monday, June 22 16:00 – 20:00
Tuesday, June 23 13:00 – 20:00
Wednesday, June 24 07:15 – 18:00
Thursday, June 25 07:15 – 18:00

SMOKING
Smoking is not permitted inside the conference venue.

TAXIS
There are plenty of taxis and their service is very
good. A taxi ride from the airport to the congress
centre should be around € 15.00, to the city centre
approximately € 20.00. A trip from the city centre to
the beach will cost € 10.00 – € 11.00.
Radio Taxi +34 96 3703 333
Tele Taxi +34 96 3571 313
Auto-Taxis +34 96 3959 560

25
EVENING EVENTS

TUESDAY, JUNE 23, 2009

OPENING AND AWARD CEREMONY/ WELCOME RECEPTION AND

ESGAR ANNIVERSARY LECTURE ANNIVERSARY PARTY
18:00 – 20:00 20:00 – 21:30

The programme of the Opening Ceremony will focus
on celebrating the 20th Anniversary of ESGAR Annual
Meetings. Prof. Nicholas Gourtsoyiannis, one of the
founding members of the Society, will give a special
Anniversary Lecture on “20 years of ESGAR”, which
will be both informative and entertaining.
There will be a Cultural Lecture by Prof. Santiago
Grisolía. The Valencian Biochemist, who was born in
Valencia in 1923, was professor Ochoa´s first graduate
student in the Chemistry Department of the University
of New York. He was a lecturer in Biochemistry and
Molecular Biology for many years at the University of
Kansas, as well as at Chicago and Wisconsin, making
classic discoveries in this university about the urea
cycle, which have both fundamental and practical
importance. He is, furthermore, an honorary professor
of the faculty of Medicine at Valencia and doctor
"honoris causa" of a number of Spanish universities,
as well as Florence and Siena, in Italy. He also was
Chairman of the UNESCO Committee for Scientifi c
Coordination for the Human Genome Project. The
Cultural Lecture will deal with “100 years later”.
A Welcome Cocktail, following the Opening Ceremony,
will take place in the foyer of the Palacio de Congresos
de Valencia and its adjacent gardens with shady trees
and gently curving asymmetrical pools. You will be able
to enjoy some drinks and Spanish tapas accompanied
by a live Jazz music act. We hope this will give you a
chance to experience the taste of delicious Spanish
cuisine, to catch up with colleagues and friends and
also to celebrate the Opening of the 20th Anniversary
Annual Meeting.
The Welcome Reception is free for registered
participants and registered accompanying persons.
This evening is kindly sponsored by Bayer Schering
Pharma, Covidien, Guerbet and Rovi.

We would like to invite you all to join the Opening

Ceremony!

26
EVENING EVENTS
WEDNESDAY, JUNE 24, 2009
ESGAR EVENING
19:30 – 23:30
The ESGAR Evening is traditionally devoted to the
local culture and life-style of the hosting country. Thus
for the ESGAR Evening 2009 a Spanish Night will be
organised at the “Oceanogràfic” of the City of Arts and
Sciences (Ciudad de las Artes y las Ciencias).
The "Oceanogràfic", which was designed by the
Spanish architect Félix Candela, is the largest
o c e a n a r i u m i n E u ro p e . T h e “ O c e a n o g r à f i c ”
incorporates two structures of a design that bears the
stamp of this distinguished architect. They are the most
emblematic buildings in the park, the white concrete
roofs of which represent a hyperbolic paraboloid figure
similar to that of a water lily. The park includes two
clearly differentiated scenarios: installations for fi sh
and invertebrates that reproduce the various marine
ecosystems and areas characterised by the presence
of sea mammals. Because of its concept and design,
its spectacular dimensions, and the species it contains,
the "Oceanogràfic" has become a point of reference
for aquariums world-wide.
This outstanding location will be the perfect setting
to meet the most exigent expectations to celebrate
the 20 th Anniversary of ESGAR Annual Meetings. A
performance at the Dolphinarium, one of the largest
in the world, is planned for all participants. This will
be a fantastic demonstration of the abilities of these
animals. Following the dolphin show a pleasant
dinner with typical Spanish food and a music group
is arranged within the gardens of the “Oceanogràfic”!
Price per ticket: € 55.00
Some tickets are still available. Please contact the
ticket counter at the registration desk.
This evening is kindly supported in part by
GE Healthcare.
27
GE Healthcare

Imaging innovations :
Discover new ways to predict
and diagnose disease earlier

Join us at the
20th Annual Meeting
and Postgraduate
Course of ESGAR
June 23 - 26, Valencia, Spain

ESGAR CTC Hands-on Lunch Symposium: Abdominal

Centre Imaging Innovations
Lunch boxes will be provided

GE Healthcare is proud to participate at the ESGAR

CTC Hands-on Centre. Introductory lectures
and case reviews will be featured.
Participants will also have the opportunity to get
hands-on experience with GE Healthcare's Advantage
Workstations on an individual basis.
• Wednesday, June 24, 2009 14:00 – 18:00
• Thursday, June 25, 2009 14:00 – 18:00
• Friday, June 26, 2009 08:00 – 11:00 and 12:30 – 13:30
June 23 • 12:45 - 13:45 • Auditorium II
Moderator:
Pascal Giat, PhD, Buc, France
Abdominal CT and MR Imaging for Oncologic Patients:
Added Value of Fusing Techniques
Dr Marc Zins, Paris, France

Multimodality Approach: New Tools

Professor Valérie Vilgrain, Clichy, France

CT Colonography: New Tools

for establishing Clinical Indications
Professor Andrea Laghi, Latina, Italy

GE imagination at work
PROGRAMME OVERVIEW

Mo, Tuesday Wednesday Thursday Friday

Time June June 23 June 24 June 25 June 26
22 (see page 31) (see page 40) (see page 58) (see page 76)
07:30 – 07:45
07:45 – 08:00

Exhibition (09:30 – 17:00)

08:00 – 08:15
08:15 – 08:30 Workshops Workshops Workshops

Exhibition (09:30 – 17:00)

Exhibition (09:30 – 17:00)

08:30 – 08:45

CTC Hands-on Centre

08:45 – 09:00
09:00 – 09:15
Postgraduate Course
Exhibition (09:30 – 18:00)

09:15 – 09:30
Session 1 LS 1 Auditorium 1 LS 5 Auditorium 1 LS 9 Auditorium 1
09:30 – 09:45
LS 2 Auditorium 2 LS 6 Auditorium 2 LS 10 Auditorium 2
09:45 – 10:00 Auditorium 1 IR 1 Room 6 + 7 IR 2 Room 6 + 7 IR 3 Room 6 + 7
10:00 – 10:15

|
10:15 – 10:30
10:30 – 10:45 Break
Break Break Break
|

EPOS™ Presentations (08:45 – 17:00)

10:45 – 11:00
11:00 – 11:15
SS 1 Auditorium 1 SS 6 Auditorium 1
EPOS™ Presentations (08:45 – 18:00)

EPOS™ Presentations (08:45 – 18:00)

11:15 – 11:30 Postgraduate Course SS 11 Auditorium 1
Session 2 SS 2 Auditorium 2 SS 7 Auditorium 2
11:30 – 11:45 SS 12 Auditorium 2
SS 3 Auditorium 3A SS 8 Auditorium 3A
|

SS 13 Auditorium 3A
11:45 – 12:00 Auditorium 1 SS 4 Auditorium 3B SS 9 Auditorium 3B
SS 14 Auditorium 3B
SS 5 Room 1 + 2 SS 10 Room 1 + 2
12:00 – 12:15 SS 15 Room 1 + 2
EPOS™ Presentations (07:30 – 20:00)

RC 1 Room 3 + 4 RC 2 Room 3 + 4
12:15 – 12:30

CTC Hands-
12:30 – 12:45

on Centre
12:45 – 13:00
SY 1 BAYER SCHERING SY 3 GUERBET SY 5 MEDICSIGHT
13:00 – 13:15 Auditorium 1 Auditorium 1 Auditorium 1
13:15 – 13:30 SY 2 GE HEALTHCARE SY 4 IM3D SY 6 BRACCO
Auditorium 2 Auditorium 2 Auditorium 2
13:30 – 13:45
13:45 – 14:00 Foundation Course: The Tube

|
14:00 – 14:15 Break Break Break Auditorium 2
14:15 – 14:30
|

14:30 – 14:45 SGR Honorary Lecture JSAR Honorary Lecture Registration (07:15 – 17:00)
CTC Hands-on Centre (14:00 – 18:00)

CTC Hands-on Centre (14:00 – 18:00)

14:45 – 15:00 Postgraduate Course Auditorium 2 Auditorium 2

Session 3 Foundation Course: Solid
Registration (07:15 – 18:00)

Registration (07:15 – 18:00)

15:00 – 15:15
Clincial Files 1 Clincial Files 2 Organs
15:15 – 15:30 Auditorium 1 (Interactive Case (Interactive Case Auditorium 2
|

15:30 – 15:45 Discussion) Discussion)

Auditorium 2 Auditorium 2
15:45 – 16:00 Closing Remarks
Registration (07:15 – 20:00)

16:00 – 16:15 Break

Break Break
16:15 – 16:30
Registration & EPOS™ Presentations

16:30 – 16:45
16:45 – 17:00 Postgraduate Course
Session 4
17:00 – 17:15 LS 3 Auditorium 1 LS 7 Auditorium 1
17:15 – 17:30 LS 4 Auditorium 2 LS 8 Auditorium 2
(16:00 – 20:00)

Auditorium 1
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
ESGAR General Assembly
18:15 – 18:30
Opening Ceremony Auditorium 3A
18:30 – 18:45
ESGAR Anniversary
18:45 – 19:00 Lecture
19:00 – 19:15
Auditorium 1
19:15 – 19:30
19:30 – 20:00
ESGAR Evening
Welcome Reception (Oceanogràfic)
Evening (Palacio de Congresos de see page 27
Valencia) see page 26

29
 ESGAR 2009 PROGRAMME

30
 TUESDAY, JUNE 23
PROGRAMME OVERVIEW
TUESDAY, JUNE 23, 2009

09:00 – 10:15 PG 1 Postgraduate Course Session 1 Auditorium 1

10:15 – 11:00 BREAK

11:00 – 12:15 PG 2 Postgraduate Course Session 2 Auditorium 1

12:45 – 13:45 SY 1 BAYER SCHERING PHARMA Symposium: Auditorium 1

Come! See! Diagnose!
Interactive liver diagnosis

12:45 – 13:45 SY 2 GE Healthcare Symposium: Auditorium 2

Abdominal Imaging Innovations

13:45 – 14:30 BREAK

14:30 – 15:45 PG 3 Postgraduate Course Session 3 Auditorium 1

15:45 – 16:30 BREAK

16:30 – 17:45 PG 4 Postgraduate Course Session 4 Auditorium 1

18:00 – 19:30 PS 1 Opening Ceremony (see page 39) Auditorium 1

HL 1 ESGAR Anniversary Lecture Auditorium 1

N. Gourtsoyiannis, Heraklion/GR

20:15 – 21:30 WELCOME RECEPTION

31
TUESDAY, JUNE 23

POSTGRADUATE COURSE – LIVER IMAGING:

FROM MORPHOLOGY TO QUANTIFICATION
TUESDAY, JUNE 23, 2009
09:00 – 10:15

PG 1 LIVER DISEASE: CLINICAL QUESTIONS AND AUDITORIUM 1

MORPHOLOGICAL ANSWERS
Moderators: B. Marincek, Zurich/CH; L. Martí-Bonmatí, Valencia/ES

09:00 DIFFUSE LIVER DISEASE

L. Grazioli, Brescia/IT

Lecture objectives:
To summarise the relevant clinical questions which need to be answered by imaging. To
explain how imaging can demonstrate the morphological changes of diffuse liver disease
including steatosis, iron overload, cirrhosis and inflammation and review the results of
multimodality techniques. To illustrate the main imaging findings and to review remaining
unanswered clinical questions.

09:25 BENIGN LIVER LESIONS

T. Helmberger, Munich/DE

Lecture objectives:
To summarise the relevant clinical questions in terms of detection, characterisation,
treatment planning and follow-up which need to be answered by imaging. To illustrate the
diagnostic assessment of benign lesion morhology and to review remaining unanswered
clinical questions.

09:50 MALIGNANT LIVER TUMOURS

V. Vilgrain, Clichy/FR

Lecture objectives:
To summarise the relevant clinical questions in terms of detection, characterisation,
staging, treatment planning and follow-up which need to be answered by imaging. To
illustrate the diagnostic assessment of malignant lesion morhology and to review
remaining unanswered clinical questions.

32
 TUESDAY, JUNE 23
POSTGRADUATE COURSE – LIVER IMAGING:
FROM MORPHOLOGY TO QUANTIFICATION
TUESDAY, JUNE 23, 2009
11:00 – 12:15

PG 2 IMAGING BEYOND MORPHOLOGY: AUDITORIUM 1

QUANTIFICATION METHODS
Moderators: W. Schima, Vienna/AT; J. Heiken, St. Louis, MO/US

11:00 QUANTIFICATION WITH US

W.R. Lees, London/UK

Lecture objectives:
To review the physical properties of US which can be used to measure cells, vessels and
tissue structure. To explain why intracellular fat is associated with reflectivity changes.
To summarise the pharmacodynamics of intravascular compartment US contrast media.
To discuss how contrast enhancement can be utilised for quantification. To illustrate the
advantages and limitations of US for quantification.

11:25 QUANTIFICATION WITH MDCT AND PET/CT

M. Laniado, Dresden/DE

Lecture objectives:
To review the physical properties of MDCT which can be used to measure cells, vessels
and tissue structure. To explain why fat, iron and other components are associated with
attenuation changes. To review the pharmacodynamics of iodine based contrast media. To
illustrate how contrast enhancement is used for quantification including curve parameters,
AUC and permeability maps. To discuss the physical properties of radioisotopes that can
be used for quantification and to explain the rational for different tracers. To review the
role of hybrid imaging. To explain the advantages and limitations of MDCT and PET/CT for
quantification.

11:50 QUANTIFICATION WITH MRI

N. Papanikolaou, Heraklion/GR

Lecture objectives:
To review the physical properties of MRI which can be used to measure cells, vessels and
tissue structure. To explain why tissue composition is associated with signal changes
when performing different sequences, including DWI and elastography. To discuss how
MR contrast enhancement is used for quantification including curve parameters, AUC
and pharmacokinetics. To explain the advantages and limitations of MRI for quantification.

33
 TUESDAY, JUNE 23
LUNCH SYMPOSIA
TUESDAY, JUNE 23, 2009
12:45 – 13:45

SY 1 COME! SEE! DIAGNOSE! – AUDITORIUM 1

INTERACTIVE LIVER DIAGNOSIS
Sponsored by: Bayer Schering

Moderator: D. Breen, Southampton/UK

12:45 A. Filippone, Chieti/IT; A. Huppertz, Berlin/DE

SY 2 ABDOMINAL IMAGING INNOVATIONS AUDITORIUM 2

Sponsored by: GE Healthcare

Moderator: P. Giat, Buc/FR

12:45 ABDOMINAL CT AND MR IMAGING FOR ONCOLOGIC PATIENTS:

ADDED VALUE OF FUSING TECHNIQUES
M. Zins, Paris/FR

13:05 MULTIMODALITY APPROACH: NEW TOOLS

V. Vilgrain, Clichy/FR

13:25 CT COLONOGRAPHY: NEW TOOLS FOR ESTABLISHING CLINICAL INDICATIONS

A. Laghi, Latina/IT

35
TUESDAY, JUNE 23

POSTGRADUATE COURSE – LIVER IMAGING:

FROM MORPHOLOGY TO QUANTIFICATION
TUESDAY, JUNE 23, 2009
14:30 – 15:45

PG 3 QUANTIFICATION IN DIFFUSE LIVER DISEASES AUDITORIUM 1

Moderators: S. Efremidis, Ioannina/GR; S. Jackson, Plymouth/UK

14:30 STEATOSIS, STEATOHEPATITIS AND IRON OVERLOAD

C. Sirlin, San Diego, CA/US

Lecture objectives:
To discuss the practical use of quantitative imaging methods. To review the optimal imaging
strategy including technique accuracy, reproducibility, sensitivity and standardisation. To
explain the clinical and therapeutic relevance of imaging iron overload.

14:55 FIBROSIS AND REGENERATION

B. Van Beers, Clichy/FR

Lecture objectives:
To explain the US and MR techniques used to quantify fibrosis and regeneration. To
describe the advantages and limitations of available techniques. To discuss the clinical
and biological results. What are there remaining indications for liver biopsy?

15:20 PORTAL HYPERTENSION

D. Akata, Ankara/TR

Lecture objectives:
To review the anatomy of the portal system and collateral vessels. To discuss accurate
portal pressure measurement using available techniques. To describe what factors need
to assessed in order to determine TIPS feasibility. To explain the evaluation of TIPS
function and patency.

36
 TUESDAY, JUNE 23
POSTGRADUATE COURSE – LIVER IMAGING: FROM MORPHOLOGY
TO QUANTIFICATION
TUESDAY, JUNE 23, 2009
16:30 – 17:45

PG 4 QUANTIFICATION IN LIVER TUMOURS AUDITORIUM 1

Moderators: F. Caseiro-Alves, Coimbra/PT; B.I. Choi, Seoul/KR

16:30 ASSESSMENT OF TUMOUR AGGRESSIVENESS AND GRADING

L. Martí-Bonmatí, Valencia/ES

Lecture objectives:
To explain how imaging findings are related to tumour composition and perfusion
characteristics. To describe how these characteristics can be accurately quantified to
assess tumour aggressiveness and provide accurate grading.

16:55 STAGING OF LIVER TUMOURS AND TREATMENT PLANNING

B. Marincek, Zurich/CH

Lecture objectives:
To discuss the optimal imaging techniques for the evaluation of tumour volume and staging.
To illustrate how liver volume and function can be assessed for treatment planning. To
explain how liver regeneration can be predicted and evaluated.

17:20 EVALUATION OF TUMOUR RESPONSE TO TREATMENT

Y. Menu, Paris/FR

Lecture objectives:
To explain systemic post treatment changes and how they represent tumour response. To
discuss changes after local therapy and how imaging can predict and assess treatment
outcome and efficacy.

37
 EPOS TM
CASES-OF-THE
- DAY
HAVE YOU SOLV
ED TODAY’S
UNKNOWN CAS
ES YET?

Cases-of-the-da
y can be access
EPOSTM Area on ed in the
Level 1! We invite
participate in the you to
competition.
 TUESDAY, JUNE 23
OPENING CEREMONY / HONORARY LECTURE /
WELCOME RECEPTION
TUESDAY, JUNE 23, 2009

18:00 – 20:00 OPENING CEREMONY/ AUDITORIUM 1

HONORARY FELLOWSHIP AWARDS/
ANNIVERSARY LECTURE
18:00 WELCOME ADDRESSES

L. Martí-Bonmatí, Valencia/ES
Meeting President

B. Marincek, Zurich/CH
ESGAR President

18:15 HONORARY FELLOWSHIP/ GOLD MEDAL AWARDS

A.H. Freeman, Cambridge/UK

A.J. Megibow, New York, NY/US

C. Bartolozzi, Pisa/IT

18:45 EUROPEAN RADIOLOGY AWARD 2008

19:00 ESGAR ANNIVERSARY LECTURE

N. Gourtsoyiannis, Heraklion/GR

19:35 CULTURAL LECTURE

S. Gisolía, Valencia/ES

Musical performance by “La Tilera”

20:15 – 21:30 WELCOME RECEPTION

39
 PROGRAMME OVERVIEW
WEDNESDAY, JUNE 24, 2009

08:00 – 08:45 WS 1 Incidental liver lesions: Diagnostic work up Auditorium 3A

08:00 – 08:45 WS 2 Contrast enhanced US of the pancreas and liver Auditorium 3B
08:00 – 08:45 WS 3 Acute abdomen: Diagnosis and pitfalls Room 1 + 2
08:00 – 08:45 WS 4 CT Colonography: Technical aspects Room 3 + 4
08:00 – 08:45 WS 5 From the European Curriculum (2.8): Room 6 + 7
Segmental anatomy of the liver
08:00 – 08:45 WS 6 EBP (Evidence-Based Practice I) Room 5
Introduction and overview. How to improve your
literature searches.
08:00 – 08:45 WS 7 Interactive Workshop: MRI of Rectal Carcinoma (1) EPOS™ Area

09:00 – 10:30 IR 1 Intervention - a practical approach: Liver tumour ablation Room 6 + 7

WEDNESDAY, JUNE 24

09:00 – 10:30 LS 1 MR of Focal Liver Lesions: Optimising contrast display Auditorium 1

09:00 – 10:30 LS 2 Imaging inflammatory small bowel disease: How and Auditorium 2
why in the era of capsule endoscopy

10:30 – 11:00 BREAK

11:00 – 12:30 RC 1 Research Corner: Room 3 + 4

Functional evaluation of the effect of therapy

11:00 – 12:30 SS 1 Liver HCC Diagnosis Auditorium 1

11:00 – 12:30 SS 2 Pancreatic neoplasms Multimodality approach Auditorium 2
11:00 – 12:30 SS 3 Colon and Rectum 1 Auditorium 3A
11:00 – 12:30 SS 4 Technical Issues in Oncology Auditorium 3B
11:00 – 12:30 SS 5 Gut: from esophagus to rectum Room 1 + 2

12:45 – 13:45 SY 3 GUERBET Symposium: Auditorium 1

Why and how Gd-complexes are still needed in
abdominal MRI

12:45 – 13:45 SY 4 im3D Symposium: Auditorium 2

Clinical significance of intermediate size CR lesions
and how to improve their detection with CAD

13:45 – 14:30 BREAK

14:00 – 18:00 CTC 1 CTC Hands-on Centre Room 8 + 9

14:30 – 15:00 HL 2 SGR Honorary Lecture Auditorium 2

15:00 – 16:00 PS 2 Clinical Files (Interactive Case Discussion): Auditorium 2

HCC: Controversies in diagnosis and treatment

16:00 – 16:30 BREAK

16:30 – 18:00 LS 3 Diffusion weighted abdominal MRI: Auditorium 1

Characterisation and post treatment evaluation
16:30 – 18:00 LS 4 Abdominal Trauma: Limitations of MDCT imaging Auditorium 2

19:30 ESGAR EVENING (SEE PAGE 27)

40
WORKSHOPS
WEDNESDAY, JUNE 24, 2009
08:00 – 08:45

WS 1* INCIDENTAL LIVER LESIONS: Auditorium 3A

DIAGNOSTIC WORK UP
A. Palkó, Szeged/HU
C.J. Zech, Munich/DE

WS 2 CONTRAST ENHANCED US OF THE PANCREAS Auditorium 3B

AND LIVER
M. D’Onofrio, Verona/IT
S.D. Yarmenitis, Heraklion/GR

WEDNESDAY, JUNE 24
WS 3 ACUTE ABDOMEN: DIAGNOSIS AND PITFALLS Room 1 + 2
S. Jackson, Plymouth/UK
R.M. Mendelson, Perth, WA/AU

WS 4 CT COLONOGRAPHY: TECHNICAL ASPECTS Room 3 + 4

P. Lefere, Roeselare/BE
A. Laghi, Latina/IT

WS 5 FROM THE EUROPEAN CURRICULUM (2.8): Room 6 + 7

SEGMENTAL ANATOMY OF THE LIVER
L.H. Ros Mendoza, Zaragoza/ES
D. Cioni, Pisa/IT

WS 6* EBP (EVIDENCE-BASED PRACTICE I) Room 5

INTRODUCTION AND OVERVIEW.
HOW TO IMPROVE YOUR LITERATURE SEARCHES.
D.E. Malone, Dublin/IE
M. Staunton, Toronto, ON/CA

WS 7* INTERACTIVE WORKSHOP: EPOS™ Area

MRI OF RECTAL CARCINOMA (1)
R.G.H. Beets-Tan, New York, NY/US

*=workshop fully booked.

DETAILED WORKSHOP DESCRIPTION PLEASE SEE PAGES 21 – 22

41
 INTERVENTIONAL RADIOLOGY
WEDNESDAY, JUNE 24, 2009
09:00 – 10:30

IR 1 INTERVENTION – A PRACTICAL APPROACH: ROOM 6 + 7

LIVER TUMOUR ABLATION
Moderator: A.R. Gillams, London/UK

09:00 CLINICAL RESULTS FOR HCC

P.L. Pereira, Heilbronn/DE

Lecture objectives:
To summarise the indications and in particular discuss the appropriate case selection of
WEDNESDAY, JUNE 24

patients with HCC. To review the role of image-guided ablation in the context of other
treatments for the patient group. To emphasise relevant tips and tricks and describe
clinical results, potential complications and imaging criteria for assessing procedural
outcome.

09:20 CLINICAL RESULTS FOR LIVER METASTASES

A.R. Gillams, London/UK

Lecture objectives:
To summarise the indications and in particular discuss appropriate case selection of
patients with liver metastases. To review the role of image-guided ablation in the context of
other treatments for the patient group. To emphasise relevant tips and tricks and describe
clinical results, potential complications and imaging criteria for assessing procedural
outcome.

09:40 CURRENT LIMITATIONS AND TECHNICAL ADVANCES

D.J. Breen, Southampton/UK

Lecture objectives:
To review the current limitations of image-guided ablation techniques. To discuss technical
advances and future developments in the field.

10:00 PANEL DISCUSSION

42
 LECTURE SESSIONS
WEDNESDAY, JUNE 24, 2009
09:00 – 10:30

LS 1 MR OF FOCAL LIVER LESIONS: AUDITORIUM 1

OPTIMISING CONTRAST DISPLAY
Moderators: M. Laniado, Dresden/DE; G. Brancatelli, Palermo/IT

09:00 DYNAMIC IMAGING

C. Ayuso, Barcelona/ES

Lecture objectives:
To describe the pulse sequence protocols and optimal timing of dynamic imaging. To
WEDNESDAY, JUNE 24

review the pathophysiological basis of both the vascular and interstitial distribution of
extracellular contrast agents in focal liver lesions. To discuss the time course of this
distribution relevant to lesion pathology and to address wash-in and wash-out phenomena.
To explain the contrast mechanisms of dynamic imaging with Gd-based liver specific
agents and to comment on dynamic imaging with SPIOs.

09:20 CELLULAR IMAGING

W. Schima, Vienna/AT

Lecture objectives:
To describe the pulse sequence protocols and optimal timing of cellular imaging with
liver specific contrast agents. To review the physiology of hepatobiliary contrast agent
uptake into both normal and pathological liver tissue. To discuss the timing of tumour-to-
liver contrast enhancement based on agent-specific pharmacokinetics and lesion type.
To explain SPIO related contrast mechanisms and to address the principles of double
contrast MRI.

09:40 DIFFUSION IMAGING

M. Lewin, Paris/FR

Lecture objectives:
To understand the technical parameters of DWI of the liver and to appreciate the specific
influence of perfusion. To explain how to select optimal b values for lesion detection/
characterisation and discuss the role of ADC maps. To address clinical results, limitations,
pitfalls and future trends of the technique.

10:00 DIFFERENCES WITH ALTERNATIVE IMAGING MODALITIES

G. Morana, Treviso/IT

Lecture objectives:
To describe the principles of contrast enhanced CT/US of focal liver lesions. To summarise
the physical properties and pharmacokinetics of relevant contrast agents. To explain the
similarities and differences in contrast enhancement of focal liver lesions with CT/US. To
illustrate the contrast mechanisms of FDG PET/CT.

10:20 PANEL DISCUSSION

44
LECTURE SESSIONS
WEDNESDAY, JUNE 24, 2009
09:00 – 10:30

LS 2 IMAGING INFLAMMATORY AUDITORIUM 2

SMALL BOWEL DISEASE: HOW AND WHY
IN THE ERA OF CAPSULE ENDOSCOPY
Moderators: O. Ekberg, Malmö/SE; V. Valek, Brno-Bohunice/CZ

09:00 AIR/BARIUM ENTEROCLYSIS

D. Maglinte, Indianapolis, IN/US

Lecture objectives:

WEDNESDAY, JUNE 24
To review the indications for enteroclysis in the era of cross-sectional imaging techniques
and capsule endoscopy. To critically appraise the strengths and weaknesses of the
technique in a mulitmodality imaging environment. To summarise the specific clinical
applications for contrast enteroclysis when evaluating mucosal abnormalities and discuss
the future clinical role of the technique.

09:20 US AND CEUS

J.B.C.M. Puylaert, The Hague/NL

Lecture objectives:
To describe the technical aspects of US and CEUS as applied to patients with IBD. To
illustrate the spectrum of findings with US in both uncomplicated and complicated Crohns
disease. To review the key diagnostic features and clinical indications which require the
specific use of CEUS in particular with regard to the assessment of disease activity. To
appraise the clinical role and strength and weaknesses of US/CEUS in a multimodality
imaging environment.

09:40 CT ENTEROGRAPHY / ENTEROCLYSIS

G.A. Rollandi, Genova/IT

Lecture objectives:
To review the specific protocols for MDCT enterography and enteroclysis. To critically
appraise the advantages and limitations of a MDCT approach for the diagnosis and
characterisation of patients with IBD. To review the clinical role of MDCT in a multimodality
imaging environment.

10:00 MR ENTEROGRAPHY / ENTEROCLYSIS

N. Papanikolaou, Heraklion/GR

Lecture objectives:
To review the technical requirements and protocols for MR assessment of the small bowel.
To discuss the advantages and limitations of MR enterography/enteroclysis in patients
with IBD. To review the imaging criteria and role of MRI when assessing disease activity
and to summarise disease sub-types based on MRI features. To critically evaluate the
contribution of MRI in the management of patients with Crohns disease when compared
to alternative imaging techniques.

10:20 PANEL DISCUSSION

45
 RESEARCH CORNER
WEDNESDAY, JUNE 24, 2009
11:00 – 12:30

RC 1 RESEARCH CORNER: FUNCTIONAL EVALUATION ROOM 3 + 4

OF THE EFFECT OF THERAPY
Moderator: Y. Menu, Paris/FR

11:00 HOW TO DO IT WITH US

S. Rafaelsen, Vejle/DK

Lecture objectives:
To define the most important biomarkers which can be assessed using US and CEUS
WEDNESDAY, JUNE 24

examinations. To demonstrate how US contrast media can evaluate tumour perfusion and
angiogenesis.

11:15 CONTRIBUTION OF MDCT

B.I. Choi, Seoul/KR

Lecture objectives:
To describe the most important MDCT imaging appearances which can be used for the
evaluation of tumour response. To assess the functional capabilities of contrast enhanced
MDCT when evaluating tumour necrosis. To demonstrate the use of whole organ MDCT
perfusion for the evaluation of tumour response.

11:30 POSSIBILITIES WITH MRI

M.C. Della Pina, Pisa/IT

Lecture objectives:
To review the various MR parameters (signal intensity, diffusion and perfusion imaging,
spectroscopy) to evaluate post treatment response. To discuss the advantages and
limitations of these biomarkers when evaluating tumour viability. To comment on the use
of MR in clinical trials for the assessment of tumour response.

11:45 THE ROLE OF PET/CT

T. Lauenstein, Essen/DE

Lecture objectives:
To explain the role of different tracers used in PET/CT to demonstrate tumour viability,
necrosis and response to treatment. To illustrate the advantages and pitfalls of PET/CT for
the evaluation of tumour response. To discuss the synergistic information from both PET
and CT for the assessment of tumour response.

12:00 PANEL DISCUSSION

46
SCIENTIFIC SESSIONS
WEDNESDAY, JUNE 24, 2009
11:00 – 12:30

SS 1 LIVER HCC DIAGNOSIS AUDITORIUM 1

Moderators: B. Gallix, Montpellier/FR; P. Belo-Soares, Coimbra/PT

11:00 SS 1.01 Detection of HCC on CT with pathologic correlation

H. Addley, N. Griffin, A. Shaw, l. Mannelli, V. Polydoropoulou, S. Aitken, T. Prevost,
D. Lomas; Cambridge/UK

11:08 SS 1.02 Intraindividual comparison of hepatic venous phase and delayed phase for
the detection of washout contrast-enhancement pattern of HCC at MDCT of
the liver

WEDNESDAY, JUNE 24
A. Furlan1, G. Brancatelli2, D. Marin3, G. Palermo Patera2, A. Ronzoni4, M. Midiri2,
M. Bazzocchi5, A. Vanzulli4;
1
Pittsburgh, PA/US, 2Palermo/IT, 3Rome/IT, 4Milano/IT, 5Udine/IT

11:16 SS 1.03 Quadriphasic CT in the diagnosis of 1–2 cm HCC: measuring performance of each
phase and combination
H. Jang, K. Khalili, T.K. Kim; Toronto, ON/CA

11:24 SS 1.04 Detection and characterization of focal liver lesions by MDCT in cirrhotic patients
undergoing liver transplantation
E. Bozzi, V. Battaglia, I. Bargellini, C. Bartolozzi; Pisa/IT

11:32 SS 1.05 The combination of CEUS and MDCT in the non invasive diagnostic criteria for
HCC in patients with chronic liver disease: prospective validation of EASL/AASLD
criteria
E. Gatti, M. Morone, P. Cabassa, C. Morelli, S. Gandolfi, R. Maroldi; Brescia/IT

11:40 SS 1.06 Analysis of multiple imaging parameters of MRI for characterizing small (1–2 cm)
nodules in high-risk patients for HCC
K. Khalili, T.K. Kim, M. Haider, M. Sherman, H. Jang; Toronto, ON/CA

11:48 SS 1.07 Detection of HCC in cirrhotic patients: qualitative comparison of gadoxetic acid
enhanced MRI and multiphasic 64-slice CT
M. di Martino, D. Marin, A. Guerrisi, F. Galati, G. de Filippis, C. Catalano, R. Passariello;
Rome/IT

11:56 SS 1.08 Gd-EOB-DTPA -enhanced dynamic and hepatobiliary phase MRI for Detection of
HCC: comparison with multiphase multidetected CT
S.J. Kim, J.M. Lee, J.Y. Lee, S.H. Kim, S.H. Kim, J.K. Han, B.I. Choi; Seoul/KR

12:04 SS 1.09 Growth rate of small (≤2 cm) HCC in cirrhotic patient: determining optimal
screening interval with serial CT or MRI
F. Agnello1, G. Brancatelli1, A. Furlan2, D. Marin3, A. Taibbi1, V. Bova1, T. Bartolotta1,
M. Midiri1; 1Palermo/IT, 2Pittsburgh, PA/US, 3Rome/IT

12:12 SS 1.10 What is the best imaging method to detect HCC in patients with chronic liver
disease: an evaluation using evidence-based practice methods
D. Moran, I. Heaslip, D. Malone; Dublin/IE

47
 SCIENTIFIC SESSIONS
WEDNESDAY, JUNE 24, 2009
11:00 – 12:30

SS 2 PANCREATIC NEOPLASMS AUDITORIUM 2

MULTIMODALITY APPROACH
Moderators: A. Megibow, New York, NY/US; A. Guarise, Bassano del Grappa/IT

11:00 SS 2.01 Contrast-enhanced US of pancreatic lesions: pancreatic multicenter

US study, preliminary results
M. D’Onofrio1, E. Barbi1, C.F. Dietrich2, M. Kitano3, K. Numata4, A. Sofuni5, F. Principe1,
A. Gallotti1, R. Pozzi Mucelli1;
1
Verona/IT, 2Bad Mergentheim/DE, 3Osaka/JP, 4Yokohama-shi/JP, 5Tokyo/JP
WEDNESDAY, JUNE 24

11:08 SS 2.02 US-guided fine-needle aspiration cytology of 545 focal pancreatic lesions:
accuracy and short-term complications
G. Zamboni, M. D’Onofrio, A. Idili, R. Iozzia, E. Manfrin, R. Pozzi Mucelli; Verona/IT

11:16 SS 2.03 Technical feasibility and first results of 64-row MDCT

perfusion of pancreatic adenocarcinoma
G. Zamboni, M. D’Onofrio, R. Malago, L. Bernardin, N. Faccioli, M. Contini; Verona/IT

11:24 SS 2.04 Perfusion imaging with dynamic volume CT in pancreatic cancer patients
C. Kloeters, S. Kandel, H. Meyer, G. Diederichs, P. Hein, P. Rogalla; Berlin/DE

11:32 SS 2.05 Pancreatic adenocarcinoma tumor grade determination

using contrast-enhanced MRI
T. Lauenstein1, R. Morreira2, J. Sarmiento2, V. Adsay2, D. Martin2;
1
Essen/DE, 2Atlanta, GA/US

11:40 SS 2.06 Pancreatic ductal adenocarcinoma versus focal chronic pancreatitis:

utility of diffusion-weighted MRI with parallel imaging technique and
multiple b gradient factor values
P. Boraschi, F. Donati, C. Bertucci, S. Salemi, R. Gigoni, C. Bartolozzi, F. Falaschi; Pisa/IT

11:48 SS 2.07 MRI versus 18F-FDG PET/CT in the differential diagnosis of benign
and malignant lesions of the pancreas
S. Salemi, P. Boraschi, F. Donati, A. Giorgetti, M. del Chiaro, D. Campani, U. Boggi,
F. Falaschi; Pisa/IT

11:56 SS 2.08 Diagnostic value of image fusion of MRI and FDG-positron emission tomography
in patients with suspected primary liver and pancreatic malignancies
C. Reiner, O. Donati, T. Hany, G.K. von Schulthess, B. Marincek, D. Weishaupt; Zurich/CH

12:04 SS 2.09 MRI with diffusion-weighted imaging for detecting endocrine pancreatic tumor
C. Caramella, C. Dromain, F. Bidault, M. Schlumberger, M. Ducreux, E. Baudin; Villejuif/FR

12:12 SS 2.10 Virtual MDCT pancreatoscopy of intraductal papillary mucinous

neoplasm of the pancreas
S. Mazzeo, V. Battaglia, C. Cappelli, B. Pontillo Contillo, C. Bartolozzi; Pisa/IT

48
SCIENTIFIC SESSIONS
WEDNESDAY, JUNE 24, 2009
11:00 – 12:30

SS 3 COLON AND RECTUM 1 AUDITORIUM 3A

Moderators: A.H. Freeman, Cambridge/UK; U. Korman, Istanbul/TR

11:00 SS 3.01 Perfusion CT assessment of the large bowel: assessment of normal colonic
perfusion, blood volume and vascular leakage
E. Tam1, S. Khan1, J. Juttla1, V. Goh1, C. Bartram2, S. Halligan3;
1
Northwood, Middlesex/UK, 2Harrow/UK, 3London/UK

11:08 SS 3.02 Diagnostic performance of radiographers as compared to radiologists in MR

colonography

WEDNESDAY, JUNE 24
F. Zijta, J. Florie, S. Jensch, S. Bipat, J. Stoker; Amsterdam/NL

11:16 SS 3.03 Validation of T2-weighted MRI derived colonic inflammation score for patients with
acute colitis
R. Hafeez, S. Punwani, D. Pendse, P. Boulos, S. Bloom, S. Halligan, S.A. Taylor; London/UK

11:24 SS 3.04 Correlation of colonic mural apparent diffusion coefficient and clinical/biochemical
markers of inflammation in severe acute colitis
R. Hafeez, S. Punwani, D. Pendse, P. Boulos, S. Bloom, S. Halligan, S.A. Taylor; London/UK

11:32 SS 3.05 MR for rectal cancer at 1.5 Tesla is sufficient for T staging, 3.0 Tesla MRI does not
necessarily improve radiologist’s performance
M. Maas, D. Lambregts, J. Wildberger, M. Lahaye, S. Engelen, G. Lammering,
V. Cappendijk, G. Beets, R. Beets-Tan; Maastricht/NL

11:40 SS 3.06 Diffusion weighted MRI for prediction of nodal status in rectal cancer patients: a
lesion by lesion analysis in a referral centre
D. Lambregts, M. Maas, F. Bakers, G. Beets, A. de Bruïne, J. Wildberger, R. Beets-Tan;
Maastricht/NL

11:48 SS 3.07 High-resolution 3D MR sequences for nodal staging of rectal cancer

T. Baumann, G. Pache, A. Schäfer, M. Langer; Freiburg/DE

11:56 SS 3.08 Diagnostic performance of USPIO-enhanced MRI for nodal staging in primary rectal
cancer is dependent on the number of lymph nodes harvested at histology
M. Maas, D. Lambregts, M. Lahaye, G. Beets, V. Cappendijk, J. Wildberger, R. Beets-Tan;
Maastricht/NL

12:04 SS 3.09 Accuracy of Gadofosveset-enhanced MRI for predicting nodal status in primary
rectal cancer
D. Lambregts, M. Maas, F. Bakers, G. Beets, A. Kessels, M. Lahaye, S. Engelen,
A. de Bruïne, J. Wildberger, R. Beets-Tan; Maastricht/NL

12:12 SS 3.10 Study of perineal hernias performed with defeco-MRI

F. Maisto, A. Reginelli, G. Lombardi, P. Liguori, L. Casale, M. Barbieri, A. Rotondo,
R. Grassi; Naples/IT

49
 SCIENTIFIC SESSIONS
WEDNESDAY, JUNE 24, 2009
11:00 – 12:30

SS 4 TECHNICAL ISSUES IN ONCOLOGY AUDITORIUM 3B

Moderators: M. Bellomi, Milan/IT; A. Ghiatas, Athens/GR

11:00 SS 4.01 Abdominal diffusion-weighted imaging: how specific is restricted

water diffusion for malignancy?
S. Feuerlein, S. Pauls, M. Juchems, T. Stuber, M. Hoffmann, H. Brambs, A. Ernst; Ulm/DE

11:08 SS 4.02 The clinical role of 18FDG PET/CT with iodinated contrast medium (contrast
enhanced 18FDG PET/CT): comparison with conventional 18FDG PET/CT
E. Biscaldi, M. Iacozzi, A. Piccardo, G. Villavecchia, G.A. Rollandi; Genoa/IT
WEDNESDAY, JUNE 24

11:16 SS 4.03 18F-FDG PET/CT versus contrast-enhanced 64-row MDCT of the chest and
abdomen for assessment of tumor recurrence in patients with colorectal cancer
and elevated carcinoembryonic antigen
U. Metser1, J. You2, S. McSweeney1, M. Freeman1; 1Toronto, ON/CA, 2Hamilton, ON/CA

11:24 SS 4.04 Incremental value of PET/MR retrospective image fusion in detection

of hepatic metastases compared to hybrid 18F-FDG-PET/CT and
Gd-EOB-DTPA enhanced MRI
O. Donati, C. Reiner, T. Hany, G.K. von Schulthess, B. Marincek, D. Weishaupt; Zurich/CH

11:32 SS 4.05 The difference of accuracy between FDG PET and FDG-PET/CT investigations
in follow-up of GIST patients
P. Fencl, Z. Linke; Prague/CZ

11:40 SS 4.06 Accuracy of retrospective multimodality image fusion between 18F-FDG-PET

and MRI in patients with malignancies of the liver and pancreas
O. Donati, C. Reiner, T. Hany, J. Fornaro, G.K. von Schulthess, B. Marincek,
D. Weishaupt; Zurich/CH

11:48 SS 4.07 Dual-energy CT for therapy monitoring of patients with advanced

GI stromal tumours under targeted treatment: initial results
N. Schramm, M. Schlemmer, E. Englhart, K. Nikolaou, C. Becker, M. Reiser, F. Berger;
Munich/DE

11:56 SS 4.08 Monitoring of molecular therapies in advanced GI stromal tumours: comparison

of tumour-response assessment according to RECIST with volumetry
N. Schramm, M. Schlemmer, E. Englhart, M. Reiser, F. Berger; Munich/DE

12:04 SS 4.09 Density changes in liver parenchyma and lesions in contrast enhanced CT
in patients with colorectal liver metastases after neoadjuvant
chemotherapy (CELIM trail)
A. Bethke, K. Kühne, G. Folprecht, P. Kamusella, M. Laniado, C. Stroszczynski;
Dresden/DE

12:12 SS 4.10 Multidetector-row CT in the preoperative staging of peritoneal carcinomatosis: are

arterial and delayed contrast-enhanced phases useful for the visualization of the
peritoneal implants?
R. Cianci, A. Filippone, S. Valeriano, G. Patriarca, F. Sabatino, R. Massari, F. Marino,
M. Storto; Chieti/IT

50
SCIENTIFIC SESSIONS
WEDNESDAY, JUNE 24, 2009
11:00 – 12:30

SS 5 GUT: FROM ESOPHAGUS TO RECTUM ROOM 1 + 2

Moderators: A. Laghi, Latina/IT; D. Maglinte, Indianapolis, IN/US

11:00 SS 5.01 T staging of oesophageal carcinoma: role of MDCT multiplanar reformatting

and vessel probe reconstructions
M. Moschetta, A. Stabile Ianora, A. Scardapane, G. Angelelli; Bari/IT

11:08 SS 5.02 The performance of hydro-multidetector CT in staging

of esophageal cancer in comparison to endscopic US
A. Ba-Ssalamah, W. Matzek, S. Baroud, N. Bastati-Huber, P. Pokieser, W. Schima,

WEDNESDAY, JUNE 24
J. Zacherl, A. Poespuek; Vienna/AT

11:16 SS 5.03 Volumetric assessment of gastric pouches with CT:

method comparison and interobserver agreement
T. Baumann, G. Pache, A. Schäfer, M. Langer; Freiburg/DE

11:24 SS 5.04 Ileo-cecal valve incompetence in patients undergoing same-day completion CTC:
a case control study
M. Sangwaiya, A. Singh, M. Cushing, C. Magee, I. Kazam, M. Zalis; Boston, MA/US

11:32 SS 5.05 Is colonoscopy necessary in all patients under 50 diagnosed

with diverticulitis on MDCT?
P. Nikolaidis, S. Dhand, N. Hammond, F. Miller, S. Berggruen, V. Yaghmai; Chicago, IL/US

11:40 SS 5.06 Colon cancer size measured on abdominal CT compared to histopathology

M. Torkzad1, C. Suzuki2, M. Golubovik1, S. Nilsson1, L. Blomqvist2;
1
Uppsala/SE, 2Stockholm/SE

11:48 SS 5.07 IMV: a prognostic indicator in rectal tumours

R. Botchu, K. Damodharan, A. Khan, B. Morgan, M. Elabassy; Leicester/UK

11:56 SS 5.08 Efficacy of Rectal detension after CTC

F. Iafrate1, A. Pichi1, A. Stagnitti1, M. Ciolina1, P. Baldassarri1, C. Hassan1, A. Laghi2;
1
Rome/IT, 2Latina/IT

12:04 SS 5.09 MRI in perianal Crohn’s disease: STIR versus T1w post-contrast fat-sat imaging
G. Lo Re1, M. Galia1, E. Grassedonio1, S. Lo Coco1, A. Carcione1, T. Bartolotta1,
F. Coppolino2, M. Midiri1; 1Palermo/IT, 2Siracusa/IT

12:12 SS 5.10 Abdominal staging of rectal cancer with continuously moving table MRI
T. Baumann, G. Pache, A. Schäfer, M. Langer; Freiburg/DE

51
 LUNCH SYMPOSIA
WEDNESDAY, JUNE 24, 2009
12:45 – 13:45

SY 3 WHY AND HOW GD-COMPLEXES ARE STILL AUDITORIUM 1

NEEDED IN ABDOMINAL MRI
Sponsored by: GUERBET

Moderator: M. Laniado, Dresden/DE

12:45 INTRODUCTION
M. Laniado, Dresden/DE
WEDNESDAY, JUNE 24

12:50 DO WE STILL NEED ENHANCED ABDOMINAL MRI?

M. Laniado, Dresden/DE

13:05 EXAMPLE IN ABDOMINAL TUMOURS

M. Lewin, Paris/FR

13:20 DYNAMIC MRI IN ANTI-VGEF TREATMENT RESPONSE

P. Smeets, Gent/BE

13:35 QUESTIONS AND CONCLUSION

M. Laniado, Dresden/DE

SY 4 CLINICAL SIGNIFICANCE OF INTERMEDIATE SIZE AUDITORIUM 2

CR LESIONS AND HOW TO IMPROVE THEIR
DETECTION WITH CAD
Sponsored by: im3D

Moderator: D. Regge, Candiolo/IT

12:45 INTRODUCTION
D. Regge, Candiolo/IT

12:50 RELEVANCE OF INTERMEDIATE SIZE LESIONS AND COST-EFFECTIVENESS

IN SCREENING PROGRAMS
C. Hassan, Rome/IT

13:00 INTERMEDIATE LESIONS: SURVEILLANCE OR POLYPECTOMY?

PRELIMINARY RESULTS OF A PROSPECTIVE MULTI-CENTRE STUDY
USING CAD AS A 2ND READER
D. Regge, Candiolo/IT

13:15 CAD DETECTION OF INTERMEDIATE AND SMALL LESIONS: PRACTICAL ISSUES

P. Rogalla, Berlin/DE

13:30 QUESTIONS AND ANSWERS

D. Regge, Candiolo/IT

52
HONORARY LECTURE / PLENARY SESSION
WEDNESDAY, JUNE 24, 2009
14:30 – 16:00

14:30 – 15:00
HL 2 SGR HONORARY LECTURE AUDITORIUM 2
NOVEL IMAGING METHODS OF TUMOUR RESPONSE ASSESSMENT
D. Sahani, Boston, MA/US

WEDNESDAY, JUNE 24
15:00 – 16:00
PS 2 CLINICAL FILES: AUDITORIUM 2
(INTERACTIVE CASE DISCUSSION)
HCC: CONTROVERSIES IN DIAGNOSIS AND TREATMENT
Moderator: C. Bartolozzi, Pisa/IT

Panellists: O. Akhan, Ankara/TR

C.D. Becker, Geneva/CH
L. Bolondi, Bologna/IT

53
CTC HANDS-ON CENTRE
WEDNESDAY, JUNE 24, 2009
14:00 – 18:00

CTC 1 CTC HANDS-ON CENTRE ROOM 8 + 9

14:00 INTRODUCTION OF THE CHAIRMAN OF THE CTC COMMITTEE

A. Laghi, Latina/IT

14:05 INTRODUCTORY LECTURE STATE-OF-THE-ART

E. Neri, Pisa/IT

WEDNESDAY, JUNE 24
14:30 HOW TO READ CTC: 2D VERSUS 3D
P. Vagli, Pisa/IT

15:30 CASE REVIEW

M.H. Liedenbaum, Amsterdam/NL

17:00 FREE TRAINING

M.H. Liedenbaum, Amsterdam/NL

y supported by
on Centre is kindl
The CTC Hands-

55
 LECTURE SESSIONS
WEDNESDAY, JUNE 24, 2009
16:30 – 18:00

LS 3 DIFFUSION WEIGHTED ABDOMINAL MRI: AUDITORIUM 1

CHARACTERISATION AND POST
TREATMENT EVALUATION
Moderators: C.J. Zech, Munich/DE ; D.J. Lomas, Cambridge/UK

16:30 LIVER
E.J. Rummeny, Munich/DE

Lecture objectives:
WEDNESDAY, JUNE 24

To review the parameters (sequence characteristics, b values, specific role of ADC maps)
and the optimal technical configuration for lesion characterisation. To illustrate the results
of DWI in focal liver lesions including cysts, hemangiomas, metastases and HCC. To show
how a background of chronic liver disease may affect overall DWI contrast. To discuss
sensitivity and specificity of the technique for lesion detection and characterisation. To
explore the potential role of DWI for post treatment evaluation.

16:50 PANCREAS
M.A. Bali, Brussels/BE

Lecture objectives:
To review the parameters (sequence characteristics, b values, specific role of ADC maps)
and the optimal technical configuration for lesion characterisation. To illustrate the results
of DWI in both cystic and solid pancreatic lesions and explain the role of the technique
in detection, characterisation and staging. To explore the potential role of DWI in acute/
chronic pancreatitis and illustrate how a background of inflammation may affect the
evaluation of focal pancreatic pathology.

17:10 RECTUM
S. Gourtsoyianni, Heraklion/GR

Lecture objectives:
To review the parameters (sequence characteristics, b values, specific role of ADC maps)
and the optimal technical configuration for lesion characterisation. To discuss the role
of DWI in initial local tumour staging and the assessment of post neoadjuvant treatment
downstaging. To describe the potential role of DWI in the detection of local recurrence.

17:30 LYMPH NODES AND PERITONEUM

C. Dromain, Villejuif/FR

Lecture objectives:
To review the parameters (sequence characteristics, b values, specific role of ADC
maps) and the optimal technical configuration for lesion characterisation. To review the
sensitivity and specificity of DWI when compared with other imaging techniques (PET/
CT and tissue specific contrast enhanced MRI) for the assessment of lymph node and
peritoneal pathology. To discuss the future role of DWI in the management of abdominal
malignancies.

17:50 PANEL DISCUSSION

56
LECTURE SESSIONS
WEDNESDAY, JUNE 24, 2009
16:30 – 18:00

LS 4 ABDOMINAL TRAUMA: LIMITATIONS AUDITORIUM 2

OF MDCT IMAGING
Moderators: D.F.C. Shepherd, Bournemouth/UK; R. Bouzas, Vigo/ES

16:30 ABDOMINAL INJURIES: IMAGING PITFALLS AND ERRORS

R.F. Dondelinger, Liège/BE

Lecture objectives:
To summarise and review the factors which may be responsible for errors when diagnosing

WEDNESDAY, JUNE 24
abdominal injuries, including pitfalls of MDCT examination technique and imaging of the
shocked patient. To explain how an understanding of the pathophysiology of trauma
reduces diagnostic errors. To review the diagnosis of thoracic and retroperitoneal injuries
which may be associated with or mimick intraperitoneal abdominal trauma. To illustrate
potential MDCT pitfalls when imaging trauma to both solid organs and the GI tract.

16:50 PHRENIC RUPTURE: A DIAGNOSTIC DIFFICULTY

B. Ghaye, Liège/BE

Lecture objectives:
To provide an overview of the clinical symptoms and signs of phrenic rupture. To illustrate
the appearances of phrenic rupture on MDCT and discuss the diagnostic value of MPR
images. To summarise the results of MDCT. To list the potential complications of a delayed
or missed diagnosis.

17:10 TRAUMA TO THE GI TRACT: VARIOUS FACETS

S. Romano, Naples/IT

Lecture objectives:
To review the clinical signs and symptoms of injuries to the gastrointestinal tract. To
illustrate the various aspects of injuries on MDCT, including vascular and mesenteric
trauma. To summarise optimal examination technique and introduce the concept of
micropneumoperitoneum.

17:30 POST TRAUMATIC HEMORRHAGE: MDCT DIAGNOSIS

A.J. Aschoff, Ulm/DE

Lecture objectives:
To discuss the optimal examination technique to diagnose post traumatic hemorrhage
and underlying vascular injury. To illustrate the imaging features and explain the clinical
relevance of arterial versus venous bleeding and active versus arrested hemorrhage on
MDCT. To review the complications of vascular trauma including pseudoaneurysm and
arteriovenous fistula formation. To summarise the concept of a “tension hematoma”.

17:50 PANEL DISCUSSION

57
 PROGRAMME OVERVIEW
THURSDAY, JUNE 25, 2009

08:00 – 08:45 WS 8 Cholangiocarcinoma: Diagnosis and staging Auditorium 3A

08:00 – 08:45 WS 9 MRCP: Technique and clinical applications Auditorium 3B
08:00 – 08:45 WS 10 Appendicitis and diverticulitis: Diagnosis and Room 1 + 2
mimicking pathology
08:00 – 08:45 WS 11 CT Colonography: Pitfalls Room 3 + 4
08:00 – 08:45 WS 12 From the European Curriculum (2.4 and 2.7): Room 6 + 7
Mesenteric ischaemia
08:00 – 08:45 WS 13 EBP (Evidence-Based Practice II) Appraising literature Room 5
about diagnostic test performance – keeping it simple;
applying results when “ruling in” or “ruling out” clinically
suspected conditions.
08:00 – 08:45 WS 14 Interactive Workshop: MRI of Rectal Carcinoma (2) EPOS™ Area

09:00 – 10:30 IR 2 Intervention - a practical approach: GI interventions Room 6 + 7

09:00 – 10:30 LS 5 Screening CTC: Current status Auditorium 1

09:00 – 10:30 LS 6 Diagnostic challenges in biliary disease Auditorium 2

10:30 – 11:00 BREAK

11:00 – 12:30 RC 2 Research Corner: Imaging Biomarkers Room 3 + 4

11:00 – 12:30 SS 6 Liver Metastases Auditorium 1

11:00 – 12:30 SS 7 Bile ducts and pancreatitis Auditorium 2
11:00 – 12:30 SS 8 Colon and Rectum 2 Auditorium 3A
11:00 – 12:30 SS 9 Liver intervention Auditorium 3B
11:00 – 12:30 SS 10 Small and large Bowel Room 1 + 2

12:45 – 13:45 SY 5 MEDICSIGHT Symposium: Auditorium 1

CT Colonography and CAD: Promoting excellence
THURSDAY, JUNE 25

and ensuring minimum standards

12:45 – 13:45 SY 6 BRACCO Symposium: Auditorium 2

Improving outcomes in cancer care from early
detection to effective staging

13:45 – 14:30 BREAK

14:00 – 18:00 CTC 2 CTC Hands-on Centre Room 8 + 9

14:30 – 15:00 HL 3 JSAR Honorary Lecture Auditorium 2

15:00 – 16:00 PS 3 Clinical Files (Interactive Case Discussion): Auditorium 2

Bowel wall thickening: A diagnostic challenge

16:00 – 16:30 BREAK

16:30 – 18:00 LS 7 Imaging the mesentery and peritoneum Auditorium 1

16:30 – 18:00 LS 8 HCC: From diagnosis to treatment Auditorium 2

18:00 – 18:45 GA 1 ESGAR General Assembly Auditorium 3A

58
WORKSHOPS
THURSDAY, JUNE 25, 2009
08:00 – 08:45

WS 8 CHOLANGIOCARCINOMA: Auditorium 3A
DIAGNOSIS AND STAGING
L. Curvo-Semedo, Coimbra/PT
O. Matsui, Kanazawa/JP

WS 9 MRCP: TECHNIQUE AND CLINICAL APPLICATIONS Auditorium 3B

P. Paolantonio, Latina/IT
M. Sheridan, Leeds/UK

WS 10 APPENDICITIS AND DIVERTICULITIS: Room 1 + 2

DIAGNOSIS AND MIMICKING PATHOLOGY
J.B.C.M. Puylaert, The Hague/NL
Z. Tarjan, Budapest/HU

WS 11* CT COLONOGRAPHY: PITFALLS Room 3 + 4

D. Burling, Harrow/UK
E. Neri, Pisa/IT

WS 12* FROM THE EUROPEAN CURRICULUM (2.4 AND 2.7): Room 6 + 7

MESENTERIC ISCHAEMIA
R. Bouzas, Vigo/ES
S.G. Feuerbach, Regensburg/DE

THURSDAY, JUNE 25
WS 13* EBP (EVIDENCE-BASED PRACTICE II) Room 5
APPRAISING LITERATURE ABOUT DIAGNOSTIC TEST PERFORMANCE –
KEEPING IT SIMPLE; APPLYING RESULTS WHEN ‘RULING IN’ OR
‘RULING OUT’ CLINICALLY SUSPECTED CONDITIONS.
D.E. Malone, Dublin/IE
S.A. Taylor, London/UK

WS 14* INTERACTIVE WORKSHOP: EPOS™ Area

MRI OF RECTAL CARCINOMA (2)
R.G.H. Beets-Tan, New York, NY/US

*=workshop fully booked.

DETAILED WORKSHOP DESCRIPTION PLEASE SEE PAGES 21 – 22

59
 INTERVENTIONAL RADIOLOGY
THURSDAY, JUNE 25, 2009
09:00 – 10:30

IR 2 INTERVENTION - A PRACTICAL APPROACH: ROOM 6 + 7

GI INTERVENTIONS
Moderator: C. Kay, Bradford/UK

09:00 OESOPHAGEAL STENTING

H.-U. Laasch, Manchester/UK

Lecture objectives:
To review the indications, techniques, results and potential complications of oesophageal
stenting for both benign and malignant disease, including oesophageal fistulae. To
emphasise relevant procedural tips and tricks to optimise outcomes and to explain the
complementary role of endoscopy/surgery in patient management. To summarise recent
advances in stent technology.

09:20 GASTRODUODENAL STENTING

C. Kay, Bradford/UK

Lecture objectives:
To review the indications, techniques, results and potential complications of gastroduodenal
stenting for patients with gastric outlet obstruction. To emphasise relevant procedural tips
and tricks to optimise outcomes and to explain the complementary role of endoscopy/
surgery in patient management. To summarise recent advances in stent technology.

09:40 COLONIC STENTING

J. Martínez Rodrigo, Valencia/ES
THURSDAY, JUNE 25

Lecture objectives:
To review the indications, techniques, results and potential complications of colonic
stenting for both malignant and benign strictures. To emphasise relevant procedural tips
and tricks to optimise outcomes and to explain the complementary role of endoscopy/
surgery in patient management. To summarise recent advances in stent technology.

10:00 PANEL DISCUSSION

60
 LECTURE SESSIONS
THURSDAY, JUNE 25, 2009
09:00 – 10:30

LS 5 SCREENING CTC: CURRENT STATUS AUDITORIUM 1

Moderators: R.A. Frost, Salisbury/UK; F.-T. Fork, Malmö/SE

09:00 SCREENING GUIDELINES

J. Stoker, Amsterdam/NL

Lecture objectives:
To summarise the rationale for colorectal cancer screening including epidemiology, risk
factors and risk stratification of the general population. To review recently released
colorectal cancer screening guidelines. To emphasise the role of CT colonography in
screening programmes.

09:20 CURRENT STATUS OF SCREENING CT COLONOGRAPHY

D. Regge, Candiolo/IT

Lecture objectives:
To review current CTC protocols with emphasis on safety issues including radiation
exposure and perforation risk. To summarise the results from relevant multicenter trials.
To discuss the importance of study design, reader experience and reporting methods (2D,
3D, CAD) in screening CTC.

09:40 SMALL AND INTERMEDIATE SIZED POLYPS:

WHEN TO REPORT, REMOVE OR FOLLOW UP
P. Pickhardt, Madison, WI/US
THURSDAY, JUNE 25

Lecture objectives:
To define small and intermediate polyp size. To review polyp pathology including the risk
of cancer and high grade dysplasia in small and intermediate sized polyps. To summarise
the current debate with regard to intermediate polyps (conservative management versus
polypectomy) and the rationale for the non reporting of diminutive polyps.

10:00 COST EFFECTIVENESS AND IMPACT OF SCREENING

CT COLONOGRAPHY ON HEALTHCARE SYSTEMS
S.A. Taylor, London/UK

Lecture objectives:
To explain cost-effective analysis and define measurements of cost-effectiveness. To
discuss the cost-effectiveness of CT colonography and relevant impact of extra-colonic
findings. To explore the potential impact of screening CT colonography on national health
care systems.

10:20 PANEL DISCUSSION

62
LECTURE SESSIONS
THURSDAY, JUNE 25, 2009
09:00 – 10:30

LS 6 DIAGNOSTIC CHALLENGES IN BILIARY DISEASE AUDITORIUM 2

Moderators: C. Matos, Brussels/BE; J.S. Lameris, Amsterdam/NL

09:00 CYSTIC MALFORMATIONS AND COMPLICATIONS

T.K. Kim, Toronto, ON/CA

Lecture objectives:
To review the epidemiology of cystic bile duct malformations and Todani`s classification.
To discuss the various complications of cystic malformations. To illustrate the advantages
and limitations of different imaging modalities including a practical imaging algorithm for
the diagnosis of cystic bile duct malformations and their related complications.

09:20 SCLEROSING CHOLANGITIS VERSUS CHOLANGIOCARCINOMA

R. Manfredi, Verona/IT

Lecture objectives:
To review the epidemiology, pathology and clinical course of both sclerosing cholangitis
and cholangiocarcinoma. To illustrate diagnostic features for both pathologies and to
discuss the role of multimodality imaging in the differential diagnosis. To summarise
algorithms for radiological follow-up.

09:40 PERIAMPULLARY STRICTURES: DIFFERENTIAL DIAGNOSIS

D.F. Martin, Manchester/UK

Lecture objectives:

THURSDAY, JUNE 25
To review the aetiology of periampullary strictures. To provide an imaging algorithm for
the differential diagnosis of periampullary strictures. To discuss the advantages and
limitations of multimodality imaging techniques for stricture characterisation.

10:00 POST-OPERATIVE STENOSES: DIAGNOSIS AND TREATMENT

P. Huppert, Darmstadt/DE

Lecture objectives:
To review the common surgical procedures which may be complicated by biliary stricture
formation and to summarise clinical presentation. To provide an imaging algorithm for the
diagnosis of suspected post-operative biliary strictures. To discuss the indications for
either surgical or interventional management. To review current interventional management
including clinical results and complications.

10:20 PANEL DISCUSSION

63
 RESEARCH CORNER
THURSDAY, JUNE 25, 2009
11:00 – 12:30

RC 2 RESEARCH CORNER: IMAGING BIOMARKERS ROOM 3 + 4

Moderator: L. Martí-Bonmatí, Valencia/ES

11:00 DEFINITION
D.J. Lomas, Cambridge/UK

Lecture objectives:
To describe the importance of quantitative imaging biomarkers for evaluating the presence
and severity of abdominal disorders, and assessing the effect of therapy. To show the
various approaches that can be used to obtain clinically useful biomarkers. To discuss
the importance of measurement standardisation. To illustrate examples of biomarkers
obtained from different imaging sources.

11:15 DIFFUSION
C. Matos, Brussels/BE

Lecture objectives:
To illustrate the importance of diffusion weighted imaging for the prediction of lesion
aggressiveness and response to treatment. To demonstrate the importance of b values
and their magnitude when assessing the reproducibility and accuracy of diffusion. To show
the relevance of ADC maps, with fast and slow components, in lesion characterisation.

11:30 PERFUSION AND ANGIOGENESIS

T. Metens, Brussels/BE

Lecture objectives:
THURSDAY, JUNE 25

To review the different ways that imaging biomarkers can be used to evaluate vessel
properties. To demonstrate the role of cross sectional imaging techniques in the evaluation
of perfusion and permeability. To describe the most important surrogate vascular endpoints
which can be used for the assessment of inflammation and tumour evaluation. To show
how pharmacokinetic analysis and modelling can be used to characterise, predict and
evaluate the response to treatment. To explain how imaging biomarkers of perfusion and
pharmacokinetics can help in preclinical trials of drug development.

11:45 SPECTROSCOPY
B. Celda Muñoz, Valencia/ES

Lecture objectives:
To demonstrate the most important approaches to the evaluation of metabolomics
in abdominal inflammatory conditions and tumours. To discuss the most relevant
metabolomics that can be assigned for in vivo abdominal MR spectroscopy examinations.
To review the standardised and absolute measurements when assessing these components.

12:00 PANEL DISCUSSION

64
SCIENTIFIC SESSIONS
THURSDAY, JUNE 25, 2009
11:00 – 12:30

SS 6 LIVER METASTASES AUDITORIUM 1

Moderators: I. Ramos, Porto/PT; R. Hammerstingl, Frankfurt am Main/DE

11:00 SS 6.01 Value of diffusion-weighted MRI in detecting and characterising liver metastasis
C. Kenis, B. de Foer, F. van Mieghem, F. Deckers; Antwerp/BE

11:08 SS 6.02 Detection and characterization of liver lesions in patients with GI cancer with
diffusion-weighted MRI
M. Eiber, M. Bruegel, C. Ganter, J. Gaa, E. Rummeny, K. Holzapfel; Munich/DE

11:16 SS 6.03 Comparison of diffusion-weighted MRI and MDCT in the detection of liver
metastases in patients with pancreatic cancer
K. Holzapfel, C. Reiser-Erkan, A. Fingerle, E. Rummeny, J. Gaa; Munich/DE

11:24 SS 6.04 Use of primovist in the study of liver metastases of colorectal cancer
J.R. Ayuso, M. Pagés Llinás, C. Ayuso, J. Rios, J. Maurel, B. Paño, C. de Juan,
S. Rodríguez; Barcelona/ES

11:32 SS 6.05 Hepatic metastases from colorectal cancer: prospective evaluation of US, CEUS
and BOPTA-enhanced-MRI as compared with intraoperative US
V. Cantisani1, V. Maldur2, P. Ricci1, O. Medvedyeva1, U. D’Ambrosio1, G. Menichini1,
E. Marotta1, M. di Martino1, R. Passariello1; 1Rome/IT, 2Viterbo/IT

11:40 SS 6.06 To compare the diagnostic accuracy of portal-phase CT and MRI with mangafodipir
trisodium in detecting liver metastases from colorectal carcinoma following
neoadjuvant therapy
T. Gallo1, S. Cirillo1, A. Macera1, G. Iussich1, L. Scotti2, D. Campanella1, D. Regge1;
1
Candiolo/IT, 2Milan/IT

THURSDAY, JUNE 25
11:48 SS 6.07 Does preoperative chemotherapy impact on the ability of the liver to regenerate
after hepatectomy for colorectal metastases: assessment with liver volumetry
C. Reiner, S. Breitenstein, P. Samaras, M. Puhan, M. Montani, T. Frauenfelder,
K. Slankamenac, A. Rickenbacher, P. Clavien; Zurich/CH

11:56 SS 6.08 CT evaluation of the response of colorectal liver metastasis after bevacizumab
treatment: a size and density quantitative analysis correlated with patient outcome
B. Gallix, S. Aufort, M. Pierredon-Foulongne, J. Bruel; Montpellier/FR

12:04 SS 6.09 Computed assisted follow-up of hepatic metastases in CT: impact on treatment
response assessment
M. Azahaf, S. Boury, O. Ernst; Lille/FR

12:12 SS 6.10 Liver metastases follow-up: impact of semi-automated lesion volumetry

F. Vandenbroucke, F. de Munck, B. Ilsen, J. de Mey; Brussels/BE

65
 SCIENTIFIC SESSIONS
THURSDAY, JUNE 25, 2009
11:00 – 12:30

SS 7 BILE DUCTS AND PANCREATITIS AUDITORIUM 2

Moderators: H. Mori, Oita/JP; G. Zamboni, Verona/IT

11:00 SS 7.01 Morphologic classification of intraductal papillary neoplasm of the bile ducts:
radiologic-pathologic correlation
J.H. Lim, J.Y. Lee, K. Jang, H.K. Lim; Seoul/KR

11:08 SS 7.02 Diagnosis of anomalous pancreaticobiliary ductal junction using MDCT and MRI
A. Nakamoto, T. Kim, M. Hori, M. Onishi, Y. Nakaya, T. Tsuboyama, H. Higashihara, N.
Maeda, M. Tatsumi, K. Osuga, K. Tomoda, H. Nakamura; Suita/JP

11:16 SS 7.03 Safety and efficacy of CTC

K. Lim1, N. Grunshaw2; 1Yarm/UK, 2Darlington/UK

11:24 SS 7.04 Biliary anatomy of potential donor for living donor liver transplantation: the utility of
CTC in cases with indeterminate results on MRCP
S. McSweeney, T.K. Kim, H. Jang, K. Khalili; Toronto, ON/CA

11:32 SS 7.05 Ductal pancreatic abnormalities in patients with autoimmune pancreatitis at MRI
compared with chronic pancreatitis and normal patients
M. Vullierme, D. O’Toole, A. Couvelard, P. Hammel, P. Levy, P. Ruszniewski, V. Vilgrain;
Clichy/FR

11:40 SS 7.06 Stricture of end-to-end biliary anastomosis after adult orthotopic liver
transplantation: incidence, treatment and outcome
D. Botsikas, C. Becker, P. Majno, L. Rubbia-Brandt, S. Terraz; Geneva/CH

11:48 SS 7.07 Contribution of diffusion-weighted MRI in pancreatic diseases

L. Cereser, A. Nascimento, M. Coutinho, M. Arvanitakis, M.A. Bali, C. Matos; Brussels/BE
THURSDAY, JUNE 25

11:56 SS 7.08 Perfusion imaging with 320-slice CT in patients with acute pancreatitis
S. Kandel, C. Kloeters, H. Meyer, P. Rogalla; Berlin/DE

12:04 SS 7.09 Biliary complications in liver transplant patients: usefulness of mangafodipir

trisodium-enhanced MR cholangiography
F. Donati, P. Boraschi, R. Gigoni, S. Salemi, F. Filipponi, C. Bartolozzi, F. Falaschi; Pisa/IT

12:12 SS 7.10 A T2* MRI study of pancreatic overload in thalassemia major, thalassemia
intermedia and thalasso-drepanocytosis
G. Restaino1, M. Missere1, M. Ciuffreda1, E. Cucci1, A. Pepe2, G. Sallustio1;
1
Campobasso/IT, 2Pisa/IT

66
SCIENTIFIC SESSIONS
THURSDAY, JUNE 25, 2009
11:00 – 12:30

SS 8 COLON AND RECTUM 2 AUDITORIUM 3A

Moderators: G. Maskell, Truro/UK; F. Iafrate, Rome/IT

11:00 SS 8.01 Low-fiber diet in CTC bowel preparation: influence on image quality, patient
acceptance and polyp detection
M. Liedenbaum1, M. Denters1, A. de Vries1, I. Serlie2, E. Dekker1, J. Stoker1;
1
Amsterdam/NL, 2Best/NL

11:08 SS 8.02 Comparing safety and acceptability of same-day CTC and conventional
colonoscopy in a multicenter setting
G. Iussich, C. Laudi, P. Della Monica, G. Galatola, L. Bonelli, D. Regge; Candiolo/IT

11:16 SS 8.03 CTC: is the follow-up proposed in C-RADS 2 the right choice?
F. Turini, E. Neri, F. Cerri, S. Angeli, L. Cini, P. Vagli, C. Bartolozzi; Pisa/IT

11:24 SS 8.04 Building of a CTC database for clinical research

P. Della Monica1, G. Iussich1, C. Laudi1, L. Correale2, A. Bert2, D. Regge1;
1
Candiolo/IT, 2Turin/IT

11:32 SS 8.05 Value of diffusion weighted MRI for predicting tumour response to chemoradiation
therapy in patients with advanced rectal cancer
D. Lambregts1, C. Matos2, S. Gourtsoyianni3, A. Kessels1, G. Beets1, M. Maas1,
V. Cappendijk1, J. Wildberger1, R. Beets-Tan1; 1Maastricht/NL, 2Brussels/BE, 3Heraklion/GR

11:40 SS 8.06 MR tumour volumetry pre and post chemo radiotherapy in patients with rectal
cancer: can MR predict response to therapy
D. Prasad, S. Yule, L. Samuel, G. Murray, F. Gilbert; Aberdeen/UK

11:48 SS 8.07 MR-based wait-and-see policy in clinical complete responders to chemoradiation

THURSDAY, JUNE 25
in rectal cancer: a promising and controversial alternative
M. Maas, D. Lambregts, R. van Dam, P. Nelemans, G. Lammering, R. Jansen,
V. Cappendijk, G. Beets, R. Beets-Tan; Maastricht/NL

11:56 SS 8.08 MR colonography in the detection of colorectal lesions: a systematic review and
meta-analysis of prospective studies
F. Zijta, S. Bipat, J. Stoker; Amsterdam/NL

12:04 SS 8.09 The role of 3D endoanal US in the assessment of perianal disease and dysfunction
F. Maisto, A. Reginelli, G. Lombardi, L. Casale, M. Barbieri, P. Liguori, A. Rotondo,
R. Grassi; Naples/IT

12:12 SS 8.10 Diffusion tensor imaging of the anal canal at 3-Tesla: assessment of anisotropy
measures of components of the anal canal
E. Tam, N.J. Taylor, J.J. Stirling, I. Simcock, R. Glynne-Jones, A. Padhani, V. Goh;
Northwood, Middlesex/UK

67
 SCIENTIFIC SESSIONS
THURSDAY, JUNE 25, 2009
11:00 – 12:30

SS 9 LIVER INTERVENTION AUDITORIUM 3B

Moderators: E.J. Rummeny, Munich/DE; J. Martínez Rodrigo, Valencia/ES

11:00 SS 9.01 Role of 64 slices angio-CT scan in detection of early vascular complication in
piggy-back orthotopic liver transplantation
E. Siopis, A. Pecchi, M. de Santis, R. Ballarin, F. di Benedetto, G.E. Gerunda, P. Torricelli;
Modena/IT

11:08 SS 9.02 Do trauma scores predict the requirement for intervention following liver trauma?
D. Lewis, P. Kane, O. Jaffer, P. Marriot, M. Bowles, G. Auzinger, J. Karani; London/UK

11:16 SS 9.03 Bile leaks after hepatic surgery and liver transplantation: usefulness of Mn-DPDP-
enhanced 3D T1-weighted MR cholangiography
F. Donati, P. Boraschi, R. Gigoni, S. Salemi, F. Filipponi, C. Bartolozzi, F. Falaschi; Pisa/IT

11:24 SS 9.04 Hepatic encephalopaty in patients treated with expanded polytetrafluoroethylene-

covered stent grafts: initial results of a randomized trial of 8 versus 10 mm Viatorr
stent graft
E. Boatta, F. Fanelli, G. Orgera, F. Salvatori, A. Bruni, R. Passariello; Rome/IT

11:32 SS 9.05 A review of transjugular intrahepatic portosystemic shunt procedures in a regional

tertiary centre: factors affecting mortality and restenosis rates
T. Odetoyinbo1, B. Sreeharsha2, A. Ganguly1, S. Powell1; 1Liverpool/UK, 2Boston, MA/US

11:40 SS 9.06 TIPS with e-PTFE-covered stent in non-cirrhotic patients with cavernomatous
transformation of the portal vein
E. Boatta, F. Fanelli, F. Salvatori, M. Corona, A. Bruni, P. Rossi, R. Passariello; Rome/IT

11:48 SS 9.07 Colorectal cancer liver metastases treated by yttrium 90:

THURSDAY, JUNE 25

results of 64 patients’ series

C. Urigo1, E. Notarianni1, A. Saltarelli1, V. Pasqualini1, R. Salvatori1, A. D’Agostini1,
E. Cortesi2, R. Cianni1; 1Latina/IT, 2Rome/IT

11:56 SS 9.08 Transarterial chemoembolization in down-staging program for HCC prior to liver
transplantation: the Bologna work-in-progress experience
A. Cappelli, E. Giampalma, M. Renzulli, C. Mosconi, R. Golfieri; Bologna/IT

12:04 SS 9.09 A randomised phase II trial of a drug eluting bead in the treatment of HCC
by transcatheter arterial chemoembolization
R. Lencioni1, L. Crocetti1, K. Malagari2, T. Vogl3, F. Pilleul4, A. Denys5, A. Watkinson6,
J. Lammer7; 1Pisa/IT, 2Athens/GR, 3Frankfurt am Main/DE, 4Lyon/FR, 5Lausanne/CH,
6
Devon/UK, 7Vienna/AT

12:12 SS 9.10 Assessment of viable tumor tissue attached to needle applicators after local liver
ablation of liver tumors: viable tumour tissue after local ablation
M. Jansen1, N. Snoeren2, A. Rijken3, R. van Hillegersberg2, E. van der Linden4, F. ten Kate1,
T. van Gulik1; 1Amsterdam/NL, 2Utrecht/NL, 3Breda/NL, 4Rotterdam/NL

68
SCIENTIFIC SESSIONS
THURSDAY, JUNE 25, 2009
11:00 – 12:30

SS 10 SMALL AND LARGE BOWEL ROOM 1 + 2

Moderators: S. Romano, Naples/IT; A. Madureira, Porto/PT

11:00 SS 10.01 Exposure to ionizing radiation in patients with functional GI disorders

A. Desmond, K. O’Regan, K. Walsh, S. McWilliams, M. Maher, F. Shanahan, E. Quigley;
Cork/IE

11:08 SS 10.02 Accuracy of abdominal CT in the diagnosis of bowel ischemia in patients suspected
with acute abdomen in general
A. van Randen, W. Laméris, P. Bossuyt, M. Boermeester, J. Stoker; Amsterdam/NL

11:16 SS 10.03 MSCT for detection of intestinal bleeding; single or double contrast phases are
needed: an experimental setting
M. Dobritz, H. Engels, A. Schneider, E. Rummeny; Munich/DE

11:24 SS 10.04 Is MDCT able to demonstrate the type of adhesions in case of small bowel
occlusion: band or adherences?
C. Ridereau-Zins, P. Manchec, J. Lebigot, E. Lermite, C. Aube; Angers/FR

11:32 SS 10.05 MR-enteroclysis versus MSCT-enteroclysis in the diagnosis of bowel endometriosis

E. Biscaldi, A. Fasciani, S. Ferrero, V. Remorgida, G.A. Rollandi; Genoa/IT

11:40 SS 10.06 MR diffusion weighted images in patients with Crohn’s disease

F. Maccioni, V. Garbarino, F. Carrozzo, A. Kagarmanova, A. Castorino, M. Marini; Rome/IT

11:48 SS 10.07 Implementation of diffusion weighted imaging into an MR-enterography protocol:

a feasibility study
P. Paolantonio1, R. Ferrari1, C. Hassan2, G. Suma2, F. Vecchietti1, P. Lucchesi1, A. Laghi1;
1
Latina/IT, 2Rome/IT

THURSDAY, JUNE 25
11:56 SS 10.08 MR enteroclysis: the value in localizing and characterizing primary carcinoid
tumors of the small bowel
C. Schmid-Tannwald, C. Zech, M. Reiser, K. Herrmann; Munich/DE

12:04 SS 10.09 Feasibility of small bowel flow measurement with MRI: a volunteer study
A. Gutzeit1, J. Froehlich1, C. von Weymarn1, C. Binkert1, M. Patak2;
1
Winterthur/CH, 2Bern/CH

12:12 SS 10.10 “Motasso”, a new software to analyze small bowel motility: work in progress
M. Patak1, Z. Szucs-Farkas1, R. Cattin2, S. Raible2, H. Bouquet1, P. Vock1, J. Froehlich3;
1
Bern/CH, 2Biel/CH, 3Winterthur/CH

69
LUNCH SYMPOSIA
THURSDAY, JUNE 25, 2009
12:45 – 13:45

SY 5 CT COLONOGRAPHY AND CAD: PROMOTING AUDITORIUM 1

EXCELLENCE AND ENSURING MINIMUM STANDARDS
Sponsored by: MEDICSIGHT

Moderators: D. Burling, Harrow/UK; A. Laghi, Latina/IT

12:45 CT COLONOGRAPHY AND CAD –

DELIVERING BEST PRACTICE
D. Burling, Harrow/UK

13:00 A EUROPEAN PERSPECTIVE

A. Laghi, Latina/IT

13:15 CT COLONOGRAPHY EDUCATION AND TRAINING:

WHAT’S HAPPENING IN THE USA?
P. Pickhardt, Madison, WI/US

13:30 LATEST ADVANCES IN CT COLONOGRAPHY AND CAD TRAINING:

WHAT DOES THE FUTURE HOLD?
P. Lefere, Roeselare/BE

SY 6 IMPROVING OUTCOMES IN CANCER CARE AUDITORIUM 2

THURSDAY, JUNE 25
FROM EARLY DETECTION TO EFFECTIVE STAGING
Sponsored by: BRACCO

Moderator: L. Martí-Bonmatí, Valencia/ES

12:45 CANCER STAGING AND METS DETECTION: MDCT OR MR?

D. Sahani, Boston, MA/US

13:05 ROLE OF CONTRAST ENHANCED ULTRASOUND IN THE

CHARACTERIZATION OF DOUBTFUL LIVER LESIONS
L. Bolondi, Bologna/IT

13:25 SHOULD CT COLONOGRAPHY BE THE FIRST LINE TEST

FOR SCREENING AND DIAGNOSIS OF COLORECTAL CANCER?
D. Burling, Harrow/UK

71
 CTC HANDS-ON CENTRE
THURSDAY, JUNE 25, 2009
14:00 – 18:00

CTC 2 CTC HANDS-ON CENTRE ROOM 8 + 9

14:00 INTRODUCTION OF THE CHAIRMAN OF THE CTC COMMITTEE

A. Laghi, Latina/IT

14:05 INTRODUCTORY LECTURE STATE-OF-THE-ART

P. Lefere, Roeselare/BE

14:30 HOW TO READ CTC: 2D VERSUS 3D

S.A. Taylor, London/UK

15:30 CASE REVIEW

C. Robinson, London/UK

17:00 FREE TRAINING

C. Robinson, London/UK
THURSDAY, JUNE 25

TRE
0 9
0 N CEN
R 2 O 2 6 , 200
9
1)

S GA D S- , J UNE PART )
DAY 11:00 ( ART 2
THU

FRI
E HAN 0–
08:0 – 13:
0
12:3 M 8 +
30 (
9
P

CTC , JUN
E 2 4 , 20
09
ROO
Y
N E SDA 0
WE
D
– 18:0
0 9 9
14:0 M 8 + 5 , 200
2
ROO J U NE
,
R S DAY 0
0
THU – 18:
0 0 9
14: M 8 +
ROO

72
HONORARY LECTURE / PLENARY SESSION
THURSDAY, JUNE 25, 2009
14:30 – 16:00

14:30 – 15:00
HL 3 JSAR HONORARY LECTURE AUDITORIUM 2
IMAGING OF THE PERITONEUM: IMAGINE THE INVISIBLE!
M. Minami, Tsukuba/JP

15:00 – 16:00
PS 3 CLINICAL FILES: AUDITORIUM 2
(INTERACTIVE CASE DISCUSSION)
BOWEL WALL THICKENING: A DIAGNOSTIC CHALLENGE
Moderator: J.-M. Bruel, Montpellier/FR

Panellists: S. Gourtsoyianni, Heraklion/GR

T. Mang, Vienna/AT
P.J. Shorvon, London/UK

THURSDAY, JUNE 25

73
 LECTURE SESSIONS
THURSDAY, JUNE 25, 2009
16:30 – 18:00

LS 7 IMAGING THE MESENTERY AND PERITONEUM AUDITORIUM 1

Moderators: P. Pokieser, Vienna/AT; O. Akhan, Ankara/TR

16:30 ANATOMICAL LANDMARKS

J. Heiken, St. Louis, MO/US

Lecture objectives:
To review the relevant anatomy of the mesentery and peritoneal spaces which can be
illustrated by multimodality imaging techniques. To understand the normal circulation
pathways of peritoneal fluid and to illustrate their relevance to spread of intraperitoneal
pathology.

16:50 PRIMARY PERITONEAL TUMOURS

M. Zins, Paris/FR

Lecture objectives:
To review the differential diagnosis, clinical presentation and pathology of primary
peritoneal tumours. To illustrate the varied multimodality radiological appearances (US,
CT, MRI and PET/CT) of pathologies, including peritoneal mesothelioma, pseudomyxoma
peritonei, mesenteric lymphoma, and rare sarcomas. To discuss possible treatment
options and to summarise the role of radiology in the follow-up of treated patients.

17:10 PERITONEAL METASTASES

A. Filippone, Chieti/IT

Lecture objectives:
THURSDAY, JUNE 25

To discuss the epidemiology, differential diagnosis and prognosis of peritoneal

carcinomatosis. To illustrate the multimodality imaging features of the pathology. To
summarise the current treatment options including systemic chemotherapy and
intraperitoneal chemohyperthermia. To review the accuracy of different imaging modalities
for the detection of occult peritoneal carcinomatosis.

17:30 PERITONITIS AND MESENTERITIS

P. Prassopoulos, Alexandroupolis/GR

Lecture objectives:
To discuss the underlying pathologies of peritonitis and mesenteritis. To illustrate the
imaging features associated with peritonitis and mesenteritis and to define the diagnostic
appearances and significance of the term “misty mesentery”.

17:50 PANEL DISCUSSION

74
LECTURE SESSIONS
THURSDAY, JUNE 25, 2009
16:30 – 18:00

LS 8 HCC: FROM DIAGNOSIS TO TREATMENT AUDITORIUM 2

Moderators: A. Palkó, Szeged/HU; O. Matsui, Kanazawa/JP

16:30 DIAGNOSTIC IMAGING CRITERIA

R. Baron, Chicago, IL/US

Lecture objectives:
To review the role of multimodality imaging (US,CEUS,CT,MRI and PET/CT) for the
detection and characterisation of HCC, with emphasis on the diagnosis of early HCC
and differentiation of the cirrhotic nodule. To correlate imaging features including tumour
signal intensity and enhancement characteristics with underlying pathology.

16:50 INTERNATIONAL GUIDELINES FOR STAGING AND SURVEILLANCE

C. Bru, Barcelona/ES

Lecture objectives:
To summarise the international recommendations for the management of HCC. To discuss
optimal patient selection and role of US in a surveillance programme. To review the results
of diagnostic imaging for tumour staging with reference to alternative treatment options.

17:10 IMAGE GUIDED INTERVENTION

L. Crocetti, Pisa/IT

Lecture objectives:
To review the current techniques for the percutaneous ablation therapy of HCC including

THURSDAY, JUNE 25
long term results. To discuss new technical developments. To summarise recent advances
in transcatheter chemoembolisation techniques of HCC and review the clinical results.

17:30 FOLLOW UP IMAGING

B. Op De Beeck, Edegem/BE

Lecture objectives:
To explain optimal imaging algorithms for the follow up of patients treated by surgery,
percutaneous ablation, chemoembolisation or systemic chemotherapy. To illustrate the
imaging appearances of post treatment tumour response and discuss the effect on
management protocols.

17:50 PANEL DISCUSSION

18:00 – 18:45
ESGAR GENERAL ASSEMBLY AUDITORIUM 3A

75
 PROGRAMME OVERVIEW
FRIDAY, JUNE 26, 2009

08:00 – 08:45 WS 15 Paediatric tumours of the liver Auditorium 3A

08:00 – 08:45 WS 16 MDCT: abdominal protocols Auditorium 3B
08:00 – 08:45 WS 17 Oesophageal and gastric cancer: Room 1 + 2
Diagnosis and staging
08:00 – 08:45 WS 18 Fistulae in ano Room 3 + 4
08:00 – 08:45 WS 19 From the European Curriculum (2.5): Room 6 + 7
pelvic floor dysfunction
08:00 – 08:45 WS 20 EBP (Evidence-Based Practice III) Caveats and Room 5
frequently asked questions about EBP.
Constructing guidelines.
08:00 – 08:45 WS 21 Interactive Workshop: MRI of Rectal Carcinoma (3) EPOS™ Area

08:00 – 11:00 CTC 3 CTC Hands-on Centre Part 1 Room 8 + 9

09:00 – 10:30 IR 3 Intervention - a practical approach: Biliary interventions Room 6 + 7

09:00 – 10:30 LS 9 Challenges in pancreatic imaging Auditorium 1

09:00 – 10:30 LS 10 Staging of local rectal cancer Auditorium 2

10:30 – 11:00 BREAK

11:00 – 12:30 SS 11 CT Colonography Auditorium 1

11:00 – 12:30 SS 12 Benign Liver lesions Auditorium 2
11:00 – 12:30 SS 13 Liver: Tracking and Measuring Auditorium 3A
11:00 – 12:30 SS 14 Advances in multimodality techniques Auditorium 3B
11:00 – 12:30 SS 15 Small bowel Crohn’s disease Room 1 + 2

12:30 – 13:30 CTC 3 CTC Hands-on Centre Part 2 Room 8 + 9

14:30 – 15:30 PS 4 Foundation Course: Radiologic-pathologic Auditorium 2

correlations I - The Tube

15:45 – 16:45 PS 5 Foundation Course: Radiologic-pathologic Auditorium 2

correlations II - Solid Organs

16:45 – 17:00 PS 6 Closing remarks Auditorium 2

FRIDAY, JUNE 26

76
WORKSHOPS
FRIDAY, JUNE 26, 2009
08:00 – 08:45

WS 15 PAEDIATRIC TUMOURS OF THE LIVER Auditorium 3A

D. Stringer, Singapore/SG
F. Avni, Brussels/BE

WS 16 MDCT: ABDOMINAL PROTOCOLS Auditorium 3B

P. Rogalla, Berlin/DE
V. Raptopoulos, Boston, MA/US

WS 17 OESOPHAGEAL AND GASTRIC CANCER: Room 1 + 2

DIAGNOSIS AND STAGING
J.A. Guthrie, Leeds/UK
C. Aube, Angers/FR

WS 18* FISTULAE IN ANO Room 3 + 4

S. Halligan, London/UK
J. Venancio, Lisbon/PT

WS 19 FROM THE EUROPEAN CURRICULUM (2.5): Room 6 + 7

PELVIC FLOOR DYSFUNCTION
F. Maccioni, Rome/IT
S. Somers, Dundas, ON/CA

WS 20* EBP (EVIDENCE-BASED PRACTICE III) Room 5

CAVEATS AND FREQUENTLY ASKED QUESTIONS
ABOUT EBP. CONSTRUCTING GUIDELINES.
M. Staunton, Toronto, ON/CA
R.M. Mendelson, Perth, WA/AU

WS 21* INTERACTIVE WORKSHOP: EPOS™ Area

MRI of Rectal Carcinoma (3)
R.G.H. Beets-Tan, New York, NY/US

*=workshop fully booked.

DETAILED WORKSHOP DESCRIPTION PLEASE SEE PAGES 21 – 22

FRIDAY, JUNE 26

77
 CTC HANDS-ON CENTRE
FRIDAY, JUNE 26, 2009
08:00 – 11:00 (PART 1)
12:30 – 13:30 (PART 2)

CTC 3 CTC HANDS-ON CENTRE ROOM 8 + 9

08:00 INTRODUCTION
J. Stoker, Amsterdam/NL

08:05 INTRODUCTORY LECTURE STATE-OF-THE-ART

J. Stoker, Amsterdam/NL

08:30 HOW TO READ CTC: 2D VERSUS 3D

F. Iafrate, Rome/IT

09:30 CASE REVIEW

R. Ferrari, Latina/IT

11:00 BREAK

12:30 FREE TRAINING

R. Ferrari, Latina/IT

INTERESTED
IN MORE
CTC TRAININ
G?
VISIT ONE O
F OUR WORK
SHOPS:
11th ESGAR C
T-Colonogra
September 17 phy Hands-o
– 18 and 18 – n Workshop
19, 2009, Stre
sa, Italy
12th ESGAR C
T-Colonogra
April 21 – 22 an p hy Hands-on
d 22 – 23, 2010 Workshop
, Amsterdam,
The Netherland
s
13th ESGAR C
T-Colonogra
September 23 phy Hands-o
– 24 and nW orkshop
24 – 25, 2010
, Lisbon (Casca
is), Portugal
FRIDAY, JUNE 26

78
INTERVENTIONAL RADIOLOGY
FRIDAY, JUNE 26, 2009
09:00 – 10:30

IR 3 INTERVENTION - A PRACTICAL APPROACH: ROOM 6 + 7

BILIARY INTERVENTIONS
Moderator: J.S. Lameris, Amsterdam/NL

09:00 BENIGN STRICTURES

J. Karani, London/UK

Lecture objectives:
To summarise the indications and optimal timing of percutaneous biliary intervention in
patients with a benign bile duct stricture. To illustrate how technical options vary according
to underlying stricture aetiology and to explain the complementary role of endoscopy/
surgery in patient management. To provide an overview of procedure technique including
useful tips and tricks. To discuss published results and potential procedural complications.

09:20 MALIGNANT STRICTURES

J.S. Lameris, Amsterdam/NL

Lecture objectives:
To summarise the indications and optimal timing of percutaneous biliary intervention
in patients with a malignant bile duct stricture. To illustrate how technical options vary
according to stricture aetiology and position (high versus low biliary strictures) and to
explain the complementary role of endoscopy/surgery in patient management. To provide
an overview of procedure technique including useful tips and tricks. To discuss published
results and potential procedural complications.

09:40 CALCULOUS DISEASE

A. Hatzidakis, Heraklion/GR

Lecture objectives:
To summarise the indications and optimal timing of percutaneous biliary intervention in
patients with underlying biliary calculous disease and related complications. To explain
the various technical options and to summarise the complementary role of endoscopy/
surgery in patient management.

10:00 PANEL DISCUSSION

FRIDAY, JUNE 26

79
 LECTURE SESSIONS
FRIDAY, JUNE 26, 2009
09:00 – 10:30

LS 9 CHALLENGES IN PANCREATIC IMAGING AUDITORIUM 1

Moderators: G. Morana, Treviso/IT; G. Karmazanovsky, Moscow/RU

09:00 ADENOCARCINOMA VERSUS FOCAL PANCREATITIS

C. Triantopoulou, Athens/GR

Lecture objectives:
To explain the various forms of chronic pancreatitis which may present as a focal mass
including focal chronic pancreatitis, solid dystrophy of the duodenal wall and autoimmune
pancreatitis. To review the pathological appearances and highlight the relevant clinical
and morphological criteria which can help in the differential diagnosis. To discuss the role
of multimodality imaging techniques (US/CEUS, EUS, CT, MRI, PET/CT) for the diagnosis
of tumour versus inflammation.

09:20 CHRONIC PANCREATITIS VERSUS INTRADUCTAL PAPILLARY

MUCINOUS TUMOUR (IPMT)
C. Matos, Brussels/BE

Lecture objectives:
To describe the imaging characteristics of IPMT and chronic pancreatitis. To highlight
the relevant morphological appearances which can help in the differential diagnosis. To
discuss the role of multimodality imaging techniques (US/CEUS, EUS, CT, MRI, PET/CT)
for the diagnosis of chronic pancreatitis versus IPMT.

09:40 SEROUS VERSUS MUCINOUS CYSTIC TUMOURS

H.-J. Brambs, Ulm/DE

Lecture objectives:
To describe the pathological appearances which make the differential diagnosis of serous
versus mucinous cystic tumours challenging. To highlight the relevant morphological
appearances which can help in the differential diagnosis. To discuss the role of
multimodality imaging techniques (US/CEUS, EUS, CT, MRI, PET/CT) for the diagnosis
of serous versus mucinous tumours and how imaging may influence the indication for
surgery.

10:00 MANAGEMENT OF SMALL INCIDENTAL CYSTIC PANCREATIC LESIONS

B. Op de Beeck, Edegem/BE

Lecture objectives:
To review the various aetiologies of small pancreatic cysts and discuss the role of imaging
in the differential diagnosis and exclusion of malignancy. To discuss the place of imaging
algorithms in optimal patient management and follow up.
FRIDAY, JUNE 26

10:20 PANEL DISCUSSION

80
LECTURE SESSIONS
FRIDAY, JUNE 26, 2009
09:00 – 10:30

LS 10 STAGING OF LOCAL RECTAL CANCER AUDITORIUM 2

Moderators: C.D. Claussen, Tübingen/DE; M. Morrin, Dublin/IE

09:00 RELEVANCE OF STAGING TO THERAPEUTIC DECISIONS

Y. Nio, Amsterdam/NL

Lecture objectives:
To review current protocols for rectal cancer staging and how they impact on therapeutic
strategy. To critically analyse the scientific evidence for neoadjuvant therapy based on the
results of staging. To discuss how the staging of rectal cancer with multimodality imaging
influences patient management.

09:20 EARLY RECTAL CANCER

M. Marshall, Harrow/UK

Lecture objectives:
To define early rectal cancer and to summarise the various imaging modalities used to
stratify staging. To illustrate the advantages and limitations of imaging modalities, in
particular endorectal US to assess tumour infiltration of the rectal wall. To discuss the
clinical results of local therapeutic procedures and impact on patient outcome.

09:40 ADVANCED RECTAL CANCER

D. Weishaupt, Zurich/CH

Lecture objectives:
To define advanced rectal cancer and to summarise the various imaging modalities used
to stratify staging. To review patient selection, high resolution technique and relevant
anatomical considerations of rectal staging with MRI. To discuss the advantages,
limitations and results of imaging for the accurate staging of advanced rectal cancer. To
explain the role and clinical relevance of functional imaging techniques.

10:00 IMAGING FOR FOLLOW UP AND LOCAL RECURRENCE

R.G.H. Beets-Tan, New York, NY/US

Lecture objectives:
To discuss imaging algorithms for patient follow up and critically appraise published
international guidelines.To review the multimodality imaging appearances associated with
tumour recurrence including the place of functional imaging techniques. To explain the
role of imaging-guided biopsy in patient management.

10:20 PANEL DISCUSSION

FRIDAY, JUNE 26

81
 SCIENTIFIC SESSIONS
FRIDAY, JUNE 26, 2009
11:00 – 12:30

SS 11 CT COLONOGRAPHY AUDITORIUM 1
Moderators: P. Pickhardt, Madison, WI/US; D. Regge, Candiolo/IT

11:00 SS 11.01 Detection rates of diminutive polyps in CTC: implications for colorectal cancer
screening
T. Mang1, F. Kolligs2, C. Becker2, A. Graser2; 1Vienna/AT, 2Munich/DE

11:08 SS 11.02 Effect of training on different experienced readers with and without the assistance
of CAR software when a primary 3D flythrough approach is used
M. Rengo, R. Ferrari, P. Paolantonio, F. Vecchietti, P. Lucchesi, M. Maceroni, A. Laghi;
Latina/IT

11:16 SS 11.03 CTC: computer-assisted detection of colorectal cancer

C. Robinson1, S. Halligan1, G. Iinuma2, W. Topping1, S. Punwani1, L. Honeyfield1,
S.A. Taylor1; 1London/UK, 2Tokyo/JP

11:24 SS 11.04 Comparing the performance of a CTC CAD system to that of an experienced reader
in a prospective multicenter setting
P. Della Monica1, L. Morra2, G. Iussich1, I. Dmitriev2, S. Agliozzo1, D. Regge1;
1
Candiolo/IT, 2Torino/IT

11:32 SS 11.05 Why do radiologists ignore polyps correctly annotated by computer assisted
detection software during CT colonography?
S.A. Taylor, C. Robinson, D. Boone, L. Honeyfield, S. Halligan; London/UK

11:40 SS 11.06 Flat lesions and masses: characterization of CTC CAD performances on difficult
targets present in a multicenter trial data-set
G. Iussich1, P. Della Monica1, S. Delsanto2, R. Baggio2, A. Bert2, D. Regge1;
1
Candiolo/IT, 2Torino/IT

11:48 SS 11.07 CTC: evaluation and detection of colonic flat lesions using 64-MDCT colonography
and a CAD system
F. Iafrate1, A. Pichi1, A. Stagnitti1, M. Ciolina1, P. Baldassarri1, A. Laghi2;
1
Rome/IT, 2Latina/IT

11:56 SS 11.08 Towards an optimized dose and image quality balance for CTC
D.J. Bielen, H. Bosmans; Leuven/BE

12:04 SS 11.09 Radiation dose in screening patients: CTC vs double-contrast barium enema
F. Turini, E. Neri, F. Perrone, P. Vagli, F. Cerri, L. Cini, S. Angeli, C. Bartolozzi; Pisa/IT

12:12 SS 11.10 CTC with a limited bowel preparation: prospective assessment of patient
experience and preference in comparison to full-preparation colonoscopy
S. Jensch, S. Bipat, J. Peringa, A. de Vries, A. Heutinck, A. Montauban van Swijndregt,
J. Stoker; Amsterdam/NL
FRIDAY, JUNE 26

82
SCIENTIFIC SESSIONS
FRIDAY, JUNE 26, 2009
11:00 – 12:30

SS 12 BENIGN LIVER LESIONS AUDITORIUM 2

Moderators: V. Laurent, Vandoeuvre les Nancy/FR; T. Bartolotta, Palermo/IT

11:00 SS 12.01 Solid hypervascular liver lesions: value of delayed hepatobiliary phase MRI after
gadobenate dimeglumine for accurate identification of true benign lesions
G. Morana1, L. Grazioli2, G. Schneider3, M.P. Bondioni2 R. Pozzi Mucelli4, M. Kirchin1;
1
Treviso/IT, 2Brescia/IT, 3Homburg/DE, 4Milan/IT

11:08 SS 12.02 Comparison of Gd-EOB-DTPA MRI and diffusion weighted imaging in the detection
and characterization of focal liver lesions
M. Krokidis, S. Gourtsoyianni, S. Yarmenitis, N. Papanikolaou, N. Gourtsoyiannis;
Heraklion/GR

11:16 SS 12.03 MRI of focal liver lesions: Diffusion-weighted imaging versus gadoxetate-enhanced
MRI (preliminary results)
N. Bastati-Huber, W. Matzek, S. Baroud, C. Koelblinger, C.J. Herold, W. Schima,
A. Ba-Ssalamah; Vienna/AT

11:24 SS 12.04 MRI of post-contrastographic dynamic enhancement of focal liver lesions after
gadoxetic acid administration: comparison with tri-phasic MDCT
M.C. Della Pina, V. Battaglia, E. Bozzi, C. Bartolozzi; Pisa/IT

11:32 SS 12.05 Accurate differentiation between small or atypical hemangiomas and cystic or
hypervascular metastases using ferucarbutran-enhanced MRI
S. Baroud, S. Machat, N. Bastati-Huber, C. Kulinna-Cosentini, C. Herold, W. Schima,
A. Ba-Ssalamah; Vienna/AT

11:40 SS 12.06 Imaging findings of hepatic focal nodular hyperplasia in Gd-EOB-DTPA vs Gd-
BOPTA-enhanced MR: preliminary results
T. Bartolotta, A. Taibbi, G. Brancatelli, M. Galia, G. Lo Re, M. Midiri; Palermo/IT

11:48 SS 12.07 Interval growth of focal nodular hyperplasia in the liver on MRI
J. Halankar, T.K. Kim, K. Khalili, M. Haider, H. Jang; Toronto, ON/CA

11:56 SS 12.08 Hepatocellular adenomas (HCA): contrast enhancement pattern on sonography

according to genotype/phenotype classification
H. Laumonier1, H. Cailliez1, C. Laurent1, P. Bioulac-Sage1, J. Zucman-Rossi2, C. Balabaud1,
H. Trillaud1; 1Bordeaux/FR, 2Paris/FR

12:04 SS 12.09 High prevalence of hyperenhancing FNH-like hepatic lesions in patients with
hereditary hemorrhagic telangiectasia: a single centre experience
A. Scardapane, A. Stabile Ianora, M. Memeo, M. Moschetta, G. Angelelli; Bari/IT

12:12 SS 12.10 Atypical imaging findings of pyogenic hepatic abscesses

A. Linda1, C. Peterson2, K. Robinson3, M. Lin3, T. Pilgram3, J. Heiken3;
1
Udine/IT, 2Hershey, PA/US, 3St. Louis, MO/US
FRIDAY, JUNE 26

83
 SCIENTIFIC SESSIONS
FRIDAY, JUNE 26, 2009
11:00 – 12:30

SS 13 LIVER: TRACKING AND MEASURING AUDITORIUM 3A

Moderators: S. Terraz, Geneva/CH; O. Lucidarme, Paris/FR

11:00 SS 13.01 Liver fat quantification at MRI in pediatric population: comparison of out-of-phase
gradient-echo and fat-saturated fast spin-echo sequences
M. di Martino, D. Marin, V. Panebianco, D. Lisi, C. Catalano, R. Passariello; Rome/IT

11:08 SS 13.02 Hepatic steatosis, quantification with semi-quantitative US indices: a pilot study
M. Morone, P. Cabassa, R. Monesi, A. Rossini, G..B. Contessi, R. Maroldi; Brescia/IT

11:16 SS 13.03 Does apparent diagnostic coefficient measured with diffusion-weighted MRI
predict hepatic steatosis
G. Patriarca, A. Filippone, R. Cianci, A. Tartaro, M. Storto; Chieti/IT

11:24 SS 13.04 Quantification of liver steatosis before major hepatic surgery with 3.0 Tesla MR:
H1-spectroscopy versus chemical shift imaging
C. Koelblinger, T. Mang, K. Kaczirek, T. Gruenberger, A. Ba-Ssalamah, W. Schima; Vienna/AT

11:32 SS 13.05 Grading of acute hepatic inflammation and liver cirrhosis: does gadolinium-
enhanced MRI correlate with histopathology?
T. Lauenstein1, P. Sharma2, K. Salman2, R. Morreira2, D. Martin2; 1Essen/DE, 2Atlanta, GA/US

11:40 SS 13.06 Virtual touch tissue quantification: measurement repeatability and normal values
in the healthy liver
M. D’Onofrio, A. Gallotti, E. Martone, R. Pozzi Mucelli; Verona/IT

SS 13.07 Withdrawn by authors

11:48 SS 13.08 Interobserver and intraobserver variability of apparent diffusion coefficient

measurements in treated malignant hepatic lesions: measurements in the whole
lesion versus in the area with the most restricted diffusion
T. Lu, P. Marques-Vidal, R. Meuli, A. Denys, P. Bize, S. Schmidt; Lausanne/CH

11:56 SS 13.09 Evaluation of early changes in density and size in liver and other metastases from
renal cell carcinoma treated with sorafenib
J. Cazejust1, B. Bessoud1, L. Rocher2, Y. Menu1; 1Paris/FR, 2Kremlin-Bicêtre/FR

12:04 SS 13.10 Quantification of tumor microvascularity with respiratory gated contrast enhanced
US for monitoring therapy
M. Averkiou1, M. Lampaskis1, K. Kyriakopoulou2, G. Klouvas2, D. Skarlos2, E. Leen3;
1
Nicosia/CY, 2Athens/GR, 3London/UK
FRIDAY, JUNE 26

84
SCIENTIFIC SESSIONS
FRIDAY, JUNE 26, 2009
11:00 – 12:30

SS 14 ADVANCES IN MULTIMODALITY AUDITORIUM 3B

TECHNIQUES
Moderators: P. Rogalla, Berlin/DE; A. Roberts, Cardiff/UK

11:00 SS 14.01 Dual energy, 64-slice MDCT: comparison of 80- and 140-kVp for detection of
hypervascular liver tumors during the late hepatic arterial phase
S. Schindera1, R. Nelson2, E. Paulson2, L. Ho2, D. Boll2, D. Marin2; 1Bern/CH, 2Durham/US

11:08 SS 14.02 Moderate versus high concentration contrast material for the detection of HCC
at 64-section MDCT: intraindividual comparison of the effect of a fixed injection
duration or fixed injection flow protocol
A. Guerrisi, D. Marin, M. di Martino, G. de Filippis, D. Geiger, M. Baski, C. Catalano,
R. Passariello; Rome/IT

11:16 SS 14.03 Dual energy CT of the liver: virtual non-contrast versus real non-contrast images
C.N. de Cecco, V. Buffa, S. Fedeli, A. Vallone, R. Ruopoli, V. David; Rome/IT

11:24 SS 14.04 MRI of the liver: comparison of different techniques (SE vs. BLADE) of T2-weighted
fat suppressed sequences
S. Bayramoglu1, O. Kilickesmez1, T. Cimilli1, A. Kayhan1, G. Yirik1, S. Alibek2;
1
Istanbul/TR, 2Erlangen/DE

11:32 SS 14.05 Liver T2 weighted MRI: assessment of a 3D sequence at 1.5 Tesla

C. Cotereau Denoiseux, I. Boulay-Coletta, M. Zins; Paris/FR

11:40 SS 14.06 Spleen stiffness in healthy volunteers: preliminary experience with MR elastography
l. Mannelli, I. Joubert, M. Graves, A. Patterson, R. Black, D. Lomas; Cambridge/UK

11:48 SS 14.07 Different approaches to abdominal MR diffusion weighted imaging at 3T

A. Alberich-Bayarri1, L. Martí-Bonmatí1, J. Sanchez-Gonzalez2; 1Valencia/ES, 2Madrid/ES

11:56 SS 14.08 Reproducibility of values obtained with US “virtual touch” imaging: initial
experience
E. Gatti, P. Cabassa, S. Gandolfi, G..B. Contessi, A. Rossini, R. Maroldi; Brescia/IT

12:04 SS 14.09 Objective measurement of puborectalis atrophy using MR spectroscopy and its
correlation with muscular fatigue using perineal dynamometry in women with
faecal incontinence
D. Chatoor1, A. Emmanuel1, E. de Vita1, E. Cady1, S. Halligan1, R. Cohen1, C. Bartram2,
S.A. Taylor1; 1London/UK, 2Harrow/UK

12:12 SS 14.10 Abdominal MRI in familial partial lipodystrophy: quantitative analysis of adipose
tissue distribution guides medical therapy
P. Mc Laughlin, J. Ryan, K. O’Regan, D. O’Halloran, M. Maher; Cork/IE
FRIDAY, JUNE 26

85
 SCIENTIFIC SESSIONS
FRIDAY, JUNE 26, 2009
11:00 – 12:30

SS 15 SMALL BOWEL CROHN’S DISEASE ROOM 1 + 2

Moderators: J. Stoker, Amsterdam/NL; M. Patak, Bern/CH

11:00 SS 15.01 Contrast-enhanced sonography in the diagnosis of postsurgical recurrence of

Crohn´s disease: comparison with endoscopy
A. Boronat, T. Ripolles, M. Martinez, J. Paredes, C. Barber, E. Blanc; Valencia/ES

11:08 SS 15.02 Quantification of microvascular activation in ileal Crohn’s Disease by software

elaboration data applied to CEUS: correlation with biological activity indexes
A. de Franco, A. di Veronica, L. Guidi, A. Armuzzi, I. de Vitis, C. Felice, E. Bock,
L. Bonomo; Rome/IT

11:16 SS 15.03 Utility of contrast enhanced US to rapidly and non invasively monitor therapeutic
response to immuno-modulatory medication in small bowel Crohn’s disease
C. Robinson, S. Punwani, S.A. Taylor; London/UK

11:24 SS 15.04 Abdominal CT in Crohn’s disease: serum C-reactive protein concentration does not
predict the extent of non-penetrating disease activity
K. O’Regan, A. Desmond, N. Malik, S. McWilliams, F. Shanahan, M. Maher; Cork/IE

11:32 SS 15.05 Acute complications of Crohn’s disease: entero-MDCT versus entero-MRI

S. Schmidt1, A. Guibal2, J. Meuwly1, P. Schnyder1, A. Denys1; 1Lausanne/CH, 2Lyon/FR

11:40 SS 15.06 Postsurgical recurrence in Crohn’s disease: an MRI evaluation

P. Milillo, L. Stoppino, A. Centola, S. Muscarella, R. Vinci, L. Macarini; Foggia/IT

11:48 SS 15.07 Diagnostic and therapeutic impact of MR enterography in Crohn’s disease: a

prospective non-randomised study
R. Hafeez, S. Bloom, P. Boulos, S. Halligan, S. Punwani, S.A. Taylor; London/UK

11:56 SS 15.08 Is bowel wall enhancement on MR enterography associated with histopathology

in patients with active Crohn’s disease
M. Ziech, J. Roelofs, C.Y. Nio, S. Bipat, J. Stoker; Amsterdam/NL

12:04 SS 15.09 Comparison between paediatric and adult Crohn’s disease patients evaluated with
MRI with regard to lesions site, length, complications in the small and large bowels
F. Maccioni, F. Carrozzo, V. Garbarino, A. Kagarmanova, M. Marini, S. Cucchiara; Rome/IT

12:12 SS 15.10 Small bowel imaging comparing MR enteroclysis, capsule endoscopy and double-
balloon enteroscopy in patients with (suspected) Crohn’s disease: the COMRADE
study
B. Wiarda1, P. Mensink2, D. Heine1, M. Stolk3, J. van der Woude2, E. Kuipers2, J. Stoker4;
1
Alkmaar/NL, 2Rotterdam/NL, 3Nieuwegein/NL, 4Amsterdam/NL
FRIDAY, JUNE 26

86
 EPOS TM
CASES-OF-THE
- DAY
HAVE YOU SOLV
ED TODAY’S
UNKNOWN CAS
ES YET?

Cases-of-the-da
y can be access
EPOSTM Area on ed in the
Level 1! We invite
participate in the you to
competition.
 PLENARY SESSIONS
FRIDAY, JUNE 26, 2009
13:30 – 14:30

PS 4 FOUNDATION COURSE: AUDITORIUM 2

RADIOLOGIC-PATHOLOGIC CORRELATIONS I – THE TUBE
Moderator: N. Gourtsoyiannis, Heraklion/GR

13:30 ENDOSCOPIC-PATHOLOGIC CORRELATION OF COLITIDES

I. Ferrer Bradley, Valencia/ES

Lecture objectives:
To review the epidemiology, aetiology and pathology of the different types of colitides.
To describe the endoscopic characteristics of each type vis-à-vis pathologic correlation.
To discuss the advantages and limitations of endoscopic techniques in their differential
diagnosis.

13:50 RADIOLOGIC-PATHOLOGIC CORRELATION OF COLITIDES

R.M. Gore, Evanston, IL/US

Lecture objectives:
To describe the imaging techniques and protocols available to investigate the colitides. To
describe the imaging characteristics of each of these conditions vis-à-vis endoscopic and
pathologic correlation. To discuss, based on pathology, the strengths and weaknesses of
imaging techniques for the initial diagnosis and differential diagnosis of colitides.

14:10 GIST’S
P.R. Ros, Boston, MA/US

Lecture objectives:
To review the epidemiology, aetiology, classification and pathology of GIST’s . To describe
their imaging characteristics vis-à-vis pathologic/ histologic correlation. To discuss the
advantages and limitations of current imaging techniques for the initial diagnosis and
differential diagnosis of GIST’s.
FRIDAY, JUNE 26

88
PLENARY SESSIONS
FRIDAY, JUNE 26, 2009
14:45 – 16:00

14:45 – 15:45
PS 5 FOUNDATION COURSE: AUDITORIUM 2
RADIOLOGIC-PATHOLOGIC CORRELATIONS II
– SOLID ORGANS
Moderator: P.R. Ros, Boston, MA/US

14:45 NON EPITHELIAL LIVER TUMOURS

F. Caseiro-Alves, Coimbra/PT

Lecture objectives:
To review the epidemiology, aetiology and pathology of non epithelial liver tumours.
To describe their imaging features vis-à-vis pathologic correlation. To emphasise
characteristic imaging findings and discuss the potential of imaging techniques for the
initial diagnosis and differential diagnosis of these neoplasms.

15:05 FIBRO-CYSTIC LIVER DISEASE

G. Brancatelli, Palermo/IT

Lecture objectives:
To review the epidemiology, aetiology and pathology of fibro-cystic liver disease. To
describe the characteristic radiological features vis-à-vis pathologic correlation. To discuss
the advantages and limitations of current imaging techniques for the initial diagnosis and
differential diagnosis of this pathology.

15:25 SPLENIC FOCAL LESIONS

C. Stoupis, Maennedorf/CH

Lecture objectives:
To review the epidemiology, aetiology and pathology of focal splenic lesions. To describe
the characteristic radiological features vis-à-vis pathologic correlation. To discuss, on the
basis of pathology, the advantages and limitations, of current imaging techniques for the
initial diagnosis and differential diagnosis of the various focal splenic pathologies.

15:45 – 16:00
PS 6 CLOSING REMARKS AUDITORIUM 2
EPOSTM PRESENTATION AWARDS
FRIDAY, JUNE 26

89
E P O S ™ P R E S E N TATI ON S

EPOS™
Electronic Presentation Online System
 EPOS™ PRESENTATIONS

All scientific exhibits are displayed in EPOS™ format. 32 computer terminals are available for
viewing the presentations. The EPOS™ area is located on Level 1.

DIAGNOSTIC
DIAGNOSTIC / ABDOMINAL VASCULAR IMAGING

CM P-001 Imaging findings of IgG4-related multifocal systemic fibrosclerosis affecting the abdomen
P. Vlachou, K. Khalili, H. Yu, H. Jang, T.K. Kim; Toronto, ON/CA

P-002 The value of high flow rate in the study of pancreatic vessels by using multi-detector-row CT
L. Saba, R. Sanfilippo, R. Montisci, G. Mallarini; Cagliari/IT

P-003 Transient elastometry and hepatic vein transit time of an US contrast agent in fibrosing
liver disease: a comparative study
D. Marion, F. Bailly, M. Cuinet, J.Y. Scoazec, F. Zoulim; Lyon/FR

P-004 Correlative analysis between superior mesenteric artery stenosis and renal artery stenosis
by using MDCT angiography
L. Saba, R. Sanfilippo, R. Montisci, G. Caddeo, G. Mallarini; Cagliari/IT

P-005 Mesenteric ischemia: what to look for

A. Frias Vilaça1, J. Pinto1, A. Ramos2, A. Reis1, I.M. Vidal1, R. Cardoso1, J.L. Krug1;
1
Santa Maria da Feira/PT, 2Porto/PT

P-006 Portosystemic collateral vessels and intrahepatic shunts: anatomic

RECOMMENDED
POSTER and radiographic revision
J.C. Quintero, S. Mourelo, I. Guasch, C. Roqué, J. Sampere, M. Vargas; Badalona/ES

P-007 Sorafenib therapy for advanced HCC: impact of early response on contrast-enhanced US
examination and dynamic CT-scan imaging to predict survival rates
D. Marion1, E. Maillard1, M. Cuinet1, R. Aziza2, J.M. Peron2, P. Merle1; 1Lyon/FR, 2Toulouse/FR

P-008 Anatomical variants of the mesenteric vasculature: radiological detection and surgical
relevance to pancreaticobiliary surgery
C. Grierson, J. Chandra, Z. Soonawalla, H. Bungay; Oxford/UK

P-009 Imaging Landmarks for segmental lesion localization of the liver by using MDCT
L. Saba, G. Mallarini; Cagliari/IT

P-010 Evaluation of superior and inferior mesenteric arteries and their small branches
with 64-row CT angiography
C.N. de Cecco1, M. Rengo2, R. Ferrari2, P. Paolantonio2, P. Lucchesi2, A. Laghi2; 1Rome/IT, 2Latina/IT

P-011 Nephrogenic systemic fibrosis: what’s up doc?

A. Manzella, P. Borba-Filho, P. Andrade, H. Rojas; Recife/BR

P-012 MDCT anatomy of portosystemic collateral vessels in liver cirrhosis

H. Torrao, S. Kurochka, S. Dias, L. Gonçalves, V. Mendes, A.C. Costa; Braga/PT

P-013 MDCT map of inferior epigastric vessels for percutaneous transabdominal intervention
procedures
H. Genchellac1, M. Dursun2, O. Temizoz1, E. Unlu1, H. Ozdemir1, M.K. Demir1; 1Edirne/TR, 2Istanbul/TR

91
 EPOS™ PRESENTATIONS

P-014 Diagnostic imaging and interventional radiology of the hepatic artery stenosis in patients
with liver transplantation: our study and long term results
P. Rinaldi, R. Inchingolo, C. di Stasi, A.M. de Gaetano, G. Maresca, L. Bonomo; Rome/IT

P-015 The role of Doppler US in the evaluation of portal circulation pathology

M. Pereira, T. Bilhim, L. Vieira, A. Marques; Lisbon/PT

P-016 Contrast enhanced US in the evaluation of abdominal trauma: comparison with MDCT
A. Sparano, C. Acampora, M. Scaglione, R. Farina, L. Romano; Naples/IT

DIAGNOSTIC / BILE DUCTS

P-017 Detection of intra-abdominal tumor recurrence in patients with cholangiocarcinom:
comparison of contrast-enhanced MDCT and 18F FDG-PET/CT
Y.J. Kang, Y.Y. Jeong, S.S. Shin, J.W. Kim, J.J. Min, H.K. Kang; Gwang-ju/KR

P-018 MRCP of anatomic variants of biliary tree

P. Milone, S. Palmucci, M. Zagarella, L. Mauro, G. Ettorre; Catania/IT

P-019 Withdrawn by authors

P-020 Role of MR cholangiography in the detection of biliary strictures after liver transplantation
A. Pecchi, M.C. Gibertini, M. de Santis, F. di Benedetto, G.E. Gerunda, P. Torricelli; Modena/IT

P-021 Imaging and diagnosis of spontaneous biliary enteric fistulas: a review of 21 cases
I. Kalogeropoulos, K. Stefanidis, S. Gavriel, V. Ouranos, I. Scouras, C. Danika, P. Piperopoulos;
Athens/GR

P-022 Withdrawn by authors

P-023 Frequency of imaging features of primary sclerosing cholangitis on MRCP

C. Grierson, M. Betts, H. Bungay; Oxford/UK

P-024 MDCT features with histopathologic correlation of gallbladder cancers: a pictorial essay
J. Cho, K. Shin, S. Kim, B. Lee, H. Lee, I. Song, D. Kang; Daejeon/KR

P-025 MRI findings of the biliary system after liver transplantation: a pictorial review
RECOMMENDED
POSTER X. Merino-Casabiel, R. Dominguez-Oronoz, V. Pineda-Sanchez, S. Gispert-Herrero, L. Castells,
C. Vert-Soler, E. Inarejos-Clemente; Barcelona/ES

P-026 Choledocal cysts: spectrum of imaging findings

I. Santiago1, J. Maciel1, R.M. Loureiro2, C. Ruivo3, M.A. Portilha3, B. Gonçalves3, N.J. Dias3,
M. Cipriano3, F. Caseiro-Alves3; 1Aveiro/PT, 2Funchal/PT, 3Coimbra/PT

P-027 Usefulness of contrast enhanced ultrasonography in melanoma’s gallblader metastasis:

about 4 cases
L. Chami, R. Ferre, M. Chebil, S. Bidault, E. Girard, C. Robert, N. Lassau; Villejuif/FR

P-028 3D isotropic T2-weighted MR cholangiography in evaluating postcholecystectomy

syndrome: spectrum of findings and diagnostic role
R. Girometti, L. Cereser, G. Brondani, G. Como, M. Bazzocchi, C. Zuiani; Udine/IT

P-029 Diagnostic significance of MRCP in choledocholithiasis

R. Maksimovic, M. Dunjic Kratovac, G. Lilic, R. Milenkovic; Belgrade/RS

P-030 Surgical roadmap for laparoscopic cholecystectomy using MDCT and limited MRCP:
RECOMMENDED
POSTER a stepwise approach to reporting
R. Rajan1, S. Rajan2, B. Aggarwal1; 1New Delhi/IN, 2Delhi/IN

92
 EPOS™ PRESENTATIONS

DIAGNOSTIC / GI TRACT / COLON

P-031 Complicated diverticulitis: optimising management algorithms using
a modified Hinchey classification
V. Var, R. Nensey, T. Ninan, S.A. Jackson; Plymouth/UK

P-032 Mucocele of the appendix: a pictorial review

H. Matos, H. Patricio, T. Couto, D. Condesso, F. Fonseca, A. Estevão; Coimbra/PT

CM P-033 Named signs of bowel related pathology on abdominal CT: an aide memoire
K. Jackson, A. James, S. Sukumar; Manchester/UK

P-034 Research on the relationship between intra-abdominal fat distribution and rectosigmoid
colon cancer in Japanese patients using MDCT data
T. Ogura1, T. Tachikawa2, Y. Nishimura2, T. Ikari2, Y. Shimomura3, S. Suda3, A. Kono2; 1Maebashi/JP,
2
Tokyo/JP, 3Takasaki/JP

P-035 Can the size of the appendicolith be used to predict the evidence of perforation
in pediatric appendicitis?
J.Y. Woo, I. Yang, S.Y. Chung, J.W. Kim; Seoul/KR

P-036 Radiological management of Ogilvie’s syndrome in a 70-year-old

P. Marques, J. Costa, L. Rodrigues, F. Cavalheiro, F. Caseiro-Alves; Coimbra/PT

P-037 Asymptomatic pneumatosis and pneumoperitoneum in metastatic colorectal cancer

undergoing chemotherapy
L. Bacigalupo, S. Sarzi, A. Garlaschi, E. Melani, A. Decensi, G.A. Rollandi; Genoa/IT

P-038 Study on visceral fat obesity of rectal cancer patients in Japanese

Y. Nishimura1, T. Ogura2, T. Tachikawa1, M. Oya1, Y. Shimomura3, S. Suda3, A. Kono1; 1Tokyo/JP,
2
Maebashi/JP, 3Takasaki/JP

P-039 CT appearances of pharmacobezoar

H. Addley1, R. Darrah2, R. Guirguis2; 1Cambridge/UK, 2Bury St. Edmunds/UK

P-040 CT findings of infectious colitis: a review

C. Dewhurst, K. O’Regan, M. Maher; Cork/IE

P-041 Inflammatory bowel disease and colitis: the role of plain abdominal film
and CT in the diagnosis and detection of complications
S. Biswas, L. Grant, N. Griffin; London/UK

P-042 Caecal bascule: a pictorial review

P. Patel, O. Jaffer, S. Ryan; London/UK

P-043 Not every pain in the right lower quadrant is acute appendicitis
RECOMMENDED
POSTER A. Tilve, C. Rodriguez, P. Rodriguez, A. Casal Rodríguez, C. Zueco, C. Sobrido; Vigo/ES

P-044 Neutropenic enterocolitis

A. Salgado, C. Fernandes, P. Oliveira, L. Ramos, F. Ribeiro, M. Gouvêa; Porto/PT

P-045 Diffusion weighted imaging in the assessment of endometriosis: preliminary results

L. Bacigalupo, S. Sarzi, A. Garlaschi, G.A. Binda, A. Fasciani, E. Biscaldi, G.A. Rollandi; Genoa/IT

P-046 Evaluation of a new system (Qontrast, e-AMID/Bracco, Italia) of semi-quantitative analysis

of the enhancement of the bowel wall after contrast enhanced ultrasonography with
SonoVue in patients with inflammatory bowel diseases
L. Romanini, M. Chiari, M. Navarria, S. Bertolazzi, V. Villanacci; Brescia/IT

93
EPOS™ PRESENTATIONS

P-047 The sonographic evaluation of small bowel, colon and appendix in cystic fibrosis patients
M. Uliasz, H. Bragoszewska, B. Iwanowska, A. Romaniuk-Doroszewska, B. Kowalska,
M. Jastrzebska, S. Szkudlinska-Pawlak, J. Madzik; Warsaw/PL

DIAGNOSTIC / GI TRACT / CT COLONOGRAPHY

P-048 Top ten difficult lesions discovered on CTC: an expert reader put them
under magnifying glass
F. Iafrate1, A. Pichi1, A. Stagnitti1, M. Ciolina1, P. Baldassarri1, A. Laghi2; 1Rome/IT, 2Latina/IT

P-049 Influence of CAR software on different experienced readers: primary 3D flythrough approach
versus 3D + CAR approach
R. Ferrari, P. Paolantonio, M. Rengo, F. Vecchietti, P. Lucchesi, M. Maceroni, A. Laghi; Latina/IT

P-050 Colon CAD: what the radiologists need to know

R. Ferrari, P. Paolantonio, M. Rengo, F. Vecchietti, P. Lucchesi, D. Caruso, A. Laghi; Latina/IT

P-051 Efficacy of an additional phosphate enema as part of non laxative CTC

using barium based faecal tagging
W. Davis1, A. Nisbet2, C. Hare2, P. Cooke2, S.A. Taylor1; 1London/UK, 2Jersey/UK

P-052 Ileocecal valve at CTC: normal findings, anatomic variants and pathology
R. Ferrari, P. Paolantonio, M. Rengo, F. Vecchietti, P. Lucchesi, D. Bellini, A. Laghi; Latina/IT

P-053 Effect of a reduced laxative, faecal tagging regimen on patient experience

and adequacy of colonic preparation at CTC
D. Burling1, R. Ilangovan1, J. Muckian1, A. Gupta1, P. Wylie1, R. Ahmad1, M. Marshall1, S.A. Taylor2;
1
Harrow/UK, 2London/UK

P-054 Colonic cancer detection using 64-MDCT colonography and a CAD system:
results on non expert reader
A. Stagnitti1, F. Iafrate1, A. Marini1, A. Pichi1, M. Marini1, A. Laghi2, M. Ciolina1, P. Baldassarri1;
1
Rome/IT, 2Latina/IT

P-055 Incidental gynaecological findings on CTC: a mixed blessing

J. Chuah, A. James, S. Liong, V. Rudralingam, S. Sukumar; Manchester/UK

P-056 Evaluation of potential advantages of computer-aided diagnosis in reporting CTC with a

primary 2D approach
R. Ferrari, P. Paolantonio, M. Rengo, F. Vecchietti, P. Lucchesi, D. Caruso, A. Laghi; Latina/IT

P-057 Our journey: creating the perfect pneumocolon for CTC

T. Westwood, J. Bell, A. Taylor, C.L. Tam; Lancaster/UK

P-058 Optimising bowel cleansing and faecal tagging in CT colonography without cathartic agent
R. Kenningham, K. Damodharan, M. Elabassy; Leicester/UK

P-059 A comparison of three same-day colon preparations for virtual colonoscopy

R. Ferrari, P. Paolantonio, M. Rengo, F. Vecchietti, P. Lucchesi, D. Bellini, A. Laghi; Latina/IT

P-060 Evaluation of a new software for the follow-up of liver metastasis in oncologic patients
R. Ferrari, P. Paolantonio, M. Rengo, F. Vecchietti, P. Lucchesi, M. Maceroni, A. Laghi; Latina/IT

P-061 Non-neoplastic colonic findings at CTC: a review of typical imaging findings

C. Ridge, V. Chan, C. Hegarty, S. McDermott, D. Malone; Dublin/IE

94
 EPOS™ PRESENTATIONS

DIAGNOSTIC / GI TRACT / MR OF BOWEL

P-062 MRI of fistula in ano: what the surgeons want to know
A. Jacob1, D. Awad1, K. Subramanian2, R. Dobrashian2; 1Manchester/UK, 2Blackburn/UK

P-063 MR enterography: the essential beginners guide

RECOMMENDED
POSTER D. Tolan1, R. Hyland1, A. Chalmers1, S.A. Taylor2; 1Leeds/UK, 2London/UK

P-064 Dynamic MRI of the pelvic floor: comparison between straining phase and defecatory phase
A. Reginelli, F. Maisto, L. Casale, M. Barbieri, G. Lombardi, P. Liguori, A. Rotondo, R. Grassi;
Naples/IT

P-065 The role of MR enterography for detection of efficiency of biological therapy

in patient with Crohn’s disease
K. Katulska, M. Stajgis, A. Dobrowolska-Zachwieja, D. Mankowska-Wierzbicka, K. Linke,
W. Paprzycki; Poznan/PL

P-066 MR enteroclysis versus conventional enteroclysis in Crohn’s disease patients

M. Galia, G. Lo Re, E. Grassedonio, M. Cappello, T. Bartolotta, A. Carcione, M. Midiri; Palermo/IT

P-067 Large bowel pathology incidentally detected on MR enterography

R. Kirke, R. Singh; Derby/UK

P-068 Crohn’s disease activity: evaluation with MR time signal-intensity curves

S. Giusti, P. Giusti, E. Fruzzetti, C. Bartolozzi; Pisa/IT

P-069 MR enteroclysis in the evaluation of small bowel tumors

G. Masselli, E. Polettini, E. Casciani, G.F. Gualdi; Rome/IT

P-070 MRI of the small bowel: why and when

P. Paolantonio, R. Ferrari, M. Rengo, F. Vecchietti, P. Lucchesi, D. Bellini, A. Laghi; Latina/IT

DIAGNOSTIC / GI TRACT / OESOPHAGUS

P-071 Usefulness of MDCT for evaluation of esophagogastric dysphagia
S. Setola, E. de Lutio di Castelguidone, M. Mattace Raso, O. Catalano, A. Siani; Naples/IT

P-072 Progressive radiographic findings of caustic esophagitis

I. Kalogeropoulos, V. Ouranos, C. Stefanidis, I. Skouras, I. Lapas, M. Skabardoni, P. Piperopoulos;
Athens/GR

P-073 Conventional radiology of the esophagus: a pictorial review

A. Ramos1, A. Frias Vilaça2, J. Pires1, M. Franca1, R. Themudo1; 1Porto/PT, 2Santa Maria da Feira/PT

P-074 The leaking esophagus

A. Frias Vilaça, J. Pinto, A. Reis, I.M. Vidal, J.L. Krug; Santa Maria da Feira/PT

P-075 Giant leiomyosarcoma of the esophagus

M. Ballesta Moratalla, R. García Marcos, J. Rambla, M. Lloret, O. Ramírez, A. Ballesta Cuñat;
Valencia/ES

P-076 Dosimetric analysis in the diagnosis of foreign body in the pharingo-esophageal district:
low-dose CT versus conventional radiology
G. Addonisio, S. Doratiotto, A. Dorigo, S. Bertolo, N. Roma, G. Morana; Treviso/IT

95
 EPOS™ PRESENTATIONS

DIAGNOSTIC / GI TRACT / OTHER

P-077 Analysis of the normal appendix on CT
I. Willekens, E. Peeters, F. Vandenbroucke, J. de Mey; Brussels/BE

P-078 Melanoma metastasis to the gallbladder: spectrum of imaging findings

O. Catalano, A. Nunziata, S. Setola, A. Siani; Naples/IT

P-079 Crohn’s disease complications: what to look for and the best way of finding it
R. Santos, T. Bilhim, M. Pereira, C. Lam, J. Ramos, E. Alves; Lisbon/PT

P-080 Concurrent GIST and abdominal neoplasms: initial views

C. Sobrido, J. Corroto, V. Taboada, B. Suarez, C. Zueco, R. Bouzas; Vigo/ES

P-081 The imaging of anal cancer

M. Enver, Z. Khan, W. King, R. Blaquiere; Southampton/UK

P-082 Roux loop herniation post liver transplantation

RECOMMENDED
POSTER S. Freeman, I. Amin, A. Taylor, P. Gibbs, A. Butler, C. Watson; Cambridge/UK

P-083 GI perforation: new trends with MDCT

M. Beltrán, F. Jimenez, J. Artigas, A. Riaguas, C. Bernal, E. Cañete; Zaragoza/ES

P-084 Imaging of Crohn’s disease after surgery

M. Raynal, L. Azizi, J. Cazejust, B. Bessoud, M. Lewin, L. Arrivé, Y. Menu; Paris/FR

P-085 GI stromal tumors: imaging findings with pathologic correlation

A. Salgado, P. Oliveira, C. Fernandes, F. Ribeiro, M. Gouvêa; Porto/PT

P-086 Imaging findings and radiologic-pathologic correlation of GI lymphoma

H.J. Kim1, S. Yoon2, K.A. Kim1; 1Sungnam-si, Kyonggi-do/KR, 2Seoul/KR

P-087 Ultrasonography of GI tract abnormalities

C. Paulino, J. Costa, M. Seco, F. Cavalheiro, M. Martins, M. Gonçalo, F. Caseiro-Alves; Coimbra/PT

P-088 2D and 3D endoanal US imaging: normal anatomical features and pathology

R. Kirke, R. Singh; Derby/UK

P-089 Local staging of colorectal cancer: what the radiologist needs to know
R. Santos, T. Bilhim, L. Vieira, E. Alves; Lisbon/PT

P-090 Small and large bowel edema: imaging patterns and differential diagnosis
C. Triantopoulou, P. Maniatis, N. Mathou, K. Paraskeva, E. Kolliakou, I. Siafas, J. Karagiannis,
J. Papailiou; Athens/GR

P-091 Appendiceal diverticulitis: presurgical diagnosis is possible

C. Rodríguez Paz, C. Zueco, C. Sobrido Sampedro, A. Casal Rodríguez, P. Rodriguez, A. Tilve;
Vigo/ES

P-092 MRI of anal carcinomas

J. Parikh, A. Shaw, L. Grant, N. Griffin; London/UK

P-093 Withdrawn by authors

P-094 Significance of incidental colonic foci in PET/CT

K. Tweed, A. Slater, F. Gleeson, K. Bradley; Oxford/UK

96
 EPOS™ PRESENTATIONS

P-095 Bouveret syndrome

S. Bohata, R. Simunek, J. Husty, V. Valek; Brno-Bohunice/CZ

P-096 Metastatic melanoma in the abdomen and pelvis: a pictorial review

P. Oliveira, A. Salgado, F. Pires, C. Fernandes, S. Dias; Porto/PT

P-097 The role of radiology in management of GI stromal tumours

RECOMMENDED
POSTER R. Kochhar, B. Taylor, M. Leahy, P. Manoharan; Manchester/UK

P-098 GI stromal tumors: a pictorial essay

N. Ribeiro1, F. Costa1, F. Cavalheiro2, P. Cruz1, M. Tavares3, I. Beirão1; 1Viseu/PT, 2Coimbra/PT,
3
Matosinhos/PT

P-099 Gastrointestinal stromal tumours: imaging features with pathological correlation

K. MacDonald1, V. Markos2, N. Shepherd2; 1Bath/UK, 2Gloucester/UK

P-100 Acute appendicitis: spectrum of CT findings

V. Maniatis1, E. Stamoulis2, J. Tzovara2, K. Foufa2, D. Ziogana2, N. Giannoulakos2, T. Alexopoulos2;
1
Palini/GR, 2Athens/GR

P-101 Normal anatomy and complications post-bariatric surgery: a pictorial review

L. Wong, A. de Beaux, B. Tulloh, M. Duxbury, D. Patel; Edinburgh/UK

P-102 Acute appendicitis: an intra-abdominal mimic

H. Delaney, R. Killeen, S. O’Keeffe, M. Keogan, D.E. Moran; Dublin/IE

P-103 Radiologic contrast studies of the postoperative GI tract

RECOMMENDED
POSTER A. Frias Vilaça1, A. Ramos2, A. Reis1, J. Pinto1, J.P. Leao Rosas1, I.M. Vidal1, J.L. Krug1;
1
Santa Maria da Feira/PT, 2Porto/PT

MCL P-104 GI disease: can plain chest films provide any clues
C. Ruivo, P. Marques, A. Canelas, L. Semedo, J. Ilharco, F. Caseiro-Alves; Coimbra/PT

P-105 Positron emission tomography-CT imaging review of GI stromal tumours

D. Prasad, A. Denison; Aberdeen/UK

P-106 Digestive tract wall thickening as an incidental finding on MRI and CT scans: when to report
F. Gómez, J. Rambla, R. García Marcos; Valencia/ES

P-107 Fluoroscopic follow-up after surgical treatment for morbid obesity

S. Peer, R. Peer; Innsbruck/AT

P-108 Bowel obstruction: spectrum according to obstruction level, cause, severity, and other
ancillary findings on MDCT
K.N. Jee, M.H. Park; Dongnam-gu, Cheonan/KR

P-109 CT in inflammatory bowel diseases: entero CT and Crohn’s disease

T. Bilhim, C. Lam, R. Santos, P. Gil, J. Rodrigues, A. Marques, A. Cardoso; Lisbon/PT

P-110 Bowel intussusception: the role of MDCT

I. Tsota, E. Skondras, P. Kraniotis, A. Karatzas, C. Kalogeropoulou, T. Petsas; Patras/GR

P-111 Recurrent or metastatic GI stromal tumors: imatinib response evaluation with CT

G. Engin, S. Saglam; Istanbul/TR

P-112 CT findings of GIS lymphoma compared with barium studies

G. Engin, U. Korman; Istanbul/TR

P-113 Enterovesical fistulas: is abdominal CT imaging essential for the diagnosis?

S. Mylona, A. Lourbakou, N. Roppa-Lepida, S. Patsoura, A. Katsarou, N. Batakis; Athens/GR

97
EPOS™ PRESENTATIONS

P-114 GISTs, the most common group of mesenchymal tumors in the gastrointestinal tract:
diagnosis and imaging findings
J. Campos1, D. Rocha2, A. Preto2, P. Sousa2, R. Ramos2, A. Madureira2; 1V. Castelo/PT, 2Porto/PT

P-115 Radiological features of GI stromal tumors

I. Kalogeropoulos, V. Ouranos, I. Scouras, K. Stefanidis, V. Savvopoulou, E. Lazaridou,
P. Piperopoulos; Athens/GR

P-116 Imaging approaches to the diagnosis of GI obstruction

A. Frias Vilaça1, A. Ramos2, J. Pinto1, R. Cardoso1, I.M. Vidal1, J.L. Krug1; 1Santa Maria da Feira/PT,
2
Porto/PT

DIAGNOSTIC / GI TRACT / RECTUM

P-117 The role of endorectal US in the selection of patients for transanal endoscopic microsurgery
B. Thomas, A. Lowe, A. Thrower, P. Batman, M. Steward, C. Kay; Bradford/UK

P-118 CT perfusion of rectal carcinoma monitoring response to neoadjuvant treatment:

initial results
P. Paolantonio, R. Ferrari, M. Rengo, F. Vecchietti, P. Lucchesi, M. Maceroni, A. Laghi; Latina/IT

P-119 Added value of diffusion-weighted imaging for predicting tumor response to neoadjuvant
chemoradiotherapy for locally advanced rectal cancer
S.H. Kim, J.M. Lee, S.H. Hong, G.H. Kim, J.Y. Lee, J.K. Han, B.I. Choi; Seoul/KR

P-120 MRI in diagnosis and follow-up of perianal fistulazing Crohn’s disease: a pictorial essay
E. Szurowska, J. Pienkowska, J. Wypych, E. Izycka-Swieszewska, A. Szarmach, M. Studniarek;
Gdansk/PL

P-121 Evacuation proctography: a new method for rectal contrast opacification

A. Leonard, S.A. Jackson, C. Searle, E. Armstrong, J. Shirley, B. Fox; Plymouth/UK

P-122 MRI assessment of lymph nodes in rectal cancer

C. González, A. Arrillaga, E. Fernandez, J.P. Ciria, M. San Vicente, E. Salvador; San Sebastian/ES

P-123 Can MRI predict extraparietal tumour extension?

C. González, A. Arrillaga, E. Fernandez, J.P. Ciria, K. Biurrun, J. Vega; San Sebastian/ES

P-124 Pelvic MRI after surgery for anorectal disease: a pictorial review
D.H. Lee, H.J. Kim, J.W. Lim, Y.T. Ko; Seoul/KR

P-125 Does high resolution rectal MRI at 3T provide useful preoperative information about robotic
total mesorectal excision candidates?
M.J. Kim, B.J. Park, D.J. Sung, K.B. Chung, Y.W. Oh; Seoul/KR

P-126 A new semi-automatic tool for volumetric evaluation of response to treatment in rectal
cancer
A. Maroto i Genover, M. Osorio i Fernández, I. Boada i Oliveras, A. Bardera i Reig,
J. Daunis i Estadella, G. Blasco i Solà; Girona/ES

DIAGNOSTIC / GI TRACT / SMALL BOWEL

P-127 Withdrawn by authors

98
EPOS™ PRESENTATIONS

P-128 Duodenal wall masses: pictorial review of an overlooked segment

A. Snoeckx, M. Eyselbergs, B. Op de Beeck, M. Spinhoven, B. Corthouts, P. Parizel; Edegem/BE

P-129 Imaging of small bowel: current state of the art techniques

F. Rahman, S. Liong, S. Campbell, S. Lee, B. Rajashanker; Manchester/UK

P-130 Classic signs in radiology of digestive tract

A. Manzella, P. Borba-Filho, H. Rojas, P. Andrade; Recife/BR

P-131 Cystic dystrophy of the duodenal wall: imaging features and differential diagnosis
J. Brito1, L. Curvo-Semedo2, M. Lima1, J. Costa2, B. Gonçalves2, B. Graça2, M. Seco2,
F. Caseiro-Alves2; 1Angra do Heroismo/PT, 2Coimbra/PT

P-132 Small bowel malabsorption

C. Paulino, J. Costa, B. Graça, A. Canelas, J. Ilharco, M. Gonçalo, F. Caseiro-Alves; Coimbra/PT

P-133 CT for acute abdomen: think ischaemic bowel

O. Bashir1, R. Singh2, K. Latief1; 1Nottingham/UK, 2Derby/UK

P-134 The different types of internal hernia after laparoscopic Roux-En-Y gastric by-bass
for morbid obesity: MDCT features
A. Kawkabani Marchini1, A. Paroz1, S. Romy1, M. Suter2, A. Denys1, P. Schnyder1, S. Schmidt1;
1
Lausanne/CH, 2Aigle/CH

P-135 The duodenum: an often neglected segment despite its important anatomic location
and related various disease entities
Y. Kim1, W.K. Jeong1, S.Y. Song2, O.K. Cho2, B.H. Koh2; 1Kuri/KR, 2Seoul/KR

P-136 The role of unenhanced CT in the evaluation of the small bowel obstruction
P. Dvorak1, J. Novotny2, P. Hoffmann1, Z. Sedlacek1; 1Hradec Kralove/CZ, 2Dumfries/UK

DIAGNOSTIC / GI TRACT / STOMACH

P-137 Preoperative node staging in gastric cancer by using multi-detector-row CT and MR
L. Saba, G. Mallarini; Cagliari/IT

P-138 Imaging of bariatric surgery complications

A. Manzella, J. Campos, P. Borba-Filho, L.F. Evangelista, L. Siqueira, Á.A. Ferraz, E. Ferraz;
Recife/BR

P-139 MRI of stomach with different oral contrast agents

I. Mokali, A. Oikonomou, D. Theodorakis, A. Spanoudaki, V. Fotiadou, P. Prassopoulos;
Alexandroupolis/GR

P-140 Role of fluoroscopic examination in post-operative bariatric surgery: gastric by-pass

P. Giusti, S. Giusti, S. Canovetti, V. Morigoni, C. Bartolozzi; Pisa/IT

P-141 Gastric surgical procedures: postoperative anatomy and pathologic findings

H. Matos, T. Couto, D. Condesso, H. Patricio, F. Fonseca, A. Estevão; Coimbra/PT

P-142 Postoperative imaging of gastric cancer: what radiologists should know

M. Kim, J. Kwon, K. Cho, Y. Kang, K. Park, S. Ryu; Daegu/KR

P-143 The role of imaging in bariatric surgery

B. Thomas1, S. Lee2, A. Lowe1, A. Thrower1, C. Kay1; 1Bradford/UK, 2Manchester/UK

99
 EPOS™ PRESENTATIONS

P-144 MRI features of gastric cancer: a pictorial review

C. Leal, J. Raposo, P. Mendonça, A. Cordeiro, R. Mateus Marques, M. Pereira, L. Cardoso; Lisboa/PT

P-145 How to evaluate gastric cancer by using MDCT

L. Saba, G. Fantola, F. Casula, G. Mallarini; Cagliari/IT

P-146 Variants of gastric carcinoma and its mimicking diseases

Y. Kim1, W.K. Jeong1, O.K. Cho2, S.Y. Song2, B.H. Koh2; 1Kuri/KR, 2Seoul/KR

P-147 A rare cause of portal venous gas: case report of acute massive gastric dilatation
F. La Seta, F. Terrazzino, L. Tesè, S. Pirri, I. Modesto, A. La Barbera, F. Valenza, A. Buccellato;
Palermo/IT

CM P-148 Pictorial review of MDCT findings of less common gastric pathologies: correlation with
gastroscopy and pathologic findings
M. Kim, J. Kwon, Y. Kang, S. Ryu, K. Park, K. Cho; Daegu/KR

P-149 The normal imaging findings and complications of gastric banding

J. Campos1, A. Preto2, D. Rocha2, R. Ramos2, P. Sousa2, L. Guimarães2, A. Madureira2;
1
V. Castelo/PT, 2Porto/PT

P-150 Epithelial and submucosal lesions of the stomach: spectrum of CT findings

I. Santiago1, J. Maciel1, A. Canelas2, M. Seco2, B. Graça2, B. Gonçalves2, N.J. Dias2, M. Cipriano2,
F. Caseiro-Alves1; 1Aveiro/PT, 2Coimbra/PT

DIAGNOSTIC / GI TRACT / SWALLOWING

P-151 Videofluoromanometric study in the assessment of swallowing abnormalities
in amyotrophic lateral sclerosis
A. Reginelli, F. Maisto, A. Rotondo, G. Lombardi, L. Casale, M. Barbieri, P. Liguori, R. Grassi;
Naples/IT

P-152 A new approach to training the upper GI contrast examination

I. Uri, S.A. Jackson, E. Armstrong, J. Shirley, B. Fox; Plymouth/UK

P-153 Role of videofluoroscopic swallow study in management of dysphagia in neurologically

compromised patients
S. Doratiotto, M. Pasian, M. Morello, G. Morana; Treviso/IT

DIAGNOSTIC / LIVER / DIFFUSE LIVER DISEASE

P-154 High-resolution ultrasonographic evaluation of liver surface versus transient elastography
in the diagnosis of cirrhosis
A. Berzigotti, J.G. Abraldes, R. Gilabert, E. Erice, J. Garcia-Pagan, C. Bru, J. Bosch; Barcelona/ES

P-155 Withdrawn by authors

P-156 Diffusion-weighted MRI for assessment of liver fibrosis

L. Stoppino, P. Milillo, L. Loperfido, P. Ciuffreda, R. Vinci, L. Macarini; Foggia/IT

P-157 Regenerative nodular disease of the liver: a pictorial review on cross-sectional imaging
M. Seco, A. Canelas, J. Costa, B. Graça, L. Curvo-Semedo, F. Caseiro-Alves; Coimbra/PT

CM P-158 “Periportal venous-spread pattern” in hepatic parenchyma and hilum: imaging

demonstration with multi-detector row CT
M. Sai1, H. Mori2, M. Kiyonaga1, S. Tanoue2, Y. Yamada2, S. Matsumoto2; 1Yufu-shi/JP, 2Oita/JP

100
EPOS™ PRESENTATIONS

P-159 Everything you need to know about screening surveillance ultrasonography

in patients with chronic viral disease
P. Cabassa, M. Morone, V. Pavesi, E. Gatti, S. Gandolfi, R. Maroldi; Brescia/IT

P-160 Withdrawn by authors

P-161 Fatty liver revisited: imaging patterns and pitfalls

M. Seco, F. Cavalheiro, C. Paulino, P. Marques, L. Curvo-Semedo, F. Caseiro-Alves; Coimbra/PT

P-162 Correlation of sonographic assessment of hepatic steatosis with histological fat

quantification analysis
B. Palaniappan, S. Singh, T. Boyles, D. Cochlin, A. Yong; Cardiff/UK

P-163 Diffusion weighted imaging of the liver

A. Tokala, L. Williams, D. Kasir, H. Burnett; Manchester/UK

P-164 MDCT (64 slices) of the liver: optimization of scan delay for arterial phase imaging using
bolus tracking technique
P. Paolantonio, R. Ferrari, M. Rengo, F. Vecchietti, P. Lucchesi, D. Caruso, A. Laghi; Latina/IT

P-165 Correlation between MRI hepatic steatosis quantification and distribution of adipose tissue
P. Manchec-Poilblanc, V. Roullier, E. Cesbron, M. Poilblanc, P.H. Ducluzeau, C. Aube; Angers/FR

P-166 MRI in liver iron overload: thalassemia intermedia and sickle cell disease
H. Matos, A. Pereira, C. Sanches; Coimbra/PT

P-167 Application of CT in fatty liver analysis

L. Saba, G. Mallarini; Cagliari/IT

DIAGNOSTIC / LIVER / FOCAL LIVER LESIONS IN CIRRHOTIC LIVER

P-168 3D MRI for hepatobiliary disease with Gd-EOB-DTPA
S.Y. Choi1, T. Abe1, H. Shinjo1, H. Munechika1, T. Gokan2; 1Koriyama/JP, 2Tokyo/JP

P-169 A two-centre study for the comparison of GD-EOB-DTPA (PRIMOVIST):

enhanced MRI versus triple-phase MDCT for the detection of HCC in cirrhosis
L. Grazioli1, A. Luca2, R. Tinti1, S. Caruso2, M. Bondioni1, M. Milazzo2; 1Brescia/IT, 2Palermo/IT

P-170 Is this nodule a HCC? test choice and image interpretation for the general radiologist
R. Ryan, I. Heaslip, D. Moran, D. Malone; Dublin/IE

P-171 3.0-T MRI with Gd-EOB-DTPA in patients with liver cirrhosis: hepatic parenchymal
enhancement of Child-pugh classification
T. Abe1, S.Y. Choi2, H. Shinjo2, Y. Miura2, K. Kawakura2, T. Saginoya2, S. Takekawa2, H. Munechika2;
1
Fukushima/JP, 2Koriyama/JP

P-172 HCC at Gd-BOPTA-enhanced MRI: which is the best venous phase for the detection
of contrast washout?
L. Cereser, A. Furlan, D. Bagatto, R. Girometti, G. Como, C. Zuiani, M. Bazzocchi; Udine/IT

P-173 The work-up of nodules seen on HCC surveillance: comparison of single versus
multimodality approach
K. Khalili, H. Jang, T.K. Kim, M. Sherman, M. Haider; Toronto, ON/CA

P-174 Spectrum of findings of HCC with MDCT and MRI

D. Rocha, A. Carneiro, J. Campos, N. Silva, M. Pimenta, L. Guimarães, J. Gonçalves; Porto/PT

101
EPOS™ PRESENTATIONS

P-175 Hepatic carcinoma chemoembolization: what the radiologist should look for at post-
treatment evaluation with MDCT
F. Cavalheiro, B. Gonçalves, V. Carvalheiro, P. Donato, F. Caseiro-Alves; Coimbra/PT

P-176 Assessment of CT color map images of the arterial enhancement fraction with 3D
registration in diagnosis of recurrence of hepatocellular carcimoma after transcatherter
arterial chemoembolization
N. Marugami1, S. Kitano1, T. Tanaka1, H. Anai1, J. Takahama1, A. Takahashi1, S. Hirohashi2,
K. Kichikawa1, T. Itoh3; 1Kashihara/JP, 2Osaka/JP, 3Shinagawa/JP

P-177 Virtual non-contrast CT using dual energy CT in patients with HCC: comparison with native CT
S. Hirohashi1, N. Marugami2, S. Kitano2; 1Osaka/JP, 2Kashihara/JP

P-178 Withdrawn by authors

DIAGNOSTIC / LIVER / FOCAL LIVER LESIONS IN NON-CIRRHOTIC LIVER

P-179 Health technology assessment and costs: effectiveness of contrast-enhanced
ultrasonography versus CT and MR in the characterization process of focal liver lesions
L. Romanini1, M. Passamonti2, L. Aiani3, L. Grazioli1, F. Calliada4, A. Martegani3, D. Croce5;
1
Brescia/IT, 2Lodi/IT, 3Como/IT, 4Pavia/IT, 5Castellanza/IT

P-180 MRI diffusion weighted imaging of focal liver lesions: comparison of signal-to-noise ratio
and lesion-to-liver contrast-to-noise ratio in sequences with different b-values
R. Pozzi Mucelli, L. Cancian, G. Balestriero, C. Cugini, A. Dorigo, G. Morana; Treviso/IT

P-181 Super-paramagnetic iron oxide induced liver signal intensity loss in patients with colorectal
metastases: effect of chemotherapy
S. Krishan, J. Ward, J.A. Guthrie, M. Sheridan, S. Boyes, P. Robinson; Leeds/UK

P-182 Spectrum of sonographic, CT and MRI appearances of hepatic epithelioid

hemangioendotheliomas
I. Huynh-Charlier1, C. Bertin1, P. Charlier2, P. Grenier1, O. Lucidarme1; 1Paris/FR, 2Garches/FR

P-183 Added benefit of contrast-enhanced CEUS for small indeterminate liver lesions on CT/MRI
H. Yu, H. Jang, T.K. Kim; Toronto, ON/CA

P-184 Abdominal echinococcus in southeastern Europe: a pathophysiological,

clinical and imaging review
D. Cokkinos1, E. Antypa1, M. Skilakaki1, A. Tavernaraki1, I. Kyratzi1, I. Deligiannis2, P. Antonopoulou1,
P. Piperopoulos1; 1Athens/GR, 2Kaisariani, Athens/GR

P-185 Inflammatory masses in the liver mimicking malignant neoplasms

E. Maheshwari, T.K. Kim, H. Jang; Toronto, ON/CA

P-186 Focal nodular hypeplasia on liver MRI: classsical and atypical appearances
with hepatocyte-specific gadolinium versus super-paramagnetic iron oxide
M. Laugharne, J. Ash-Miles, H. Roach, M. Callaway; Bristol/UK

P-187 Intraoperative contrast enhanced US in the management of the resection

of liver metastases
M. Krokidis, S. Yarmenitis, S. Gourtsoyianni, E. Amanakis, N. Gourtsoyiannis; Heraklion/GR

P-188 Automatic segmentation tools for liver metastases on CT: does it work?
S. Egels, C. Bertin, P. Grenier, O. Lucidarme; Paris/FR

P-189 MRI enhanced with primovist: patterns of hepatic enhancement in non-cirrhotic livers
B. Paño, J.R. Ayuso, E. Pineda, J. Rios, C. Ayuso, J. Maurel, M. Pagés Llinás; Barcelona/ES

102
 EPOS™ PRESENTATIONS

P-190 MRI organ-specific contrasts in liver

A. Arrillaga1, C. González1, J. Alústiza1, J.R. Ayuso2, J. Martin3, J. Castell4; 1San Sebastian/ES,
2
Barcelona/ES, 3Sabadell/ES, 4Sevilla/ES

P-191 Diffusion-weighted MRI of colo-rectal liver metastases treated by new anti-angiogenetic

chemotherapy
M. Galia1, E. Grassedonio1, G. Lo Re1, P. Carcione1, A. Carcione1, F. Coppolino2, M. Midiri1;
1
Palermo/IT, 2Siracusa/IT

P-192 Dynamic contrast enhanced 3D US in the per-operative detection and localization

of liver metastases: early results
H. Dekker, H. Huisman, Y. Hoogeveen, J. Barentsz; Nijmegen/NL

P-193 Liver abscess: how often will X-rays and US do the job?
D. Cokkinos, E. Antypa, A. Mantzorou, E. Testempasi, A. Sofronas, C. Stefanidis, E. Kratimenou,
P. Piperopoulos; Athens/GR

P-194 Treatment success of transarterial chemoembolization for HCC:

assessment with contrast enhanced ultrasonography
P. Cabassa, E. Gatti, M. Morone, S. Mombelloni, R. Cuomo, R. Maroldi; Brescia/IT

P-195 Cystic type mesenchymal hamartoma of the liver: US and CT findings

with histopathologic confirmation
M. Cevener, A. Kabaalioglu, G. Karaguzel; Antalya/TR

P-196 Focal hepatic lesions on contrast-enhanced US: pitfalls in the interpretation

RECOMMENDED
POSTER H. Jang, T.K. Kim, H. Yu, K. Khalili; Toronto, ON/CA

P-197 Benign hepatic lesions: typical and atypical patterns as evidenced at Sonovue-low-
mechanical index US
V. Cantisani1, P. Ricci1, F. Calliada2, L. Romanini3, M. D’Onofrio4, A. Marcantonio1, U. D’Ambrosio1,
C. Marigliano1, I. Guerrisi1, R. Passariello1; 1Rome/IT, 2Pavia/IT, 3Brescia/IT, 4Verona/IT

P-198 Focal nodular hyperplasia or hepatic adenoma: how MRI can help us using liver-specific
contrast agents
P. Paolantonio, R. Ferrari, M. Rengo, F. Vecchietti, P. Lucchesi, M. Maceroni, A. Laghi; Latina/IT

P-199 The application of contrast enhanced US with sonovue in the sonographic diagnostics of
metastatic liver lesions in patients with GI tract cancer
E. Dybiec, R. Kryza, P. Wieczorek, W. Polkowski; Lublin/PL

P-200 The role of imaging and intervention in the management of HCC

R. Ryan, S. Skehan, C.P. Cantwell, D. Moran, D. Malone; Dublin/IE

P-201 Contrast-enhanced US multiparametric evaluation of gallbladder disease

V. Cantisani1, P. Ricci1, L. Perretti2, E. Pagliara1, U. D’Ambrosio1, F. Calliada3, B. Beomonte Zobel1,
R. Passariello1; 1Rome/IT, 2Castrovillari/IT, 3Pavia/IT

P-202 Comparative diagnostic value of hepatic hemangiomas by contrast enhanced US,

CT and MRI
I. Zaboriene, K. Zviniene, A. Basevicius; Kaunas/LT

DIAGNOSTIC / LIVER / OTHER

P-203 Clinical applications of diffusion-weighted imaging in the liver
RECOMMENDED
POSTER A. Luna1, I. Rivera1, L. Luna1, R. Ribes2, P. Caro3; 1Jaen/ES, 2Cordoba/ES, 3Cadiz/ES

103
 EPOS™ PRESENTATIONS

P-204 The many faces of focal nodular hyperplasia

M.A. Portilha, M. Seco, L. Semedo, F. Alves, C. Marques, F. Caseiro-Alves; Coimbra/PT

P-205 Cystic focal liver lesions in adults: a pictorial essay using a multimodality approach
RECOMMENDED
POSTER A. Jacob1, S. Lapsia2; 1Manchester/UK, 2Blackburn/UK

P-206 Periportal space, a potential intrahepatic space: a review of anatomy and imaging features
of diseases involving this space with radiopathologic correlation
A. Almeida, K. Ganesan, M. Hart, Y. Soo, M. Peterson, C. Sirlin; San Diego, CA/US

P-207 The role of Gd-BOPTA enhanced MRI in the characterization of focal liver lesions
I. Ceylan, F. Obuz, O. Sagol, S. Karademir; Izmir/TR

P-208 Periportal tracking: MDCT features and clinical significance

H. Torrao, S. Kurochka, S. Dias, L. Gonçalves, V. Mendes, A.C. Costa; Braga/PT

P-209 Abdominal multidetector-row CT: estimation of optimal contrast material dose according
to body surface area
H. Onishi1, T. Murakami2, T. Kim1, M. Hori1, M. Tatsumi1, Y. Nakaya1, T. Tsuboyama1, A. Nakamoto1,
K. Tomoda1, H. Nakamura1; 1Suita/JP, 2Osakasayama/JP

P-210 MR contrast agents for liver imaging: what every radiologist should know
M.A. Portilha, A. Canelas, B. Graça, F. Alves, C. Marques, F. Caseiro-Alves; Coimbra/PT

P-211 MRI with hepatocyte-selective contrast enhancement (gadoxetic acid) in the differential
diagnosis of focal liver lesions
E. Szurowska, J. Pienkowska, E. Izycka-Swieszewska, T. Nowicki, M. Studniarek; Gdansk/PL

P-212 Imaging of liver non traumatic emergencies

S. Giannecchini, M. Trinci, M. Galluzzo, C. Rende, V. Miele; Rome/IT

P-213 Assessment of heterogeneities in hepatocarcinoma liver lesions by pharmacokinetic MR

modeling and histogram analysis
R. Sanz-Requena, L. Martí-Bonmatí; Valencia/ES

P-214 The added value of MRI in focal hepatic lesions work-up

L. Gonçalves, S. Kurochka, S. Dias, H. Torrão, C. Pina Vaz, V. Mendes; Braga/PT

P-215 Comparison of extended field-of-view ultrasonography, conventional B-mode

ultrasonography and MDCT in measuring liver size
S. Pauls1, D. Borchert1, R. Muche1, M. Haenle1, A. Akinli1, F. Arnold1, W. Kratzer1, A. Schuler2;
1
Ulm/DE, 2Geislingen/DE

P-216 The role of MDCT in the assessment of morphologic changes occurring

RECOMMENDED
POSTER in the liver after resection
A. Riaguas, E. Cañete, L. Sarría, E. Martínez, M. Beltrán, F. Jimenez; Zaragoza/ES

P-217 Hydatid disease: a pictorial review

R. Maia, B. Ramos, M. Gomes, M. Franca, J. Reis, M. Ribeiro; Porto/PT

P-218 Liver hydatid cyst: revisited

R. Ramos1, C. Videira2, J. Traila1, M. Pimenta1, P. Carvalho2, I. Pereira3; 1Porto/PT, 2Lisboa/PT

P-219 Analysis of a blood pool contrast agent in healthy mice

I. Willekens, T. Lahoutte, N. Buls, V. Caveliers, R. Deklerck, A. Bossuyt, J. de Mey; Brussels/BE

P-220 Withdrawn by authors

104
 EPOS™ PRESENTATIONS

P-221 Current trends in pre-operative evaluation and staging of colorectal liver secondaries
S. Liong, F. Rahman, S. Gadde, S. Lee, B. Ammori, A. Siriwardena, A. Sheen, B. Rajashanker;
Manchester/UK

DIAGNOSTIC / LIVER / TRANSPLANTATION

P-222 The usefulness of contrast enhanced ultrasonography as the main radiological technique
in the first hours after liver transplantation to detect vascular complications
M. Ballesta Moratalla, A. Ballesta Cuñat, C. Ballester Vallés, J. de Juan Tomás, O. Ramírez,
M. Lloret; Valencia/ES

DIAGNOSTIC / MESENTERY AND PERITONEUM

P-223 Radiologist’s performance in the differentiation of tuberculosis peritonitis and peritoneal
carcinomatosis using specific CT criteria
M.J. Kim, B.J. Park, D.J. Sung, S.B. Cho, Y.H. Kim, K.B. Chung, Y.W. Oh; Seoul/KR

P-224 Imaging of abdominal and retroperitoneal soft tissue masses: a practical approach
RECOMMENDED
POSTER A. Snoeckx, F. Vanhoenacker, B. Op de Beeck, A. de Schepper, M. Spinhoven, P. Parizel;
Edegem/BE

P-225 Detection of peritoneal carcinomatosis: evaluation by diffusion-weighted MRI

F. Kotake1, R. Uno2, Y. Takahashi1, M. Hoshina1, R. Nishio1, K. Tokuue2; 1Ibaraki/JP, 2Tokyo/JP

P-226 Intra-abdominal complications secondary to ventriculoperitoneal shunt:

CT findings and review of the literature
J. Chung, J. Yu, J.H. Kim, S.J. Nam, M. Kim; Seoul/KR

P-227 Sclerosing mesenteritis: imaging findings and differential diagnosis

M. Gomes, J. Pires, M. Franca, A. Ramos, J. Reis, P. Varzim, M. Ribeiro; Porto/PT

P-228 CT manifestations of peritoneal and mesenteric pathology: a pictorial essay

S. Sawhney, R. Jain, A. Kakaria, S. Sawhney; Muscat/OM

P-229 Imaging characteristics of abdominal solitary fibrous tumor

S. Kurochka, H. Torrão, S. Vilaça, S. Campelos, J. Falcão, M. Reis, C. Leite; Braga/PT

P-230 Mesenteric panniculitis: MDCT findings

B. Acu, A. Altunkas, T. Pinarbasili, M. Firat; Tokat/TR

P-231 Neuroblastoma, diagnosis and staging: a pictorial review

M. Armas Goncalves1, L. Gonçalves2, M.J. Noruegas3, P. Coelho3, C. Sanches3;
1
Funchal/PT, 2Braga/PT, 3Coimbra/PT

P-232 CT and MR findings of retroperitoneal fibrosis: a pictorial review

P. Oliveira, F. Pires, A. Salgado, C. Carneiro, S. Dias; Porto/PT

P-233 Primary retroperitoneal neoplasms: a pictorial review

R. Maia, B. Ramos, P. Santos, J. Pires, J. Reis, M. Ribeiro; Porto/PT

P-234 Peritoneal compartments, folds, ligaments and recesses:

anatomy of cross-sectional imaging
O. Bashir, K. Latief, Z. Zia; Nottingham/UK

P-235 Usefulness of US-guided percutaneous core biopsy for patients having only infiltration in
mesentery or omentum on contrast-enhanced CT
J.K. Lee, S.Y. Baek; Seoul/KR

105
EPOS™ PRESENTATIONS

DIAGNOSTIC / OTHER / ACUTE AND POST-TRAUMATIC ABDOMEN

P-236 Contribution of CT to determine transparietal esophageal necrosis
after ingesting caustic substances
G. Valerie1, F. Boudghene2; 1Tremblay en France/FR, 2Paris/FR

P-237 CT of blunt liver trauma

F. Costa1, N. Ribeiro1, F. Cavalheiro2, D. Silva1, J. Carvalho1, I. Beirão1; 1Viseu/PT, 2Coimbra/PT

P-238 The impact in abdominal imaging with the introduction of a dedicated emergency CT
R. Mittal, J. Sarrazin, A. Moody; Toronto, ON/CA

P-239 Challenges and pitfalls of abdominal imaging in intensive care: a pictorial essay
V. Raju, A. Leonard, S.A. Jackson, B. Fox, E. Armstrong, J. Shirley; Plymouth/UK

P-240 Barium esophagogram: normal anatomy and pathological findings

after laparoscopic Nissen’s fundoplication
N. Roson, N. Arcalis Guaus, V. Garriga, D. Garcia, L. Berrocal, A. Conejero, S. Carbó, X. Pruna,
S. Medrano; Granollers/ES

P-241 Volume rendering of thin-section MDCT images in the evaluation of the acute abdomen:
an indispensable tool for rapid diagnosis
R. Jain, S. Sawhney, A. Kakaria; Muscat/OM

P-242 Blunt trauma to the mesentery and retroperitoneal structures: value of 64-detector rows CT
in detecting vascular, common and rare injuries
S. Romano, C. Stavolo, A. Russo, N. Gagliardi, G. Tortora, F. Maisto, L. Romano; Naples/IT

P-243 The need for enteral contrast in diagnosis of appendicitis with multidetector CT
M. Torkzad1, A. Latifi2, A. Sundin2, F. Labruto2, S. Kaiser2, U. Ullberg2; 1Uppsala/SE, 2Stockholm/SE

DIAGNOSTIC / OTHER / RADIOLOGIC-PATHOLOGIC CORRELATION

P-244 Diffusion-weighted MRI: a non-invasive biomarker for the rapid differentiation of malignant
versus benign abdominal mass lesions
R. Jain, S. Shukaili, A. Harrassi; Muscat/OM

P-245 Diffusion weight imaging in body district: from physics principles to image interpretation
P. Paolantonio1, G. Suma2, R. Ferrari1, M. Rengo1, F. Vecchietti1, P. Lucchesi1, A. Laghi1;
1
Latina/IT, 2Rome/IT

P-246 Abdominal imaging manifestations in acquired immunodeficiency syndrome

J.C. Quintero, C. Roqué, I. Guasch, D. Hernández, D. Durany, J.A. Jiménez; Badalona/ES

P-247 Abdominal radiology with an evidence-based medicine perspective

G. Neofitou, F. Laspas, J. Tzovara, G. Ptohis, G. Tsonou, E. Kyrios, A. Chalazonitis; Athens/GR

P-248 Diffusion WI in oncology at 3T: sequences, applications in detection and caracterisation

O. Bruno1, M. Rodallec2, V. Barrau2; 1Clichy/FR, 2Saint Denis/FR

P-249 Imaging of abdominal inflammatory pseudotumor

J.C. Quintero1, G. Valderas2, D. Durany1, S. Vizcaya1, S. Ruiz2, C. Roqué1;
1
Badalona/ES, 2Hospitalet de Llobregat/ES

P-250 Tailgut cyst: a rare retrorectal tumor

J. Maciel, I. Santiago, A. Vaz, F. Fîgueiredo; Aveiro/PT

106
 EPOS™ PRESENTATIONS

P-251 Role of MDCT in the emergency diagnosis of acute appendicitis

F. Terrazzino, L. Tesè, F. La Seta, S. Pirri, M. Safina, R. Ciraulo, A. Agricola, A. Buccellato, M. Midiri;
Palermo/IT

P-252 Abdominal wall masses: the spectrum of imaging findings

H.Y. Han, S.J. Park, J.H. Kim; Daejeon/KR

P-253 Semiautomated splenic volumetry based on diffusion weighted MRI

J. Koizumi1, K. Hashida1, Y. Kawawa1, T. Hashimoto1, K. Myojin1, B. D’Othée2;
1
Isehara/JP, 2Boston, MA/US

P-254 The many faces of abdominal lymphoma

M. Franca1, J. Pires2, A. Ramos2, R. Maia2, M. Certo3, M. Gomes2, P. Varzim2, P. Santos2;
1
Maia/PT, 2Porto/PT, 3Santo Tirso/PT

P-255 Inflammatory pseudotumor: a frequently forgotten entity!

A. Preto, J. Campos, S. Guimaraes, R. Cunha; Porto/PT

P-256 Abdominal wall hernias: CT findings and complications

J. Campos1, D. Rocha2, M.M. Pimenta2, P. Sousa2, R. Ramos2, A. Carneiro2, P. Madaleno2;
1
V. Castelo/PT, 2Porto/PT

P-257 A semi-automatic segmentation approach for generation of abdominal 3D models

from multi-phase MDCT images
V. Ferrari, C. Cappelli, G. Megali, A. Pietrabissa, C. Bartolozzi, F. Mosca; Pisa/IT

P-258 Echinococcosis: imaging appearances, complications and post-treatment aspects

RECOMMENDED
POSTER F. Cavalheiro, B. Graça, P. Belo-Soares, C. Paulino, F. Caseiro-Alves; Coimbra/PT

P-259 MDCT imaging of emergencies in cancer patients

A. Nunziata, O. Catalano, M. Mattace Raso, E. de Lutio di Castelguidone, A. Siani; Naples/IT

P-260 Withdrawn by authors

P-261 Congenital diaphragmatic hernias: expecting the unexpected

R. Ramos1, C. Videira2, J. Campos1, D. Rocha1, A.S. Preto1, I. Pereira3;
1
Porto/PT, 2Lisboa/PT, 3Santarem/PT

P-262 The role of conventional and dynamic biphasic CT examination

in acute mesenteric ischemia
S. Serter, N. Halac, G. Pekindil, T. Coskun, S. Ayhan; Manisa/TR

P-263 How successful is 18F-FDG PET/CT in demonstrating and characterising suspicious lung
nodules in patients with colorectal carcinoma
C. Chew, S. Rasul, S. Han, F. Poon; Glasgow/UK

P-264 Radiographic examination of French monarchs’ intestines (St Denis, 19th century):
potential interest for forensic radiology
P. Charlier1, I. Huynh-Charlier2; 1Garches/FR, 2Paris/FR

P-265 Primary retroperitoneal masses: radiologic-pathologic correlation

RECOMMENDED
POSTER Y. Kim1, W.K. Jeong1, S.Y. Song2, O.K. Cho2, B.H. Koh2; 1Kuri/KR, 2Seoul/KR

P-266 Fitz-Hugh-Curtis syndrome: incidence and laboratory change and radiologic findings
S.Y. Park1, S.S. Hwang1, Y. Ku2; 1Suwon/KR, 2Uijeongbu/KR

P-267 Imaging features of abdominal paragangliomas

M.A. Portilha1, I. Santiago2, C. Ruivo1, F. Alves1, F. Caseiro-Alves1; 1Coimbra/PT, 2Aveiro/PT

107
 EPOS™ PRESENTATIONS

DIAGNOSTIC / OTHER / ULTRASOUND

P-268 Contrast-enhanced ultrasonography and quantification of tumoral perfusion:
RECOMMENDED
POSTER early evaluation of hepatic malignant tumors response to transarterial chemoembolization
T. Lefort, A. Guibal, C. Lombard-Bohas, T. Walter, F. Pilleul; Lyon/FR

P-269 Pelvic MRI is better in the assessment of the pelvic floor in patients
with faecal incontinence than 2D endoanal US
K. Thiruppathy, S.A. Taylor, S. Halligan, A. Emmanuel; London/UK

P-270 The spectrum of US findings in splenic pathology

D. Cokkinos, E. Antypa, P. Tserotas, D. Exarchos, A. Beka, I. Skouras, G. Spiliopoulou,
P. Piperopoulos; Athens/GR

P-271 US imaging of emergencies in cancer patients

O. Catalano, A. Nunziata, S. Setola, P. Saturnino, A. Siani; Naples/IT

P-272 US quantification of tissue strain properties: a way to overcome subjectivity?

M. D’Onofrio, A. Gallotti, R. Malago, N. Faccioli, L. Nicoli, S. Mautone, R. Pozzi Mucelli; Verona/IT

P-273 US of anterior abdominal wall: normal anatomy and pathological findings.

RECOMMENDED
POSTER N. Arcalis Guaus, N. Roson, V. Garriga, S. Medrano, L. Berrocal, D. Garcia, A. Conejero, S. Carbo,
M. Cuadrado, X. Pruna; Granollers/ES

P-274 Contrast enhanced US of intrahepatic peripheral cholangiocarcinoma

in patients with liver cirrhosis
R. Vilana, L. Bianchi, C. Bru, R. Gilabert, A. Garcia, J. Rimola, A. Forner; Barcelona/ES

DIAGNOSTIC / PANCREAS

CL P-275 Multifocal pancreatic lesions: a pictorial guide to differential diagnosis

A. Snoeckx, B. Op de Beeck, M. Spinhoven, B. Corthouts, R. Salgado, K. de Jongh, P. Parizel;
Edegem/BE

P-276 Abdominal imaging findings in von Hipple-Lindau disease

RECOMMENDED
POSTER T. Ichikawa, J. Koizumi, T. Yamashita, Y. Imai; Isehara/JP

CM P-277 Imaging of pancreaticoduodenectomy and palliative entero-biliary bypass surgery:

normal and abnormal post-operative findings
R. Beable, N. Hartley, A. Rajesh, D. Berry, R. Verma; Leicester/UK

P-278 Peripancreatic lymphatic spread of the pancreatic body/tail carcinoma:

RECOMMENDED
POSTER evaluation with multi-detector row CT
M. Kiyonaga1, H. Mori2, S. Matsumoto2, Y. Yamada2, M. Sai1; 1Yufu-shi/JP, 2Oita/JP

P-279 Protocol optimisation of 64-MDCT imaging of the pancreas

using different scan delay regimes
M. Juchems1, A. Ernst1, A. Aschoff2, H. Brambs1; 1Ulm/DE, 2Kempten/DE

P-280 Imaging of pancreas transplantation and its complications: a pictorial essay

RECOMMENDED
POSTER M. Franca1, M. Certo2, J. Pires3, A. Ramos3, M. Martins3, C. Henriques3, P. Varzim3;
1
Maia/PT, 2Santo Tirso/PT, 3Porto/PT

CM P-281 Autoimmune pancreatitis: MR features before and after steroid therapy

R. Albazaz, J.A. Guthrie, C. Verbeke, M. Sheridan; Leeds/UK

P-282 Cystic pancreatic lesions: a large spectrum of imaging findings

A. Preto, N. Silva, S. Guimaraes, D. Rocha, J. Gonçalves; Porto/PT

108
 EPOS™ PRESENTATIONS

P-283 Usefulness of MDCT perfusion measurement in patients with acute pancreatitis

J. Pienkowska, E. Szurowska, J. Wierzbowski, M. Studniarek; Gdansk/PL

P-284 Accessory pancreatic duct and minor duodenal papilla: visibility, examination technique
and imaging findings at secretin-enhanced MR cholangio-pancreatography
G. Restaino, M. Missere, M.V. Occhionero, E. Cucci, M. Ciuffreda, G. Sallustio; Campobasso/IT

CM P-285 Pirouettes, spins and turning heads: the pancreas in malrotation

J. Chandra, C. Grierson, H. Bungay; Oxford/UK

P-287 Pancreatic pathology: a pictorial review

R. Sethi1, A. Tokala1, J. Evans2, L. Williams1; 1Manchester/UK, 2Liverpool/UK

CL P-288 Pancreatic pathologies with diffuse or segmental involvement: CT and MRI findings
N. Takahashi, J. Fletcher, D.M. Hough, J. Fidler; Rochester, NY/US

INTERVENTIONAL
INTERVENTIONAL / BILE DUCTS
P-289 Percutaneous transjejunal biliary intervention for benign biliary strictures and intrahepatic
stones
R. Gibson1, D. Fontein2, N. Collier1, T. Speer1, R. Dowling1, A. Robertson1, B. Thomson1;
1
Parkville/AU, 2Leiden/NL

P-290 3D rotational percutaneous cholangiography of hilar cholangiocarcinoma

G. Carrafiello, D. Lagana, D. Mariani, M. Mangini, F. Fontana, S. Cuffari, C. Fugazzola, G. Sturniolo;
Varese/IT

P-291 Endovascular glue embolization of an arteriobiliary fistula following

after laparoscopic cholecystectomy
O. Temizoz, H. Genchellac, H. Ozdemir, E. Unlu, N. Tuncbilek, M.K. Demir; Edirne/TR

P-292 Interventional radiology in the management of biliary strictures

after orthotopic liver transplantation
M. de Santis, M.C. Gibertini, A. Pecchi, A. Affinita, F. di Benedetto, G.E. Gerunda, P. Torricelli;
Modena/IT

P-293 Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience

E. Cotta, A. Ianniello, M. Mangini, F. Fontana, D. Lagana, G. Carrafiello, C. Fugazzola; Varese/IT

P-294 Technique of percutaneous transluminal forceps biopsy in patients suspected of having a

malignant biliary obstruction
G. Carrafiello, D. Lagana, F. Fontana, M. Mangini, G. Sturniolo, F. Bandiera, F. Piacentino,
D. Mariani, S. Cuffari, C. Fugazzola; Varese/IT

109
EPOS™ PRESENTATIONS

INTERVENTIONAL / GI TRACT
P-295 Local recurrence of rectal cancer after abdomino-perineal excision:
treatment with radiofrequency ablation
L. Balestreri, M. Urbani, A. de Paoli; Aviano/IT

P-296 Removable self expanding nitinol covered stent in malignant oesophageal strictures before
neo-adjuvant chemoradiotherapy: a pilot study
A. Razack, V. Arora; Hull/UK

P-297 Therapeutic intervention with CTC

J. Bell, T. Westwood, A. Taylor, C.L. Tam; Lancaster/UK

INTERVENTIONAL / LIVER / OTHER

P-298 Transjugular intrahepatic portosystemic shunt: Bologna group’s experience
C. Mosconi, A. Cappelli, E. Giampalma, M. Renzulli, R. Golfieri; Bologna/IT

P-299 Long-term results after percutaneous ethanol sclerotherapy of symptomatic liver

and splenic cysts
A. Kollár, P. Molnár, V. Bérczi; Budapest/HU

INTERVENTIONAL / LIVER / TUMOUR ABLATION

P-300 Recurrence patterns after radiofrequency ablation of HCC
A. El-Wakeel, A. Zytoon, E. El-Mekway; Shebin el-kom/EG

P-301 A multi-center initial experience of microwave ablation and correlative CT findings

for treatment of hepatocellular carcinoma
M. Knuttinen, T. van Ha, J. Bui, D. West, P. Dillon, R. Gaba, B. Martinez, C. Owens; Chicago, IL/US

P-302 If apparent diffusion coefficients’ value can be an early factor of tumor response to
radiofrequency ablation therapy in patients with hepatic metastases from colorectal cancer?
E. Szurowska, J. Pienkowska, E. Izycka-Swieszewska, T. Nowicki, M. Studniarek; Gdansk/PL

P-303 RFA of exophytic malignant liver lesions

E. Sotiropoulou, P. Filippousis, K. Stathopoulos, O. Konstantinopoulos, M. Kelogrigoris,
A. Manataki, L. Thanos; Athens/GR

P-304 Radioembolization of unresectable HCC using intra-arterial 90Y: our experience

A. Cappelli, E. Giampalma, M. Renzulli, C. Mosconi, R. Golfieri; Bologna/IT

INTERVENTIONAL / OTHER / ABDOMINAL VASCULAR

P-305 Placement of gold fiducials in metastatic abdominal lymph nodes
E. Sotiropoulou, K. Stathopoulos, O. Konstantinopoulos, P. Tsagouli, N. Salvaras, V. Kosmas,
L. Thanos; Athens/GR

P-306 Transhepatic and translumbar central venous catheter placement: a reappraisal

J. Tisnado, M. Amendola, D. Leung, D. Komorowski, M. Sydnor, J. Tisnado; Richmond, VA/US

P-307 Adrenal metastases treated with RFA

E. Sotiropoulou, P. Filippousis, K. Stathopoulos, M. Kelogrigoris, A. Manataki, I. Tsaggaridou,
L. Thanos; Athens/GR

110
LIST OF EXHIBITORS

Bayer Schering Pharma AG im3D S.p.A. - Medical Imaging Lab

Müllerstrasse 178, 13353 Berlin, Germany Via Lessolo, 3, 10153 Turin, Italy
Phone: +49 30 468 1111 Phone: +39 011 195 08 773
Fax: +49 30 468 98646 Fax: +39 011 195 08 968
E-Mail: info.diagnostics@bayerscheringpharma.de E-Mail: info@i-m3d.com
www.diagnostic-imaging.bayerscheringpharma.de www.i-m3d.com

Bracco Intrasense
Bracco International B.V., Via Cantonale, Centro Galleria 2 10, rue Saint Antoine 75004 Paris, France
Phone: +41 919 853 030 Phone: + 33 1 48 04 32 83
Fax: +41 919 853 020 Fax: + 33 1 48 04 32 83
www.braccoimaging.com E-Mail: julien.dobel@intrasense.fr
www: www.intrasense.fr
Cadens Imaging
116 Principale, suite 200, Granby, Quebec, Canada J2G 2V2 Median Technologies
Phone: +1 450 956 3456 Les 2 Arcs, Bât B, 1800 Route des Crêtes, 06560 Valbonne
Fax: +1 450 991 3456 Phone: +33 4 93 333 777
E-Mail: info@cadensimaging.com Fax: +33 4 92 90 65 99
www.cadensimaging.com E-Mail: info@mediantechnologies.com
www.mediantechnologies.com
Cook Europe
Sandet 6, 4632 Bjaeverskov, Denmark Medicsight PLC
Phone: +45 56 86 87 16 Kensington Centre, 66 Hammersmith Road, London, W14 8UD
Fax: +45 56 86 86 96 Phone: +44 207 605 1154
E-Mail: p.ryle@cook-wce.com Fax: +44 207 605 7951
www.cookmedical.com E-Mail: robert.ferguson@medicsight.com
www.medicsight.com
ESGAR
Central ESGAR Office Philips Healthcare
Neutorgasse 9, 1010 Wien P.O. Box 10 000, Veenpluis 4 – 6, 5680 DA Best, The Netherlands
AT – 1010 Vienna, Austria www.healthcare.philips.com
Phone: +43 1 535 89 27
Fax: +43 1 535 70 37 Sociedad Espanola de Radiologia Médica (SERAM)
www.esgar.org Goya 38, 28001 Madrid
Phone: +34 915 752 613
GE Healthcare Fax: +34 576 3279
283 rue de la Miniere, 78533 Buc, France E-Mail: secretaria@seram.es
Phone: +33 1 30 70 9106 www.seram.es
Fax: +33 1 30 70 4130
E-Mail: christine.sickinger@ge.com TeraRecon
www.gehealthcare.com/euen/ct/index.html Lurgiallee 10, 60439 Frankfurt
Phone: +49 6995 103 52 0
Guerbet Fax: +49 6995 103 52 200
BP 57400, 95943 Roissy CDG Cedex, France E-Mail: info@terarecon.com
Phone: +33 1 45 91 50 00 www.terarecon.com
Fax: +33 1 45 91 51 99
E-Mail: laurence.arnaud@guerbet-group.com, Vital Images Europe
veronique.coma@guerbet-group.com Muzenstraat 89, 2511 WB Den Haag, The Netherlands
www.guerbet.com Phone: +31 0 704 262 181
Fax: +31 0 704 262 111
Hitachi Medical Systems Europe Holding AG www.vitalimages.com
Sumpfstrasse 13, CH 6300 ZUG
Phone: +41 41 748 63 33 Wisepress Online Bookshop
Fax: +41 41 748 63 32 The Old Lamp Works, 25 High Path, Merton Abbey, London,
E-Mail: welcome@hitachi-medical-systems.com SW19 2JL, UK
www.hitachi-medical-systems.com Phone: +44 20 8715 1812
Fax: +44 20 8715 1722
E-Mail: bookshop@wisepress.com
www.wisepress.com

112
FLOORPLAN - EXHIBITION (ENTRANCE LEVEL)

RIUM
R
RIU
ALPHABETICAL
AB NUMERICAL

IU
ORDER
RD ORD

UM
M2
Company Name
e Booth No. Booth No. Company Name
BAYER SCHERING
NG 2 1 ESG
BRACCO 14 2 BAYER SCHERING 6
CADENS 9 3 IM3D
COOK 6 4a VITAL IMAGES
VIT
7
ESGAR 1 4b INTRASENSE 5
GE HEALTHCARE 12 5 WISEPRESS
GUERBET 15 6 COOK
HITACHI 16 7 SERAM
IM3D 3 9 CADENS 9
INTRASENSE 4b 10 PHILIPS
M
MEDIAN 11 11 MEDIAN 10
MEDICSIG
CSIGH
SIGHT 13 12 GE HEALTHCARE
PHI
PH
PHILIPS 10 13 MEDICSIGHT 4b
SERAM 7 14 BRACCO
TERARECON 17 15 GUERBET
VITAL IMAGES 4a 16 HITACHI
WISEPRESS 5 17 TERARECON 11
4a
12
3
R
CAS FEE
H BA
COF

13
AUDITORIUM 1
14

15
RE
GI
ST
RA
TIO
N
RA E

N
TIO
ST LAN

16
RE AST
GI
F

17

TR
DE AVE
SK L
RO

113
114
PR
CE EV
NT IEW
RE

CAFETERIA

RE
GI
MAIN ENTRANCE

ST
M
FLOORPLAN – ENTRANCE LEVEL

O K

RA
RO OA
CL

TIO
N
AUDITORIUM 1
AUDITORIUM
3B
AUDITORIUM 2
FAST LANE

EP
REGISTRATION

OS
COF
CAS FEE
H BA AUDITORIUM
R 3A

EXHIBITION AREA

EXHIBITION AREA
LOUNGE & INTERNET
 FLOORPLAN – LEVEL 1

CTC HANDS-ON
CENTRE
EPOSTM AREA
INTERNET CORNER

ROOM
5

ROOM
3+4

ROOM
6+7
ROOM
1+2

115
ALPHABETICAL INDEX OF FACULTY MEMBERS, MODERATORS AND
PRESENTERS OF SCIENTIFIC PAPERS AND EXHIBITS

A Bru C.: LS 8.02

Abe T.: P-171 Bruel J.-M.: PS 3
Acu B.: P-230 Burling D.: WS 11, SY 5, SY 5.01, SY 6.03
Addley H.: SS 1.01, P-039 C
Agnello F.: SS 1.09 Campos J.: P-114, P-149, P-256
Akata D.: PG 3.03 Cantisani V.: SS 6.05, P-197, P-201
Akhan O.: LS 7, PS 2 Cappelli A.: SS 9.08, P-304
Albazaz R.: P-281 Cappelli C.: P-257
Alberich-Bayarri A.: SS 14.07 Caramella C.: SS 2.09
Almeida A.: P-206 Carrozzo F.: SS 15.09
Arcalis Guaus N.: P-273 Caseiro-Alves F.: PG 4, PS 5.01
Arora V.: P-296 Catalano O.: P-071, P-078, P-271
Arrillaga A.: P-190 Cavalheiro F.: P-098, P-175, P-237, P-258
Aschoff A.: LS 4.04 Cazejust J.: SS 13.09
Aube C.: WS 17 Celda muñoz B.: RC 2.04
Averkiou M.: SS 13.10 Centola A.: SS 15.06
Avni F.: WS 15 Cereser L.: SS 7.07, P-172
Ayuso C.: LS 1.01 Cevener M.: P-195
Ayuso J.: SS 6.04, P-189 Chalazonitis A.: P-247
Azahaf M.: SS 6.09 Chami L.: P-027
B Chandra J.: P-285
Ba-Ssalamah A.: SS 5.02 Charlier P.: P-264
Bali M.: LS 3.02 Chew C.: P-263
Ballesta Cuñat A.: P-075, P-222 Cho J.: P-024
Baron R.: LS 8.01 Choi B.: RC 1.02, PG 4
Baroud S.: SS 12.05 Choi S.: P-168
Barrau v.: P-248 Chuah J.: P-055
Bartolotta T.: SS 12, SS 12.06 Chung J.: P-226
Bartolozzi C.: PS 2 Cianci R.: SS 4.10
Bastati-Huber N.: SS 12.03 Cioni D.: WS 5
Battaglia V.: SS 2.10, SS 12.04 Claussen C.: LS 10
Baumann T.: SS 3.07, SS 5.03 Cokkinos D.: P-184, P-193, P-270
Bayramoglu S.: SS 14.04 Cotereau Denoiseux C.: SS 14.05
Beable R.: P-277 Cotta E.: P-293
Becker C.D.: PS 2 Crocetti L.: LS 8.03, SS 9.09
Beets-Tan R.: WS 7, WS 14, WS 21, LS 10.04 Curvo-Semedo L.: WS 8
Bellomi M.: SS 4 Cushing M.: SS 5.04
Belo-Soares P.: SS 1 D
Beltrán M.: P-083 de Cecco C.: SS 14.03, P-010
Berzigotti A.: P-154 de Filippis G.: SS 14.02
Bethke A.: SS 4.09 de Franco A.: SS 15.02
Bielen D.J.: SS 11.08 de Lutio di Castelguidone E.: P-259
Bilhim T.: P-109 de Santis M.: P-292
Biscaldi E.: SS 4.02, SS 10.05 di Martino M.: SS 1.07, SS 13.01
Biswas S.: P-041 D’Onofrio M.: WS 2, SS 2.01, P-272
Boatta E.: SS 9.04, SS 9.06 Damodharan K.: SS 5.07, P-058
Bohata S.: P-095 Davis W.: P-051
Bolondi L.: PS 2, SY 6.02 Dekker H.: P-192
Boraschi P.: SS 2.06 Della Monica P.: SS 8.04, SS 11.04
Boronat A.: SS 15.01 Della Pina M.: RC 1.03
Botsikas D.: SS 7.06 Dewhurst C.: P-040
Bouzas R.: WS 12, LS 4 Dhillon R.: P-019, P-022
Bozzi E.: SS 1.04 Dobritz M.: SS 10.03
Brambs H.: LS 9.03 Donati F.: SS 7.09, SS 9.03
Brancatelli G.: LS 1, PS 5.02, SS 1.02 Donati O.: SS 4.04, SS 4.06
Breen D.: IR 1.03, SY 1 Dondelinger R.: LS 4.01
Brito J.: P-131 Doratiotto S.: P-153

116
Dromain C.: LS 3.04 Hassan C.: SY 4.02
Dvorak P.: P-136 Hatzidakis A.: IR 3.03
Dybiec E.: P-199 Heiken J.: PG 2, LS 7.01
E Helmberger T.: PG 1.02
Hirohashi S.: P-177
Efremidis S.: PG 3 Holzapfel K.: SS 6.03
Egels S.: P-188 Huppert P.: LS 6.04
Eiber M.: SS 6.02 Huppertz A.: SY 1.01
Ekberg O.: LS 2 Huynh-Charlier I.: P-182
El-Wakeel A.: P-300
Engin G.: P-111, P-112 I
Enver M.: P-081 Iafrate F.: CTC 3.03, SS 5.08, SS 8, SS 11.07, P-048
F Ichikawa T.: P-276
Ilangovan R.: P-053
Fencl P.: SS 4.05 Iussich G.: SS 6.06, SS 8.02, SS 11.06
Ferrari R.: CTC 3.04, CTC 3.05, P-049, P-050,
P-052, P-056, P-059, P-060 J
Ferrer Bradley I.: PS 4.01 Jackson K.: P-033
Feuerbach S.: WS 12 Jackson S.: PG 3, WS 3, P-121, P-152, P-239
Feuerlein S.: SS 4.01 Jacob A.: P-062, P-205
Filippone A.: LS 7.03, SY 1.01 Jain R.: P-241, P-244
Fontein D.: P-289 Jang H.: SS 1.03, P-196
Fork F.: LS 5 Jansen M.: SS 9.10
Franca M.: P-254, P-280 Jee K.: P-108
Freeman A.: SS 3 Jensch S.: SS 11.10
Freeman S.: P-082 Juchems M.: P-279
Frias Vilaça A.: P-005, P-074, P-103, P-116 K
Frost R.: LS 5
Kandel S.: SS 7.08
G Kang Y.: P-017
Galia M.: P-066, P-191 Kalageropoulos I.: P-021
Gallix B.: SS 1, SS 6.08 Karani J.: IR 3.01
Gallotti A.: SS 13.06 Karmazanovsky G.: LS 9
Garbarino V.: SS 10.06 Katulska K.: P-065
Gatti E.: P-194, SS 1.05, SS 14.08 Kay C.: IR 2.02
Genchellac H.: P-013 Kenis C.: SS 6.01
Ghaye B.: LS 4.02 Khalili K.: SS 1.06, P-173
Ghiatas A.: SS 4 Kim H.: P-086
Giannecchini S.: P-212 Kim M.: P-125, P-142, P-148, P-223
Giat P.: SY 2 Kim S.: P-119
Gillams A.: IR 1.02 Kim T.: LS 6.01
Girometti R.: P-028 Kim Y.: P-135, P-146, P-265
Giusti P.: P-140 Kirke R.: P-067, P-088
Giusti S.: P-068 Kiyonaga M.: P-278
Gómez F.: P-106 Kloeters C.: SS 2.04
Gomes M.: P-227 Knuttinen M.: P-301
González C.: P-122, P-123 Kochhar R.: P-097
Gonçalves L.: P-214, P-231 Koelblinger C.: SS 13.04
Gore R.M.: PS 4.02 Koizumi J.: P-253
Gourtsoyianni S.: LS 3.03, PS 3 Kollár A.: P-299
Gourtsoyiannis N.: HL 1.01, PS 4 Korman U.: SS 3
Grazioli L.: PG 1.01, P-169 Kotake F.: P-225
Grierson C.: P-008, P-023 Krokidis M.: SS 12.02, P-187
Griffin N.: P-092 Kurochka S.: P-229
Guarise A.: SS 2 L
Guthrie J.: WS 17, P-181
La Seta F.: P-147, P-251
H Laasch H.-U.: IR 2.01
Hafeez R.: SS 3.03, SS 3.04, SS 15.07 Laghi A.: CTC 1.01, CTC 2.01, CTC 3.01, WS 4, SS
Halankar J.: SS 12.07 5, SY 2.03, SY 5.02
Halligan S.: WS 18 Lambregts D.: SS 3.06, SS 3.09, SS 8.05
Hammerstingl R.: SS 6 Lameris J.: IR 3.02, LS 6
Han H.: P-252 Laniado M.: PG 2.02, LS 1, SY 3, SY 3.01, SY 3.02,
Hardie A.: P-160, P-178 SY 3.05

117
Latief K.: P-133, P-234 Metens T.: RC 2.03
Lauenstein T.: RC 1.04, SS 2.05, SS 13.05 Metser U.: SS 4.03
Laugharne M.: P-186 Milone P.: P-018
Laumonier H.: SS 12.08 Minami M.: HL 3.01
Laurent V.: SS 12 Missere M.: P-284, SS 7.10
Leal C.: P-144 Mittal R.: P-238
Lee D.: P-124 Mokali I.: P-139
Lee J.: SS 1.08, P-235 Moran D.: P-102, P-170, P-200, SS 1.10
Lees W.: PG 2.01 Morana G.: LS 1.04, LS 9, P-076, SS 12.01
Lefere P.: CTC 2.02, WS 4, SY 5.04 Mori H.: SS 7
Lewin M.: LS 1.03, SY 3.03 Morone M.: SS 13.02, P-159
Lewis D.: SS 9.02 Morrin M.: LS 10
Liedenbaum M.: CTC 1.04, CTC 1.05, SS 8.01 Moschetta M.: SS 5.01
Lim J.: SS 7.01 Mosconi C.: P-298
Lim K.: SS 7.03 Mostbeck G.: PG 2
Linda A.: SS 12.10 Mylona S.: P-113
Liong S.: P-221 N
Lo Re G.: SS 5.09
Lomas D.: RC 2.01, LS 3 Nakamoto A.: SS 7.02
Lu T.: SS 13.08 Neri E.: CTC 1.02, WS 11
Lucidarme O.: SS 13 Nikolaidis P.: SS 5.05
Luna A.: P-203 Nio Y.: LS 10.01
Lefort T.: P-268 O
M O’Regan K.: SS 10.01, SS 15.04
Maas M.: SS 3.05, SS 3.08, SS 8.07 Obuz F.: P-207
MacDonald K.: P-099 Odetoyinbo T.: SS 9.05
Maccioni F.: WS 19 Ogura T.: P-034, P-038
Maciel J.: P-250 Oliveira P.: P-096, P-232
Madureira A.: SS 10 Onishi H.: P-209
Maglinte D.: LS 2.01, SS 5 Op de Beeck B.: LS 8.04, LS 9.04
Maheshwari E.: P-185 Ouranos V.: P-072, P-115
Maia R.: P-217, P-233 P
Maisto F.: SS 3.10, SS 8.09
Palaniappan B.: P-162
Maksimovic R.: P-029
Palkó A.: WS 1, LS 8
Malone D.: WS 6, WS 13
Paolantonio P.: WS 9, SS 10.07, P-070, P-118,
Manchec-Poilblanc P.: P-165
P-164, P-198, P-245
Manfredi R.: LS 6.02
Papanikolaou N.: PG 2.03, LS 2.04
Mang T.: PS 3, SS 11.01
Park S.: P-266
Maniatis V.: P-100
Patak M.: SS 10.09, SS 10.10, SS 15
Mannelli l.: SS 14.06
Patel P.: P-042
Manzella A.: P-011, P-130, P-138
Patriarca G.: SS 13.03
Mariani D.: P-290, P-294
Paulino C.: P-087, P-132
Marincek B.: PG 1, PG 4.02
Pauls S.: P-215
Marion D.: P-003, P-007
Pecchi A.: P-020
Maroto i Genover A.: P-126
Peer S.: P-107
Marques P.: P-036
Pereira M.: IR 1.01, P-015
Marshall M.: LS 10.02
Pickhardt P.: LS 5.03, SS 11, SY 5.03
Martí-Bonmatí L.: RC 2, PG 1, PG 4.01, SY 6, P-213
Pienkowska J.: P-283
Martin D.: LS 6.03
Pokieser P.: LS 7
Martínez Rodrigo J.: IR 2.03, SS 9
Portilha M.: P-204, P-210, P-267
Marugami N.: P-176
Pozzi Mucelli R.: P-180
Maskell G.: SS 8
Prasad D.: SS 8.06, P-105
Masselli G.: P-069
Prassopoulos P.: LS 7.04
Matos C.: RC 2.02, LS 6, LS 9.02
Preto A.: P-255, P-282
Matos H.: P-032, P-141, P-166
Puylaert J.: WS 10, LS 2.02
Matsui O.: WS 8, LS 8
Mc Laughlin P.: SS 14.10 Q
McSweeney S.: SS 7.04
Megibow A.: SS 2
R
Mendelson R.: WS 3, WS 20 Rafaelsen S.: RC 1.01
Menu Y.: RC 1, PG 4.03 Rahman F.: P-129
Merino-Casabiel X.: P-025 Rajan R.: P-030
Ramos A.: P-073
118
Ramos I.: SS 6 Stoupis C.: PS 5.03
Ramos R.: P-218, P-261 Stringer D.: WS 15
Raptopoulos V.: WS 16 Szurowska E.: P-120, P-211, P-302
Raynal m.: P-084 T
Regge D.: LS 5.02, SS 11, SY 4, SY 4.01, SY 4.03,
SY 4.05 Takahashi N.: P-288
Reginelli A.: P-064, P-151 Tam E.: SS 3.01, SS 8.10
Reiner C.: SS 2.08, SS 6.07 Tarján Z.: WS 10
Rengo M.: SS 11.02 Taylor S.: CTC 2.03, LS 5.04, SS 14.09, WS 13
Restaino G.: P-284 Temizoz O.: P-291
Riaguas A.: P-216 Thiruppathy k.: P-269
Ridereau-Zins C.: SS 10.04 Thomas B.: P-117, P-143
Ridge C.: P-061 Tisnado J.: P-306
Rinaldi P.: P-014 Tolan D.: P-063
Roberts A.: SS 14 Torkzad M.: SS 5.06, P-243
Robinson C.: CTC 2.04, CTC 2.05, SS 11.03, Torrao H.: P-012, P-208
SS 11.05, SS 15.03 Triantopoulou C.: LS 9.01, P-090
Rocha D.: P-174 Tsota I.: P-110
Rogalla P.: WS 16, SS 14, SY 4.04 Turini F.: SS 8.03, SS 11.09
Rollandi G.: LS 2.03, P-037, P-045 Tweed K.: P-094
Romanini L.: P-046, P-179 U
Romano S.: LS 4.03, SS 10, P-242
Uliasz M.: P-047
Roqué C.: P-006, P-246, P-249
Urbani M.: P-295
Ros P.R.: PS 4.03, PS 5
Urigo C.: SS 9.07
Ros Mendoza L.: WS 5
Roson N.: P-240 V
Ruivo C.: P-104 van Beers B.: PG 3.02
Rummeny E.: LS 3.01, SS 9 van Randen A.: SS 10.02
S Vagli P.: CTC 1.03
Valek V.: LS 2
Saba L.: P-002, P-004, P-009, P-137, P-145, P-167
Valerie g.: P-236
Sahani D.: HL 2.01, SY 6.01
Vandenbroucke F.: SS 6.10
Sai M.: P-158
Var V.: P-031
Salemi S.: SS 2.07
Venancio J.: WS 18
Salgado A.: P-044, P-085
Vilana R.: P-274
Santiago I.: P-026, P-150
Vilgrain V.: PG 1.03, SY 2.02
Santos R.: P-079, P-089
Vlachou P.: P-001
Sawhney S.: P-228
Vullierme M.: SS 7.05
Scardapane A.: SS 12.09
Schäfer A.-O.: SS 5.10 W
Schima W.: LS 1.02, PG 2 Weishaupt D.: LS 10.03
Schindera S.: SS 14.01 Westwood T.: P-057, P-297
Schmidt S.: SS 15.05, P-134 Wiarda B.: SS 15.10
Schmid-Tannwald C.: SS 10.08 Willekens I.: P-077, P-219
Schramm N.: SS 4.07, SS 4.08 Williams L.: P-163, P-287
Seco M.: P-157, P-161 Wong L.: P-101
Serter S.: P-262 Woo J.: P-035
Shepherd D.: LS 4
Sheridan M.: WS 9
X
Shorvon P.J.: PS 3 Y
Siopsis E.: SS 9.01
Sirlin C.: PG 3.01 Yarmenitis S.: WS 2
Smeets P.: SY 3.04 Yu H.: P-183
Snoeckx A.: P-128, P-224, P-275 Z
Sobrido C.: P-043, P-080 Zaboriene I.: P-202
Sobrido Sampedro C.: P-091 Zamboni G.: SS 2.02, SS 2.03, SS 7
Somers S.: WS 19 Zech C.: WS 1, LS 3
Sotiropoulou E.: P-303, P-305, P-307 Ziech M.: SS 15.08
Sparano A.: P-016 Zijta F.: SS 3.02, SS 8.08
Stagnitti A.: P-054 Zins M.: LS 7.02, SY 2.01
Staunton M.: WS 6, WS 20
Stoker J.: CTC 3.02, LS 5.01, SS 15
Stoppino L.: P-156

119
NOTES

120
NOTES

121
NOTES

122
NOTES

123
NOTES

124
 e you at
Se
GAR ‘10
ES

ESGAR 2010
EUROPEAN SOCIETY OF GASTROINTESTINAL AND ABDOMINAL RADIOLOGY

DRESDEN / DE

JUNE 2 – 5
21ST ANNUAL MEETING AND POSTGRADUATE COURSE

CENTRAL ESGAR OFFICE MEETING PRESIDENT

Neutorgasse 9/2a Prof. Michael Laniado
AT – 1010 Vienna, Austria Technische Universität Dresden
Phone: +43 1 535 89 27 Department of Diagnostic Radiology
Fax: +43 1 535 70 37 University Hospital Carl Gustav Carus
E-Mail: office@esgar.org Fetscherstraße 74
www.esgar.org DE – 1307 Dresden, Germany
APPLICATION FOR MEMBERSHIP
EUROPEAN SOCIETY OF GASTROINTESTINAL AND ABDOMINAL RADIOLOGY

PLEASE RETURN THIS COMPLETED FORM TO:

Central ESGAR Office

Neutorgasse 9/2a
AT – 1010 Vienna, Austria
Phone: +43 1 535 89 27
Fax: +43 1 535 70 37

I wish to become a member of the European Society of Gastrointestinal and Abdominal Radiology

Type of membership requested (please tick)

Active Member Junior Member Corresponding Member Associate Member

Areas of interest (please tick)

Swallowing studies MRI EUS Endoscopy

Liver Gut motility PET CT
Intervention Pancreas The tube Other
US Contrast studies Pelvic floor

Applicant

Prof./Dr./Mr./Mrs./Ms. (please indicate) Male/Female (please indicate) Date of Birth:

Family Name: First Name:
Institution:
Hospital:
Department:
Hospital Address:
Street/no.:
City: Post Code: Country:
Phone: Fax:
Mobile:
E-Mail:
Private Address:
Street/no.:
City: Post Code: Country:
Phone: Fax:
Mobile:
E-Mail:
Signature Applicant:

Please contact me preferentially at my Hospital Address Private Address

Proposer*
Family name: First name:
Hospital/Institution:
Department:
City: Country:
Signature Proposer:

* If you do not have a proposer please submit your CV together

Date of Application
with the application for Membership.

127
MEMBERSHIP INFORMATION
MEMBERSHIP CATEGORIES
Active Members
A c t iv e M e m bers hi p o f the S o ci ety i s o pen t o
European Radiologists who have a prime interest in
gastrointestinal and abdominal Radiology. By this it is
assumed that they will spend at least 50 % of their time
working in the subspeciality and will have published in
this field.
Junior Members
Residents can become junior members while training for
specialisation in General Radiology and/or training for
Sub-specialisation in (1) Gastrointestinal and Abdominal
Radiology and/or (2) Interventional Radiology.
Application for Junior Membership must be
accompanied by a confirmation about the residency
status of the applicant, signed by the head of the
department. Junior Membership is valid for three years
at maximum or will end once the residency in radiology
is terminated.
Fellows
Fellowship is conferred on those individuals who have
been members of the Society for at least three years
and who have made significant contributions both
to the Society and to the field of gastrointestinal and
abdominal Radiology.
Corresponding Members and Fellows
Radiologists from outside Europe can be considered for
Corresponding Membership and Fellowship.
Associate Members
Non-Radiologists with a special interest in
gastrointestinal and abdominal Radiology such
as radiographers, nurses and individual members
of industry, etc. can be considered for Associate
Membership.
Corporate Members
Corporations or other organisations, including
commercial enterprises, interested in the activities and
objectives of the Society, contributing to the Society by
funding.
128
ANNUAL MEMBERSHIP FEES
Active Members, Fellows: € 110,00
Corresponding Members, Fellows: € 110,00
Associate Members: € 55,00
Junior Members: € 55,00
HOW TO BECOME A MEMBER OF ESGAR
Please fill in the application form, have it signed by a
proposer and send it to the address shown on the
form. If you do not know any ESGAR members and
therefore do not have a proposer, please send the
application form together with a short Curriculum
Vitae to the address shown on the application
form. There are national representatives of ESGAR
i n m a n y E u ro p e a n c o u n t r i e s . P l e a s e re f e r t o
the ESGAR website www.esgar.org for the contact
addresses and further information. The application form
can also be downloaded from our website.
Applications are received by the Chairman of the
Membership Committee. Proposed candidates for
membership are admitted by the Executive Committee
and will be approved by the General Assembly.
MEMBERSHIP BENEFITS
– Reduced registration fee at the Annual Meetings and
Workshops of the Society
– Newsletter
– Member’s Handbook
– Personal ESGAR Account at www.esgar.org:
• Member’s Directory
• E-Congress (including EPOS™ and web-casts)
YOU’VE ONLY JUST
ARRIVED & ALREADY
WE’RE THINKING OF
YOUR NEXT TRIP
As the official airline network for ESGAR 2009, we’d like to thank
you for choosing the Star Alliance™ network and hope that all goes
really well for you here today.

Whilst you concentrate on the day’s events, we hope you’ll consider

us the next time you need to attend a conference.

With over 18,100 flights a day to 975 airports across 162 countries,
our 24 member airlines will extend a wide choice of flights to any future
conference you’re planning to attend. And no matter which of those
airline’s frequent flyer programmes you belong to, you can earn and
redeem miles across all of them.

So the next time you want to concentrate all your energies on your
conference, we hope you’ll decide to leave the travel arrangements
to us.

www.staralliance.com

Information correct as at 07/2008

 ES IN
YOU CAN TR UST A CAD

TI N
SI TIO
V
PO C VA L I D A T E D O N O N E O F T H E
E DU
LS E
A R

WO R L D ’ S L A R G E S T DATA BA S E S
F %
50

Unbelievably, some computer-aided detection (CAD) systems have only been tested against
data from a small number of patients. This means you can’t really rely on them
to give you the solid support you need.
Medicsight on the other hand, have validated their ColonCAD system using one of the world’s largest
and most population-diverse optically verified CT Colongraphy scan databases to help you better detect
and analyse potential abnormalities within the colon. Better still, the latest version 4.0, marks a significant
increase in performance with a 50% reduction in false positives without any loss in sensitivity.*
Trust Medicsight to make your job easier, but more importantly,
give you the reassurance and confidence to make
a more reliable, accurate diagnosis.

Medicsight PLC, Kensington Centre, 66 Hammersmith Road, London W14 8UD.

www.medicsight.com

* Data on file Medicsight PLC.

© 2009 Medicsight PLC.